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ABSTRACT   
The advent of new high throughput technology allows for increasingly detailed characterization of 
the immune system in healthy, disease, and age states.  The immune system is composed of two 
main branches: the innate and adaptive immune system, though the border between these two 
states is appearing less distinct.  The adaptive immune system is further split into two main 
categories: humoral and cellular immunity.  The humoral immune response produces antibodies 
against specific targets, and these antibodies can be used to learn about disease and normal 
states.  In this document, I use antibodies to characterize the immune system in two ways: 1. I 
determine the Antibody Status (AbStat) from the data collected from applying sera to an array of 
non-natural sequence peptides, and demonstrate that this AbStat measure can distinguish 
between disease, normal, and aged samples as well as produce a single AbStat number for each 
sample; 2.  I search for antigens for use in a cancer vaccine, and this search results in several 
candidates as well as a new hypothesis.  Antibodies provide us with a powerful tool for 
characterizing the immune system, and this natural tool combined with emerging technologies 
allows us to learn more about healthy and disease states. 
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PREFACE  
 The chapters and appendix sections in this dissertation cover a wide variety of topics.  
However, all of these topics are connected by the themes of health and the immune system. 
 The first chapter about an AbStat from an antibody peptide fluorescence intensity 
distribution became an increasingly larger part of my dissertation work as time went on.  The work 
from this section was originally something I did in my spare time.  Around this time, I was listening 
to an audiobook titled “The Information: A History, a Theory, a Flood” by James Gleick which 
discussed Claude Shannon and entropy among many other things.  This book along with many 
others increased my general curiosity in the concept of entropy.  I, like others, had the general 
notion that living things are not random, and entropy provided a method for quantitating how 
random a system is.  I thought that perhaps a living system that is more random than another 
might be sicker or less optimal in some way.  Since our lab was quantitating the humoral immune 
response with a new type of peptide array, I figured that I would try out an entropy calculation to 
compare a group of young mice with a group of aged mice.  I then started writing a Java program 
to handle the large amounts of data that our lab produces.  I was delighted to find that there 
certainly was a difference between the groups.  I would like to express my appreciation to 
Anshuman Sahu and John Lainson who helped me, through various conversations, to outline my 
ideas more precisely in order to reach this point.  From that time on, as more and more datasets 
were analyzed the concept seemed to gain more validity.  After several initial results, the director 
of the lab, Dr. Johnston, strongly supported investigating the concept in further detail.  Eventually 
we began using other measures in addition to entropy, and the lab decided by vote to call the 
concept of measuring the immune response with these broad measures the AbStat for Antibody 
Status.  This exciting development may provide new methods for assessing the state of the 
immune system. 
 Chapters 2 and 3 cover my main project with Dr. Sykes.  I spent the most time on this 
project over the years to develop a high-throughput method for screening a tumor cDNA library 
for immunogens.  The immunogens from this type of screening could potentially be used in a 
cancer vaccine, and several antigens were identified which could be investigated further.  
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Chapter 4 covers a project which I worked closely with Luhui Shen on to use non-natural 
sequence peptides to identify epitopes and isolate specific antibodies.  The first appendix section 
covers a project in which I carried out an experiment to test a hypothesis I started to develop in 
my comprehensive exam document before starting my work in the CIM lab.  The project was to 
use a cytotoxic lymphocyte assay with stem cells to test a hypothesis that part of the aging 
process is due to an acquired autoimmune disease against stem cells.  This work was made 
possible by an innovative competition which Dr. Johnston and our lab created called the Gemini 
project.  The idea was that anyone in the lab could write a proposal and the proposals that were 
selected would be funded by our lab.  The proposal of Alexander Carpenter who wanted to test 
synbodies against acne and my proposal was selected, and I began to perform the experiments 
to test the hypothesis.  The last three appendix sections (phage antibody library, purification of 
antibodies with non-natural sequence peptides, and automatic array alignment) are projects in 
which some initial work was performed.
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1: ABSTAT FROM ANTIBODY FLUORESCENCE INTENSITY DISTRIBUTION ON A PEPTIDE 
MICROARRAY 
1.1 Introduction 
Methods for determining whether an organism is healthy or sick are very useful for 
diagnosis as well as for aiding in the prevention of illness.  One system of the body that plays 
some role in virtually every illness is the immune system.  The adaptive immune system will often 
respond in a manner that is specific and unique for the illness, and the B cells of the adaptive 
immune system will produce antibodies in the sera which bind to specific protein, carbohydrate, 
and lipid targets.  A technology for acquiring information from these antibodies by applying them 
to a non-natural sequence peptide array has recently been developed 1.  When sera antibodies 
react with an array of non-natural sequence peptides, each peptide will exhibit a different level of 
binding of antibodies which are quantified using a fluorescent secondary antibody.  The 
distribution of fluorescent intensities will depend on the number, affinities, and avidities of the 
antibodies for various peptide sequences.  The presumption of the technology is that the number 
of antibodies, the affinities of the antibodies, and the avidities of the antibodies will depend on the 
health state of the organism: healthy or disease as well as young or aged.  Can the information 
acquired from the fluorescence intensity distribution resulting from sera antibodies reacting with 
an array of random sequence peptides be used to distinguish healthy or disease states?  Can this 
information be compressed into a single quantified variable?  This research shows that several 
measures from the fluorescence intensity distribution can be combined to produce an Antibody 
Status (AbStat) capable of distinguishing healthy and disease states. 
1.1.1 Measure humoral immune responses 
Methods for interrogating the details of the humoral antibody response have evolved over 
the years.  One of the first methods, ELISA, allows antibodies to react with antigen coated wells 
in a 96 well microtiter plate 2.  This method is still very popular and useful, but the amount of 
information that can be acquired is limited since only one antigen is coated per well.  In a western 
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blot, all of the proteins in pathogen lysate are electrophoretically separated in a gel which is then 
probed with the antibody containing sera 3.  This method surveys many proteins at one time, but 
there are limits to the amount of separation that can be achieved between proteins with similar 
sizes and isoelectric points.  Note that the proteins on the membrane are largely denatured.  High 
throughput methods have also been developed in which many different proteins are placed in an 
array and queried with sera 4, 5.  The ELISA, western blot, and protein microarrays provide 
information about whether an antibody or antibody containing sera binds to a whole protein, but 
these methods do not provide information about the specific epitope within the protein to which an 
antibody binds.  Some epitopes are conformational, but there are also many epitopes which are 
linear and would correspond to a short linear sequence within the protein.  In order to obtain this 
epitope information, peptide microarrays consisting of tiled peptides from protein sequences have 
been used 6.  One disadvantage with this method is that the researcher must know which proteins 
are present in the pathogen being studied so that peptides from this protein can be tiled on the 
array.  However, there are many situations in which the target antigen is unknown: a patient may 
be infected with an unknown but previously identified pathogen, the patient may be infected with 
a new foreign pathogen, or a researcher may be searching for new unidentified mutated proteins 
in cancer.  One method for addressing these situations is to use a peptide microarray consisting 
of non-natural peptides with sequences randomly selected from all peptide sequence space 1, 7. 
These non-natural sequence peptide microarrays have been used for a variety of 
purposes.  The specific epitope of an antibody can be discovered.  A few selected peptides from 
the total array can also be identified which are unique to certain types of diseases.  These peptide 
features are part of the immunosignature, which is a medical diagnostic test obtained by using 
arrays of non-natural sequence peptides to associate antibodies in a blood sample with disease 1, 
8-10.   The peptide features selected from the immunosignature can be used for diagnosis as well 
as for further characterization of the disease.  These peptides are unique for the disease because 
they have sequences which are mimotopes of epitopes which antibodies for that disease bind to.  
Note that within one feature on the microarray there are many peptides, but they all have the 
same sequence.  The sequence of the peptide used for each different feature is chosen from 
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random sequence space as opposed to natural protein sequence space, but the peptide 
sequence and location of each feature on the array is known.  Therefore, if a given feature has a 
very high intensity whenever breast cancer sera is applied to the microarray, the user will know 
the sequence of the peptides located at this feature and can study how this may relate to breast 
cancer for example. 
Is there more information that can be obtained from the non-natural sequence peptide 
microarray in addition to specific peptides that are high or low for a given sera type?  When 
antibodies are applied to the peptide microarray there is a whole feature intensity distribution that 
results since each feature will have some intensity value which will reflect how much binding with 
that peptide occurred.  This peptide distribution may exhibit behavior characteristic of disease or 
normal states irrespective of the few specific peptides that are mimotopes of an epitope relevant 
to the disease.  In total, there are approximately 1011 B cells in an individual’s lymphocyte 
population 11, and therefore there are many different antibodies in sera.  The nature of all of the 
different affinities and avidities present in the antibody repertoire in a healthy state may be 
different than the affinities and avidities present in a disease state, and these differences may be 
detectable in the fluorescence intensity distribution resulting from interaction of these antibodies 
with a non-natural sequence peptide microarray. 
There may be detectable differences in the affinities and avidities of the antibody repertoire 
in young and aged sera as well as disease.  These differences may manifest themselves in the 
fluorescence intensity distribution that results from applying these antibodies to an array of non-
natural sequence peptides.  As organisms age, the antibodies they produce against new targets 
have lower affinities for those targets 12-14.  This would explain why the immune system responds 
less effectively to vaccines with age 15.  Not only is there a decrease of antibody specificity, but 
the prevalence of autoimmune disorders tends to increase with age as well 16.  This indicates that 
the aged immune system is more broadly and non-specifically reactive, and there is evidence of 
general increased inflammation known as “inflamm-aging” 17, 18.  An abundance of low affinity 
non-specific antibodies may bind to an array of non-natural sequence peptides in a different 
manner than antibodies which have very high affinities for their target sequences. 
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1.1.2 Measures that compose the AbStat 
The antibody repertoire will bind to each peptide on the non-natural sequence peptide 
array with a different level of binding.  This level of binding is detected from a scanner which 
detects the intensity of certain wavelengths of light emitted by a dye conjugated to a secondary 
antibody that binds to all antibodies of a certain isotype.  The final output from this scan is a 
distribution of intensity numbers corresponding to each peptide in the array.  There are a variety 
of techniques for characterizing a distribution of numbers and compressing this information into a 
single quantitative value.  This quantitative value can then be used for statistics and direct 
comparisons to other samples that have been applied to the array.  The following quantitative 
measures were used in this research: entropy, minimum, maximum, coefficient of variation, 
standard deviation, mean, median, 5th percentile, 95th percentile, kurtosis, skew, and dynamic 
range 19-22.  These measures combined define the AbStat which can be used to distinguish 
healthy and disease states. 
All of these measures characterize the fluorescence intensity distribution in slightly different 
ways.  Data from the peptide microarrays is often median normalized by dividing the fluorescence 
intensity of each feature by the median fluorescence intensity of all of the feature intensities.  This 
median normalization allows data from different experiments and times to be compared.  Median 
normalizing the data changes the values of some of the measures but not others.  The following 
AbStat measures remain unchanged when analyzing raw data or data that has been median 
normalized: entropy, coefficient of variation, kurtosis, skew, and dynamic range.  All of the other 
measures will have different values depending on whether the data has been median normalized 
or not.  The minimum and maximum values are simply the lowest and highest values of the 
fluorescence intensity distribution.  The mean aids in defining the “middle” of the distribution, and 
the median does the same but is less affected by outliers.  The standard deviation indicates the 
level of dispersion from the mean.  The coefficient of variation is a normalized measure of 
dispersion and is defined as the ratio of the standard deviation to the mean.  The 95th percentile 
defines the intensity value which is greater than 95% of all of the other intensity values, the 5th 
percentile defines the intensity value which is greater than 5% of all of the other intensity values, 
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and the dynamic range is defined as the ratio of the 95th percentile to the 5th percentile.  A high 
dynamic range indicates that there is a wide range of intensities in the distribution.  The kurtosis 
is the measure of "peakedness" of a distribution, and higher values indicate tighter peaks.  The 
skewness measures the extent to which a distribution "leans" to one side of the mean.  The 
skewness can be positive or negative with zero skew indicating that the distribution is symmetric 
about the mean without leaning to one side.  A large positive value would indicate that there is a 
long tail on the right side of the distribution with most of the mass on the left.  Larger absolute 
values of skew would indicate a greater degree of lean. 
1.1.3 Nature of entropy measure 
One measure which distinguishes between healthy and disease samples the best among 
these measures is entropy, and evidence for this fact is provided in Section 1.3.8 Rank of 
Measures in this dissertation chapter (crosslink here: 1.3.8 Rank of Measures).  Entropy takes on 
a value of zero when all of the numbers in a distribution have the same value, and the value 
increases as the distribution becomes more heterogeneous.  The maximum value for entropy 
occurs when each value is represented one time.  This is the type of distribution that is most 
similar to the distribution produced by a random number generator since this algorithm will 
produce each value with an equal likelihood.  The maximum possible value of entropy depends 
on the number of elements in the distribution.  If there are more elements in the distribution, then 
the maximum possible value of entropy is higher.  Entropy can also be conveniently normalized to 
a value in-between zero and one by dividing the value of entropy by the logarithm (with the same 
base used in the entropy calculation) of the number of possible values in the distribution.  Note 
that median normalizing a dataset does not affect the value of entropy.  In order to calculate the 
entropy, one must count the number of times that each unique value occurs, and the number of 
unique values does not change if all of the numbers are multiplied or divided by the same 
number.  
How is the entropy of the fluorescence intensity distribution calculated, and how is this 
entropy related to statistical thermodynamic entropy and information entropy?  The mathematical 
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concept of entropy was first developed during the 1800s as scientists found that some energy 
was always lost and not transformed into useful work in combustion engines.  The first 
mathematical formulation of entropy was put forth by Rudolf Clausius in English in 1856, and this 
representation consisted of bulk quantities that do not consider the state of individual molecules.  
The formulation took on the form of the ratio of the transfer of heat (Q) to temperature (T) 23.  
Ludwig Boltzmann later viewed entropy from a statistical thermodynamic perspective and defined 
entropy in terms of the distribution of microstates of the system in 1877 24, and this was later 
represented in the Gibbs entropy equation (Equation 1).  In 1948, Claude Shannon defined the 
statistical nature of "lost information" in phone-line signals at Bell Telephone Laboratories 22 
(Equation 2).  Shannon was originally unaware that his equation for “uncertainty” was virtually 
identical to the thermodynamic entropy developed by Boltzmann and Gibbs 25.  As a brief aside, 
note that the base of the log only affects the units of the result.  In information theory, the base of 
the log used is often base 2 which results in bits.  Using base 10 results in units of dits, and using 
a base of e (the base for the natural logarithm) results in units of nats.  Specifically, Shannon 
information entropy is a measure of the uncertainty of a system represented by discrete 
outcomes or “information”, and this uncertainty is defined by the number of bits necessary to 
define the information.  An alternative to this definition is that entropy is the average minimum 
number of yes-no questions necessary to identify an item randomly drawn from a known and 
discrete probability distribution 26.  High entropy indicates there is a high degree of uncertainty 
and more information is necessary to define the system. 
 
Equation 1 Gibbs entropy 
Gibbs entropy where kb is the Boltzmann constant (usually expressed in units of Joules/Kelvin), 
and p(x) is the probability of a microstate. 
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Equation 2 Shannon information entropy 
Shannon information entropy where p(x) is the probability of outcome x 
Although both the statistical thermodynamic entropy and the Shannon information entropy 
equation operate on different input (microstates or energy vs information), they both measure 
how homogenous or heterogeneous a distribution is.  For example, in the statistical 
thermodynamic form of entropy, a distribution in which many molecules all have the same energy 
level would have a lower entropy than a distribution in which the energy levels of all of the 
molecules are more evenly distributed.  A bucket of liquid water has a lower entropy than the 
same water molecules in the form of steam since the molecules in the liquid form will occupy 
fewer energy levels.  Also, note that steam at a higher temperature would occupy more possible 
energy levels than steam at a lower temperature.  In this example, the energy level histogram 
with a more homogenous distribution with a peaked shape (liquid water) would have a lower 
entropy than the energy level histogram with a more heterogeneous distribution with a broader 
peak (gas) since the gas will have molecules at very low energy levels occupied in the water state 
as well as very high energy levels only occupied in the gas state. 
Note that in the high entropy configuration of water molecules there are many more 
possible ways to set the energy level for each molecule to achieve the same frequency of energy 
levels, i.e. more possible microstates, whereas a low entropy configuration allows for fewer 
variations in which molecule occupies which energy level.  Many of the molecules need to occupy 
the same energy level.  When transitioning from a liquid to a gas there is an increase in entropy 
because there are more possible microstates or configurations in the gas than in the liquid.  A low 
entropy energy distribution in a gas is very unlikely because it is very unlikely that many of the 
gas molecules will suddenly occupy the same energy level.  Instead the energy levels will be 
more evenly distributed, i.e. more randomly distributed.  More molecules will occupy the same 
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energy level in a liquid.  Therefore, high entropy configurations are more likely to occur by chance 
since there are more possible ways to randomly arrive at such configurations. 
In information theory, the entropy can be determined from the frequency of values for all of 
the elements contained in an object of information.  For example, the entropy of the message 
“aaaa” would be lower than the entropy of the message “abcd”.  The first message would have a 
more homogenous frequency distribution since all of the values are “a”, but the second message 
would have a more heterogeneous distribution with a higher entropy since “a”, “b”, “c”, and “d” 
occur with an equal frequency/probability.  Distributions with higher entropy in which the letters 
occur with equal probability have more possible states than lower entropy distributions, and they 
are therefore more likely to occur by chance.  This is not just true in this particular example, but 
with any example of information.  An object of information with high entropy in which all of the 
elements of information occur with equal probability have more possible states than low entropy 
versions of the same type of information.  Therefore, high entropy objects are easier to generate 
with a random information generator than low entropy objects because there are more possible 
ways to end up in a high entropy state.  In order to clarify this point, let’s revisit the “a”, ”b”, ”c”, ”d” 
example.  Note that there are only four ways to write a four character message in which all four  
positions have the same  letter (“aaaa”, “bbbb”, “cccc”, “dddd”), but there are 24 ways (4!=24) to 
write a message with equal frequency for all four letters (“abcd”, “abdc”, “acbd”, etc.).  Therefore, 
a random letter generator has 24 ways that it could randomly generate one of the highest entropy 
four character messages, but only four ways of generating the lowest entropy four character 
message (“aaaa”, “bbbb”, “cccc”, “dddd”). 
In summary, entropy is essentially the disorder of a distribution.  The most disordered state 
is the state that is most likely to occur by chance, and this occurs when all of the different 
elements of the distribution have an equal probability of having any value.  The lowest entropy 
state occurs when all of the different elements of the distribution have exactly the same value, 
which is less likely to occur by chance.  In other words, a high entropy number distribution is most   
easily reproduced by a random number generator, whereas it is very unlikely for a random 
number generator to produce a low entropy number distribution in which most of the numbers 
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have the same value.  Therefore, entropy can measure how random a system is.  Extending this 
concept further, many people have a general notion that living systems are ordered and non-
random 27.  Therefore, perhaps as a living system becomes more or less ordered from the norm, 
this deviation will indicate a progression toward a disease state, and the living system will 
become less lifelike.  However, more rigorous scientific data is needed to support this notion. 
Since entropy can provide a quantitative value for the homogeneity of a frequency 
distribution, this concept could also be applied to other types of distributions that do not derive 
directly from thermodynamic microstates or energy or information.  Actually, any system can 
ultimately be represented as information.   In order to calculate the entropy of the fluorescence 
intensity distribution resulting from the application of antibodies to a non-natural sequence 
peptide array, one can simply determine the frequency that each intensity value occurs.  With the 
data analyzed in this work, the intensity is acquired from a 16 bit TIFF image, and therefore the 
intensity can have a value ranging from 0-(2^16-1) or 0-65,535.  The entropy can be calculated 
from the histogram of the fluorescence intensities.  A peptide distribution in which there are three 
peptides with intensity values of 5, 5, and 768 respectively would have an entropy value of           
–(2/3*ln(2/3) + 1/3*ln(1/3))=0.637.  A homogenous distribution in which all of the intensities are 
very near 0 would have a very low entropy since all of the peptides have nearly the same value.  
A heterogeneous distribution in which all of the different peptides have different intensities 
resulting in a large dynamic range would have a higher entropy.   
Characteristics of the antibody repertoire such as the number of antibodies, the affinity of 
the antibodies for their target sequences, and the avidity of the antibodies will affect the shape of 
the resulting fluorescence intensity distribution which will be reflected in the quantitative value of 
the entropy of the distribution.  As one quick example, if a monoclonal antibody were applied to a 
non-natural sequence peptide array, and this monoclonal antibody has a very low affinity for its 
target sequence but binds randomly with a variety of intensities to other peptides, then this 
monoclonal antibody would have a higher entropy than an antibody which binds tightly to all 
peptides with its target sequence with similar intensity.  Antibodies with low specificity that bind 
randomly will result in a higher entropy than antibodies with very high specificity and non-random 
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binding.  Additionally, an antibody mixture with many different specificities with different affinities 
will result in a higher entropy than a mixture in which more of the antibodies are against a single 
target with similar affinities.  Therefore, entropy is one of the key measures in the list of measures 
used to define the AbStat for an organism. 
1.1.4 Entropy with previous biological data 
Using the concept of entropy to provide quantitative correlations with health and disease 
states has been explored previously.  The concept has been used with data associated with 
cancer, the heart, the brain, the immune system, and infectious diseases.  The entropy of these 
various biological data has also been investigated with regard to age, and changes during the 
aging process have been observed.  These previous research projects provide a foundation and 
framework of concepts which the AbStat can integrate into.  As far as I know, the antibody profile 
has not been used for this type of assessment.  Ultimately, the entropy measurement can be 
used to assess the health of many different biological systems, and the immune system is an 
ideal candidate system for health assessment. 
There are several papers relating the entropy of biological data with cancer.  Many 
datasets have been analyzed, and the result demonstrates that genomic entropy calculated from 
aberrations in DNA copy number is higher in a variety of cancer types 28.  Additionally, the 
increase in genomic entropy is correlated with an increase in gene expression entropy.  A 
separate mathematical study claimed that the increased mortality rates and cancer rates with age 
observed in models such as the Gompertz equation, Weibull function, and Strehler-Mildvan 
modification of the Gompertz equation can be associated with increased informational entropy of 
the genome with time 29.  The author also suggests that increased genomic informational entropy 
can even be caused by mutations induced by thermal noise over time in the absence of chemical 
mutagens and radiation.   
In addition to DNA focused studies, the entropy of RNA has also been investigated.  The 
entropy of alternative splicing in cancer cells was explored, and the results demonstrate that the 
alternative splicing entropy is significantly higher in 13 of 27 cancers investigated when compared 
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to normal tissues of the same anatomical site 30.  The distribution of splicing isoforms present in 
cancer cells was much broader and flatter, resulting in a higher entropy.  Interestingly, the genes 
that presented the highest entropy in their splicing isoform distribution are splicing factor genes 
themselves.  The study also found that there was a positive linear correlation (correlation 
coefficient of 0.81) of proliferation level and entropy value for tumors.   
If we zoom out from the DNA and RNA level, we find that the entropy of the cell at higher 
levels has also been determined.  In one study, the entropy of structural and numerical 
chromosomal aberrations were compared among 14 solid tumor types in 1,232 karyotypes 31.  
Some cancer types such as lung cancer typically had higher entropy values than other tumor 
types, and high entropy values were associated with a shorter mean survival time for the patients.  
In another study, researchers discovered that the entropy of a random walk on the protein 
interaction network graph was higher in cancer cells than normal cells in all of the 6 different 
cancer tissue types investigated 32.   
Cancer data at the tissue level has also been examined.  Histological analysis of 
photographs of tumor tissue at various magnifications also benefits from the use of entropy as a 
measure to distinguish normal from tumor tissue 33.  In the histological study, three measures 
were suggested as particularly useful for diagnosing a sample as a tumor sample using tissues 
from 34 prostate tumor samples, 34 benign hyperplastic samples, and 34 normal prostate 
samples: fractal dimension, cell nuclei number, and entropy.  All three of these measures were 
determined from an image file of tumor tissue.  Researchers have also calculated the entropy of 
data from thermal images of women with or without breast cancer.  They were able to use these 
results and other attributes of the thermal image along with classification algorithms to classify 
samples as cancer better than would be expected by chance 34. 
Researchers have correlated health conditions with the entropy of biological data related to 
the heart.  In one study, researchers discovered that the “band limited transfer entropy” 
decreases with age as heart rate complexity also decreases 35.  In the study, the heart rate, 
respiration rate, and blood pressure were monitored for 20 young subjects aged 21-34 years old 
and 20 older subjects aged 68-85 years old as they watched the movie Fantasia from Disney.  
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The researchers then used sophisticated non-linear dynamics techniques to calculate the joint 
entropy and conditional entropy to determine the contribution of respiration and blood pressure 
data to correlate with heart rate complexity.  They found that the lag between respiration and 
heart rate was longer in older subjects and the entropy calculated from the data was decreased in 
older subjects.  This age associated effect was more pronounced in the males than the females.  
Another group found that the spectral entropy of electrocardiogram (ECG) data recorded during 
sleep was negatively correlated with age 36.  In another study, the researchers calculated the 
entropy of magnetocardiography data, input these entropy values into a multilayer perceptron 
neural network as training data, and then classified whether heartbeats were from patients with 
coronary artery disease or normal individuals with 98% accuracy 37.  The entropy of one of the 
regions of interest in the magnetocardiography data was considerably lower in the patients 
diagnosed with coronary artery disease. 
Several researchers have used entropy associated with biological data for the brain.  One 
group correlated an increase in entropy in fMRI data with age in a very large dataset with 1,248 
samples 38.  The entropy measured the dispersion of the functional connectivities that exist within 
the brain.  In addition to a correlation with age, they found that males exhibit a higher increase of 
entropy with age then females.  They also discovered that schizophrenic patients had a lower 
functional entropy than normal people.  This result illustrates that normal individuals fall within an 
entropy range, and a value too high or low from this range can indicate a deviation from optimal 
health, and this also turns out to be the case with AbStat as well.  Another MRI study investigated 
the entropy of the cortical structure complexity determined from images constructed from MRI 
brain data 39.  They determined that this entropy increases with age, and the value of the entropy 
was also higher for Alzheimer’s patients compared to age-matched controls. 
In other studies, researchers have measured the ability of the brain to process information.  
For example, researchers measured the ability of the brain to process linguistic information at 
different ages 40.  The researchers asked old and young adults to identify and repeat words which 
had high or low response entropy.  For example, a word with a very high response entropy would 
occur in a neutral context such as in the sentence: “The word is __.”.  The final word in this 
 13 
sentence could be many different words resulting in a very large degree of uncertainty.  On the 
other hand, a word with a very low response entropy would occur in a sentence such as “He 
wondered if the storm had done much __”.  Based on the responses from 100 previous 
volunteers, the final word in this sentence has a very high probability of being “damage” so there 
is less uncertainty (and lower response entropy) in this “high context” situation.  Older individuals 
failed to identify the last word of the sentence more often than younger individuals even in low 
entropy response situations, and the researchers make the argument that this is not due to the 
loss of hearing acuity that occurs with age.  In short, the concept of entropy can also be 
correlated with the ability of the aged brain to process linguistic information.  In a more visually 
oriented study, older individual’s display a higher variability in an attempt to remember the 
location of an object, and the researchers claim this is due to a higher entropy in neuronal 
processing 41.  They create some new terms for their molar entropy model for spatial memory and 
suggest that the slower processing speed and less accurate outcomes of older individuals is 
caused by increased neuronal noise or “computational temperature”. 
In one study, the researchers did more than just monitor the entropy of the brain, they 
intervened and changed the entropy.  In the study, they found that rhesus monkeys with induced 
Parkinson’s disease exhibited an increased level of neuronal firing entropy in the subthalamic 
nucleus area of the brain compared to the entropy in the control group of rhesus monkeys 42.  
They then implanted an electrode into the brain and induced high frequency stimulation or low 
frequency stimulation.  High frequency stimulation resulted in lower entropy and a reduction of 
Parkinson’s disease symptoms, whereas low frequency stimulation increased entropy and 
exacerbated symptoms. 
Researchers have also investigated the entropy of data associated with the immune 
system, but no one has investigated the entropy resulting from antibodies reacting with an array 
of thousands of peptides as outlined in this dissertation since this technology is relatively new.  
Several of these immune research projects are related to the entropy of the sequences of viral, 
antibody, or MHC elements.  One group explored the sequence positional entropy of 
immunoglobulin C-class and V-class sequences to show that domains can be identified without 
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any structural information 43.  Entropy has also been used to determine whether certain 
immunoglobulin domains in aquatic Antarctic species were highly variable or conserved 44.  Other 
investigations of CDR entropy without the use of structural information have also been performed 
45.  Inside a cell, the chromatin textural entropy of erythroid precursor cells in the mouse spleen 
also increases with age 46.  Note that entropy calculations have not been restricted to 
immunoglobulins as the entropy of MHC class II promoters has also been investigated 47. 
Several studies explore the entropy of infectious diseases.  One study found that the rate 
of HIV virus escape depended on the sequence entropy of the epitope targeted by the immune 
system of individual patients 48.  In another study, they found that the most effective T cell 
responses against HIV occurred when the entropy of the overlapping peptides targeted was low 
49.  A different study found that the entropy of viral types present in the blood decreased when 
immunosuppression drugs were administered after an organ transplant 50.  Therefore, one viral 
type became predominant.  Entropy has also been used to measure the diversity of sequences in 
the influenza virus associated with antibody binding, and the investigators used this entropy 
metric to determine which regions of the virus were evolving most rapidly 51.  The entropy of 
epidemiological data has also been explored as researchers used a maximum entropy model to 
reliably predict the distribution of malaria in Africa 52.  Using this model, they found that the most 
important factor associated with malaria risk was human population density. 
One group developed a method for determining the conformational entropy of protein-
protein interactions 53.  They then found that the conformational entropy of the immunoglobulin 
CDR3 region is significantly correlated with kinetic and affinity constants.  They then go one step 
further and propose an algorithm to replace amino acids with prolines to restrict conformational 
flexibility and increase antibody affinity. 
Immune disorder from the viewpoint of more traditional thermodynamic entropy associated 
with antibody binding rather than information entropy has also been explored.  For example, in 
one study researchers used isothermal titration calorimetry to identify the thermodynamic entropy 
change that occurs when the broadly neutralizing 2F5 antibody binds to the HIV gp41 protein 
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epitope 54.  Isothermal titration calorimetry has also been used to determine the change in entropy 
when antibodies bind to high-molecular-weight capsular polysaccharides 55. 
The entropy of immune structures has also been investigated.  The germinal center texture 
entropy from photographs was negatively correlated with the number of plaque-forming cells 56.  
Another study found an increase in information entropy and structural disorganization during the 
course of proinflammatory diseases 57.  Therefore, just as with cancer, the entropy of the immune 
system has been calculated from many different types of data at many different levels of 
biological organization. 
In addition to some of the studies mentioned previously with the heart, brain, and immune 
system which associated entropy measures with age, there are also other measures.  One 
biological characteristic that increases with age is the entropy of DNA methylation.  Researchers 
demonstrated that the methylation changes of the DNMT1 gene, which itself codes for a DNA 
methyltransferase, exhibited aging-driven entropy characteristics in a White Leghorn chicken 
model 58.  A larger study in humans with two different cohorts with an n of 482 and 174 with an 
age range from 19 to 101 has also been performed, and the researchers also found a correlation 
between the entropy of methylation and age 59.  Another author has discussed the general 
concept of an increase in entropy among many biological systems with age 27. 
There are a few trends in these research articles which address the entropy of biological 
data.  In all of the studies, the value of entropy increases with age, with the exception of the heart 
studies.  The complexity of heart rate data actually decreases with age.  Additionally, higher than 
normal entropy values are correlated with disease states such as cancer.  Normal healthy states 
are demonstrated or implied to fall within a certain entropy range, and values that are too far 
above or below this range indicate a problem with the system.  As an example of an entropy 
value that was too low, schizophrenic patients exhibited lower than normal entropy values 
associated with fMRI data as mentioned previously 38.  All of this collective information supports 
the ideas that entropy is an important measure correlated with health states, healthy systems 
exhibit entropy within a certain range, and that entropy tends to shift away from this normal range 
with age. 
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One could argue against the significance of these ideas.  All of these studies start with two 
diagnosed conditions, and then look for entropy differences.  We already know that there are two 
distinct groups so it is almost circular to show that the entropy between the two groups is different 
– not necessarily in a predictable direction.  Therefore, what good is this entropy measurement 
for this biological data?  The first point to counter this argument is that there is no guarantee that 
the entropy measure would have been different between the two groups.  Many other metrics 
would fail to exhibit a statistical difference.  For example, in my own AbStat analysis, many of the 
metrics were not significantly different between the groups.  One of the simplest examples of this 
is with the maximum value metric.  The maximum value was often exactly the same between 
normal and disease groups.  Other metrics were often not exactly the same, but failed to be 
statistically different.  Therefore, the fact that entropy is significantly different between the two 
groups is interesting in itself.  The second point that makes the entropy measure noteworthy is 
that this measure may reveal some interesting attributes about the mechanism of the diseases in 
question.  Entropy is a measure of how chaotic a system is, or to think of the metric another way, 
how likely it would be for a random information generator to produce the system.  Therefore, 
since cancer systems tend to have a higher entropy than normal systems, as suggested via 
numerous types of biological data, then this may imply that a progression towards cancer is also 
a progression of the cell towards more chaotic behavior.  This observation provides a perspective 
for viewing cancer which could lead to new discoveries and treatments. 
The entropy measure has been applied to many different types of biological data in 
numerous studies, but the AbStat measure is unique for a few reasons.  The first reason the 
AbStat measure is unique is that it combines entropy with many other global measures to boost 
the power of classification and diagnosis even further.  This type of combination with this many 
global attributes was not performed in any of the articles previously reviewed.  The second 
reason that the AbStat is unique is that it determines the entropy calculated from the interactions 
of antibodies with a large number of peptides rather than from the original source of the health 
problem.  The nature of the response of the immune system can often determine the outcome of 
the patient.  Since the immune system plays a very large role in the health of the patient, and 
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since the immune system responds to many different problems in the body, using the immune 
system to provide information about the body is a logical strategy. 
1.1.5 AbStat applications 
The AbStat measures were used to analyze many different types of samples and datasets.  
The behavior of these measures during controlled antibody experiments was investigated.  The 
behavior of these measures before and after mouse vaccines and infections, human vaccines, 
lymphomas which decrease antibody repertoire complexity, mouse cancer progression, human 
disease, and changes with age was analyzed.  Throughout the analysis of this data, trends can 
be identified which can be used to predict the outcome of other datasets, and the interpretation of 
the results from one experiment to another is fairly compatible.  In general, antibody solutions 
which are more similar to a monoclonal antibody will have a fluorescence intensity distribution 
with tight “ordered” peaks, whereas antibody solutions which have many different antibodies with 
many different affinities, particularly low affinities for their targets, result in broad “chaotic” 
fluorescence intensity distributions.  The broadness and degree of chaotic behavior of the 
fluorescence intensity distribution is quantitated quite well with the entropy measure.  A thorough 
analysis of the ranking of all of the measures for their ability to distinguish healthy from disease 
and aged states reveals that entropy is indeed one of the best measures to capture differences in 
these states.  However, all of the metrics measure slightly different characteristics of the 
fluorescence intensity distribution, and there is power in using them all together as input for 
standard classification algorithms such as SVM and classification trees. 
The AbStat could prove useful for a variety of different situations, including situations which 
cannot be imagined at the present time.  For example, individuals could obtain their AbStat on a 
regular basis.  They would be able to observe changes in this measure when they have a vaccine 
or develop an infection such as the common cold.  With a large population undergoing constant 
monitoring, trends in lifestyle patterns could be correlated with certain AbStat values and health 
states.  This information could be used to improve the health of the population by motivating 
individuals to make changes that can be observed in the AbStat feedback.  The AbStat could also 
 18 
be used to help diagnose whether someone has a serious illness such as cancer.  If the AbStat 
measures of an individual are far from normal, then this could prompt further investigation into the 
exact nature of the problem.  The behavior of the fluorescence intensity distribution when 
antibodies bind to a non-natural sequence peptide array can provide information about health, 
and the patterns identified from constant data collection could ultimately be used to improve 
health. 
1.2 Materials and Methods 
1.2.1 Array platforms 
Two different non-natural sequence peptide array platforms were used: one platform 
consisted of an array of 10k peptides (CIM10K) and the other platform consisted of an array of 
330k peptides (HT330K).  There were actually two different CIM10K platforms.  The 10k 
platforms consist of 10k 20 amino acid peptides with sequences of 17 amino acids that were 
randomly generated, and these peptides covalently bind to a glass slide 60.  The three amino 
acids of the peptide sequence were constant as glycine, serine, cysteine 61.  These three amino 
acids formed the linker for attachment to the aminosilane coated glass surface.  This linker is on 
the carboxyl terminus for CIM10Kv1 and on the amino terminus for CIM10Kv2.  The CIM10Kv1 
arrays were produced by spotting peptides synthesized by Alta Biosciences using a NanoPrint 
LM60 microarray printer (Arrayit, Sunnyvale, CA).  For CIM10Kv2, the peptides were synthesized 
by Sigma Genosys (St. Louis, MO), and they were printed by Applied Microarrays (Tempe, AZ) 
using a piezo non-contact printer. 
The 330k platform was based on the fabrication of 330k peptide microarrays on a silicon 
wafer.  This platform also makes use of peptides selected from random space to maximally 
distribute the peptides in that space.  On this platform, not all of the peptides have exactly the 
same length, but the average length is 12 amino acids.  The manufacturing process used borrows 
many techniques from the electronics industry during the production of computer processor chips.  
Once the peptides were synthesized onto the silicon wafer, the arrays were deprotected and 
soaked overnight in DMF.  The arrays were then stepwise transitioned to an aqueous solution.  
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The residual DMF was removed by two 5 min washes in distilled water, the arrays were soaked in 
PBS for 30 min, blocked with an incubation buffer (3% BSA in Phosphate Buffered Saline, 0.05% 
Tween 20 (PBST)), washed, and then spun dry.  At this point the, the arrays were ready for the 
application of sera. 
1.2.2 Array procedures with samples 
The data I analyzed throughout this chapter was obtained by applying antibodies to 
peptide microarrays.  These experiments were performed by other researchers in the Center for 
Innovations in Medicine.  The key researchers who performed the different experiments will be 
briefly listed.  The “1.3.1.1 Monoclonal affinities and AbStat Measures” experiment was performed 
by Rebecca Halperin; the “1.3.1.2 Spiking antibody into sera” experiment with antibodies against 
the GFOD1 protein was performed by Josh Richer; the “1.3.1.2 Spiking antibody into sera” 
experiment with antibodies against the gp120 HIV protein was performed by Heidi Larsen and 
Bart Legutki; the “1.3.2 Mouse vaccines and infections” (“1.3.2.1 246 day time course”, “1.3.2.2 
Multiple mouse immunizations”, and “1.3.2.3 6 day time course”), the “1.3.4 Reduction in antibody 
repertoire complexity with lymphoma”, and the “1.3.7.1 Changes with age in mice” experiments 
were performed by Bart Legutki; the “1.3.5 Mouse cancer progression” experiment was 
performed by Hu (Tiger) Duan; the “1.3.6.4 Alzheimer’s disease” experiment was performed by 
Lucas Restrepo; the “1.3.3 Human vaccines”, “1.3.6.1 HT330K first chip disease dataset”, 
“1.3.6.2 HT330K wafer 46”, “1.3.6.3 CIM10K”, and “1.3.7.2 Changes with age in humans” 
experiments were performed by the Peptide Array Core under the direction of Zbigniew Cichacz.  
The description of the procedure for the experiments with sera samples and peptide microarrays 
performed by these researchers follows. 
The general assay conditions have been published previously 10, 62-64, but they will briefly 
be described here as well.  The procedure for applying sample to the arrays of the two different 
types of platforms is nearly identical, and less than 1 µl of sample is required.  For the CIM10K 
platform, the microarrays are pre-washed in 10% acetonitrile, 1% BSA to remove unbound 
peptides.  Then the slides are blocked with 1XPBS pH 7.3, 3% BSA, 0.05% Tween 20, 0.014% β 
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-mercaptohexanol for 1 hr RT.  Without drying, slides are immersed in sample buffer consisting of 
3% BSA, 1X PBS, and 0.05% Tween 20 pH 7.2.  Serum is diluted 1:500 and applied to the 
peptide array for 1 hr at 37 0C.  The slides are washed in 1X Tris-buffered saline with 0.05% 
Tween 20 (TBST) pH 7.2.  Then a mouse anti-human secondary antibody conjugated to a dye is 
applied to the array.  The slides are washed again as before and dried by centrifugation.  The 
slides are then scanned in an Agilent ‘C’ scanner to determine the intensity of each peptide. 
For the 330k platform, the arrays were loaded into a multi-well Array-It gasket.  Then a 
volume of 100 µl of incubation buffer was added to each well, and then 100 µl of 1:2,500 diluted 
sera was added for a final concentration of 1:5,000.  Arrays were incubated for 1 hr at room 
temperature (RT) with rocking, and then washed with PBST using a BioTek 405TS plate washer.  
An anti-human IgG-DyLight 549 secondary antibody with a conjugated dye (KPL, Gaithersburg, 
MD) was added to the sera at a final concentration of 5 nM.  This solution was incubated 1 hr at 
RT with rocking, and unbound secondary was then removed with PBST followed by distilled 
water.  The arrays were removed from the gasket while submerged, dunked in isopropanol, and 
centrifuged dry at 800Xg for 5 min.  These arrays were then scanned with a commercially 
available scanner to determine the intensity of a certain wavelength at each peptide feature 
position. 
Once the 16 bit TIFF image file from either type of array was obtained, the intensity 
values from each feature were obtained using GenePix 8.0 (Molecular Devices, Santa Clara, CA).  
I then used these intensity values as input to obtain the AbStat. 
1.2.3 Mathematical measures 
The AbStat is composed of several measures which are calculated from all of the 
intensity values from the fluorescence intensity distribution obtained from reacting antibodies with 
an array of non-natural sequence peptides.  The final output for each measure of the 
fluorescence intensity distribution is a single number.  The AbStat consists of the following 
measures: entropy, minimum, maximum, coefficient of variation, standard deviation, mean, 
median, 5th percentile, 95th percentile, kurtosis, skew, and dynamic range.  The following 
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measures do not change when working with median normalized data or raw data: entropy, 
coefficient of variation, kurtosis, skew, and dynamic range.  For the numbers that do change, the 
value from raw data and the value from normalized data were both included in the list of AbStat 
measures.  The values are calculated by a custom Java program, but the resulting values match 
the values that would be obtained by the corresponding function in Excel, with the exception of 
entropy since entropy is not a default function in excel.  The minimum, maximum, mean, standard 
deviation, and median are all calculated using very common formulas.  The coefficient of variation 
is the ratio of the standard deviation to mean.  The dynamic range is defined as the ratio of the 
95th percentile to the 5th percentile.  The equations for Shannon information entropy (Equation 2), 
kurtosis (Equation 3) 65, and skew (Equation 4) 65 are presented.  The procedure and equations 
for calculating the percentile is presented in Equation 5 65. 
 
 
Equation 3 Kurtosis 
Kurtosis where n is the number of elements, xj is element j, xˉ  is the mean, and s is the standard 
deviation. 
 
 
Equation 4 Skew 
Skew where n is the number of elements, xj is element j, xˉ  is the mean, and s is the standard 
deviation. 
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Equation 5 Procedure for calculating the value at a percentile 
Procedure for calculating percentile where n is the number of elements, P is the percentile, and ⌊⌋ 
is the mathematical floor function to obtain the integer part of a number. 
1.2.4 Java AbStat Program 
A custom Java program was written to determine the numerical values of all of the AbStat 
measures.  Calculating the results can be performed in Excel, but this is not practical for a 
number of reasons.  The data from one 330k array file is contained within a GenePix result (gpr) 
file that is about 40 Mb, and processing this data in excel takes a long time.  In fact, using Excel 
with this data causes many standard desktop computers to freeze for a time before becoming 
operational.  Even if performing the calculations in Excel could be very quick, manually doing this 
for hundreds of different gpr files in each dataset would be impractical.  The custom Java 
program written is much quicker than excel, and it also automatically process hundreds of gpr 
files in a matter of minutes.  Note that the accuracy of the Java program was validated by 
manually obtaining all of the AbStat results of a few gpr files in Excel. 
The program is run by making a call to a Java jar file from the command line, and the 
program has six main capabilities: 1. Calculate measures from one gpr file; 2. Calculate 
measures from a folder of gpr files; 3. Calculate measures from raw data from many samples in 
one tab delimited text file; 4 °Calculate measures from normalized data from many samples in 
one tab delimited text file; 5. Collect many different output files into one table; and 6. Place all of 
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the gpr files in a folder into a new separate folder.  The 5th and 6th capabilities can come in handy 
when there are an extremely large number of files and the user of the program wants to have 
many different instances of the program running, perhaps even on several different computers.  
When the operator is using a gpr file as the input, the name of the column with the intensity data 
is specified, and the program can automatically find this column even if there is a header in the 
file which takes up several rows before the table of data begins.  When the operator is using a tab 
delimited text file as input, the tab delimited text file can be arranged in any possible manner, and 
the row and column at which the data starts along with the column at which the data ends is 
specified.  There is no need to format the table of data in a specific way just for the program. 
The output of the program is a tab delimited text file with columns for the following values: 
name of the gpr file, entropy, normalized entropy, max, min, cv, stdev, mean, median, 5th 
percentile, 95th percentile, max from normalized data, min from normalized data, mean from 
normalized data, 5th percentile from normalized data, 95th percentile from normalized data, 
kurtosis, skew, and dynamic range.  Each row is then filled for each gpr file which came from one 
application of sera to a non-natural sequence peptide array.  The program takes just a few 
seconds to complete per 330k gpr file on a standard pc, which is not possible with Microsoft 
Excel.  Using this program one can very quickly determine the AbStat of a sample. 
This AbStat program is stored at the following location as of this writing: 
“\\biofs.biodesign.asu.edu\CIM\Administration\Biostatistics\Immunosignature Entropy\Code”. 
1.2.4.1 Optimization of Java AbStat Program 
The program underwent many revisions before it could quickly calculate all of the 
measures from a large 330k 40 MB data file.  Originally, the program required about 7 min on a 
standard pc to calculate the entropy value from a 10k peptide file, but the program also was much 
more customizable and output much more information at the end.  For example, one could 
specify the size of the bin to use when determining the frequency for the entropy calculation, and 
the program would output all kinds of details such as which peptides were in a certain bin.  Later, 
however, our lab started using 330k gpr files from the new peptide arrays, and the program 
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required about two days on a standard pc to compute the results.  In order to speed up the 
program dramatically, many changes were made such as removing the customization, removing 
the detailed output, and replacing many of the modular Java classes with a single class in which 
primarily primitive types were used such as int and double arrays rather than storing values in the 
more flexible ArrayLists which would often need to be converted to Strings and then double 
values.  In this lean and fast version of the program, many options are not customizable.  Options 
which seemed useful initially were not necessary for accomplishing the ultimate goal of acquiring 
information from the peptide arrays which can distinguish between healthy and disease states.  
The end result of these various optimizations was a very lean and fast program, even on large 
datasets.  
1.2.5 Methods of analysis 
The custom AbStat Java program was used to obtain the measures for each sample.  This 
Java program was written using the Eclipse IDE for Java developers (Kepler Service Release 1) 
66.  Then several methods and programs were used to analyze the AbStat measures in the 
different datasets.  Grouped box and dot plots of the measures for many samples were often 
used to get an overview of overall differences between groups.  These box and dot plots were 
created using Deducer (version 1.7-9) 67, which is a graphical user interface for the R statistics 
software (version 2.15.0) 68.  Student’s t-test was performed in Microsoft Excel 2013 (version 
15.0.4551.1003) 69 to obtain a p-value and determine if there was a significant difference between 
groups.  Hierarchical clustering of the measures for many samples was performed using the JMP 
software (JMP Pro 11), and heatmaps were also made from these hierarchical clusters in JMP 70. 
Classification machine learning algorithms were also employed using the Weka software 
(version 3.6.10) 71.  The SMO algorithm (support vector machine using sequential minimal 
optimization) support vector machine (SVM) was used for input in which there were samples with 
a given classification (a classification with one of two values) 72, and the attributes for each 
sample were all of the measures.  All of the default values of the SVM were applied, and 10-fold 
cross validation was used to train and test the machine learning algorithm.  The absolute values 
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of the SVM weights of the measures were often presented in a bar graph to visually determine 
which measures were the most critical in order for the SVM to distinguish between two classes.  
Although the SVM classifier can often perform very well, this algorithm is somewhat like a black 
box and provides the user with little information about how it is making the decision to assign a 
certain class to a sample.  Therefore, a J48graft tree algorithm was also employed.  This 
algorithm outputs a tree displaying which ranges of values for certain measures are associated 
with certain class assignments.  All of the default values for the tree were used, and 10-fold cross 
validation was set for the training and testing of the machine learning algorithm.  The tree output 
from the algorithm is often presented as a figure, and the tree is made up of lines such as "cv > 
1.466364: D (46.0/12.0)".  This line indicates that at this level of the tree, if the sample has a cv 
greater than the indicated value, then it is assigned the class of disease.  In this case the 
algorithm made this assignment 46 times and was incorrect 12 times.  A Naïve Bayes algorithm 
was also employed since this is one of the most commonly used classification algorithms in the 
Center for Innovations in Medicine. 
The classification performance with the AbStat measures is also often compared to the 
classification performance using a specific peptide analysis.  A specific peptide analysis was 
performed by choosing the top 100 peptides which distinguish samples from two different groups.  
These peptides were determined by choosing the peptides with the most significant p-value from 
a t-test with the peptide fluorescence intensity values for the samples in the two groups.  
However, performing the t-test to select the peptides with the whole dataset can lead to 
overtraining.  Therefore, the samples were split so that half of the samples were randomly 
assigned to the training set, and the other half was assigned to the test set.  Once the peptides 
were selected, the values for the training set were input into a classification algorithm.  This 
classification algorithm was then used to predict the class of the samples in the test set. 
A table for the machine learning results is also presented for many datasets.  In this table, 
the following values are given: percent of instances that were correctly classified, the kappa 
statistic, and the receiver operating characteristic (ROC) area.  The kappa statistic indicates the 
level at which the classifier performed better than chance.  The larger the value of the kappa 
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statistic from zero, the better the algorithm performed.  Zero or lower indicates poor performance.  
The ROC area is the area under the curve resulting from plotting the true positive rate vs the false 
positive rate.  An area of 1 indicates the best performance, and an area as low as 0.5 indicates 
poor performance.  The tables used also provide data for the performance of the classifier when 
the class of each sample was randomly assigned in a manner so that the total count of normal 
and disease or young and aged samples remains the same as the count before the random 
assignment.  With random class assignment, one would expect the machine learning algorithm to 
acquire little knowledge from the training data, and to perform very poorly when attempting to 
make classifications.  Good performance with the actual class assignments and poor 
performance with random classifications would indicate that the values of the sample attributes 
are capable of distinguishing the classes, and that the classifier is not just finding patterns in 
noise or extraneous data.  Therefore, these machine learning algorithms can help determine 
whether the AbStat measures are useful for diagnosis. 
All of these different methods provide information from different angles about the 
association between certain measures, values, and the state of the sample. 
1.3 Results 
1.3.1 AbStat changes with artificial antibody experiments 
Are there changes in the AbStat measurement with artificial antibody experiments?  For 
example, are there relationships between antibody affinities and changes in the AbStat 
measures?  What happens when increasing concentrations of monoclonal antibody is added to 
sera? 
What prompted these questions?  After examining some preliminary datasets, it was 
clear that there was a difference in entropy between normal and disease groups.  Therefore, I 
had to think of a possible explanation for this difference.  The hypothesis I proposed was that the 
differences in entropy were due to a difference in the number of high and low affinity antibodies.  
This hypothesis is based on the assumption that antibody specificity is correlated with affinity.  
More precisely, the assumption is that antibodies with low affinity for their cognate epitope would 
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have less specificity and bind more chaotically to the peptide microarray.  Antibodies with high 
affinity for their cognate epitope would have more specificity and bind less chaotically to the 
peptide microarray.  This assumption of a link between specificity and affinity is not always true.  
However, the link between the two concepts is hard to investigate quantitatively because 
specificity is rarely quantified by researchers and companies that produce antibodies, whereas 
affinity is often quantified.  Despite these caveats, perhaps there is a relationship between 
antibody affinity and specificity, which would lead to a relationship to the entropy calculated from 
the data from the peptide microarray.  A non-specific antibody would bind to many different 
peptides at a different level for each peptide which would result in varying fluorescence intensities 
and ultimately a high calculated entropy.  A correspondence between entropy and specificity 
could even serve as a new metric for quantitating the specificity of monoclonal antibodies.  The 
following sections address these questions and display changes in AbStat measures with varying 
conditions. 
1.3.1.1 Monoclonal affinities and AbStat Measures 
Understanding the way that antibody affinities affect the AbStat measures is an important 
concept that provides information about the behavior of normal, disease, and age sera.  Antibody 
affinities are different in normal, disease, and aged states.  In order to test the effects of antibody 
affinity, three different antibodies with different affinities for their cognate epitope were applied to 
the peptide array.  Note that the affinity of an antibody will affect how the antibody will bind to its 
cognate epitope, and this will also affect how the antibody binds to an array of non-natural 
sequence peptides.  For example, an antibody with a very low Kd, and thus a very high affinity for 
its cognate sequence, should bind to a few peptides on the array which contain a sequence that 
closely resembles the original cognate epitope.  Therefore, the fluorescence intensity for these 
peptides would be very high, while the fluorescence intensity for all of the other peptides would be 
much lower.  A fluorescence intensity distribution with a few very high fluorescence intensities 
would have a high and tight peak near a fluorescence intensity of zero since most of the features 
would have a very low fluorescence intensity. 
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A low affinity antibody should exhibit a different behavior.  A low affinity antibody would 
not bind tightly to its cognate epitope, and therefore a low affinity antibody would also not bind 
tightly to non-natural sequence peptides containing a sequence similar to the cognate epitope.  
The binding pattern of a low affinity antibody would therefore have less specificity and exhibit 
more chaotic and random binding.  The antibody would bind loosely to a wide variety of different 
features, but none of these features would be expected to have a very high fluorescence 
intensity.  The resulting fluorescence intensity distribution would be a much broader peak near 
zero fluorescence intensity when compared to the tight peak produced from an antibody with high 
specificity and affinity.  The relative values of the AbStat measures can be approximated from the 
shape of the fluorescence intensity distribution. 
The researcher Rebecca Halperin applied three monoclonal antibodies with different 
affinity Kd constants to the CIM10Kv1 non-natural sequence peptide array: mouse IgG1 anti-h-
cMyc antibody from AbD Serotec (Cat No MCA2200G) with a Kd of 80 nM, mouse IgG1 anti-h-
proenkephalin-B with a Kd of 1.95 nM from AbD Serotec (Cat No 4140-0159), and mouse IgG1 
anti-h-p53 with a Kd <0.1 nM from Millipore (Cat No CBL404).  Note that one of the key findings 
from Rebecca Halperin’s research with monoclonal antibodies is that different antibodies exhibit 
vastly different binding distributions since some can bind as much as 70% of the peptides and 
other antibodies only bind 0.1% of the peptides 73.  These very different binding distributions 
should result in different entropy values.  A line graph of the entropy for the three different Kd 
values is displayed (“Figure 1 Entropy of antibodies versus affinity for cognate sites”).  Note that 
the change in entropy is not linear with the Kd which may hint that the relationship between the 
affinity of an antibody for its cognate epitope and the degree of randomness with which this 
antibody binds to a microarray of non-natural sequence peptides is a complex relationship.  More 
data points could help define the relationship more precisely.  A heatmap displaying the general 
trends (increasing or decreasing) for all of the AbStat measures across the Kd range is displayed 
in “Figure 2 Heatmap of AbStat measures for antibodies versus affinity for cognate sites”. 
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Figure 1 Entropy of antibodies versus affinity for cognate sites 
An anti-h-cMyc antibody with a Kd of 80 nM, an anti-h-proenkephalin-B antibody with a Kd of 1.95 
nM, and an anti-h-p53 antibody with a Kd<0.1 nM was applied to a peptide microarray separately.  
The resulting entropy of each sample was calculated and plotted. 
 
Figure 2 Heatmap of AbStat measures for antibodies versus affinity for cognate sites 
Each column corresponds to an AbStat measure and each row corresponds to an antibody.  The 
relative average value of each AbStat measure for three different antibodies is represented by a 
color with blue indicating the lowest relative value and red indicating the highest relative value.  
This indicates for example that the 80 nM antibody exhibits the highest entropy (red) while the 0.1 
nM antibody exhibits the lowest entropy (blue).  Each of the three antibodies represented has a 
different Kd value for its cognate epitope.  The three rows correspond to antibodies with a Kd 
value of <0.1, 1.95, or 80 nM. 
 A histogram and box plot of the raw intensities from one of the gpr files for the <0.1 nM 
antibody is displayed in Figure 3, and a histogram of the raw intensities from one of the gpr files 
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for the 80 nM antibody is displayed in Figure 4.  The high tight peak for the antibody with higher 
affinity (lower Kd) for its cognate epitope may be the result of tight high intensity binding to a few 
peptides with mimotopes to the cognate epitope on the non-natural sequence peptide microarray.  
Therefore, a few peptides bind with high intensity, and the majority of the distribution of peptides 
does not bind well and exhibits a fluorescence intensity near zero.  The antibody with low affinity 
(high Kd) on the other hand, may not bind to mimotopes of its cognate epitope very well and bind 
loosely to many different peptides on the array.  This would result in a broader flatter fluorescence 
intensity distribution as many peptides exhibit a fluorescence intensity above zero, but still at a 
low level. 
 
Figure 3 Histogram and box plot for <0.1 nM Kd antibody 
Histogram of fluorescence intensities of all 10,000 peptides after an antibody with <0.1 nM Kd for 
its target is applied.  The bin width for this histogram is 140.  A box and dot plot is displayed 
above the histogram with outliers displayed as dots.  In this graph, almost all of the fluorescence 
intensities are less than 1,000, and the “box” part of the box and dot plot is not visible. 
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Figure 4 Histogram and box plot for 80 nM Kd antibody 
Histogram of fluorescence intensities of all 10,000 peptides after an antibody with 80 nM Kd for its 
target is applied.  The bin width for this histogram is 140.  A box and dot plot is displayed above 
the histogram with outliers displayed as dots. 
 These results match the predictions.  A high affinity antibody produced a fluorescence 
intensity distribution with a high tight peak near zero.  Figure 3 illustrates that the highest count 
for a given fluorescence intensity bin exceeds 2,500 with a high affinity (low Kd) antibody.  Figure 
4 illustrates that the highest count for a given fluorescence intensity bin is less than 500 for a 
lower affinity antibody.  Therefore, the low affinity antibody produced a fluorescence intensity 
distribution with a much broader flat peak near zero.  This is the result one could expect from 
more random binding.  If we were to use a random number generator to pick 10,000 intensities, 
the result would certainly look more similar to Figure 4 than Figure 3 since a perfectly random 
distribution would appear most like a flat square.  Ultimately, the shape of the fluorescence 
intensity distribution indicates the specificity of the antibody, and these monoclonal antibody 
results support these claims. 
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1.3.1.2 Spiking antibody into sera 
In the previous example, monoclonal antibodies were applied to the array, but this is far 
from a practical case.  In a real situation, the blood will contain a high diversity of many different 
antibodies since there are a total of about 1011 cells in the B-cell population of an individual 11.  
Additionally, the complexity of a whole antibody repertoire can change as a few single antibodies 
against a few targets may come to dominate the mixture.  This scenario can occur when there is 
a strong immune response against a single virus or bacteria type.  Alternatively this scenario 
could also occur when a lymphoma causes a single B cell to proliferate out of control and 
produce many antibodies against a single target.  In these scenarios, the complexity of the 
antibody repertoire is reduced as copies of antibodies against a single target make up an 
increasingly greater portion of the antibody repertoire.  This type of situation was simulated by 
spiking increasing concentrations of monoclonal antibody into sera.  The expectation is that a 
reduction in the antibody repertoire complexity that interacts with the peptide microarray will result 
in a reduction in complexity in the fluorescence intensity distribution.  A lower complexity 
fluorescence intensity distribution will result in changes in the AbStat measures.  For example, 
the entropy will decrease as the concentration of monoclonal antibody in the sera is increased. 
Two experiments were performed in which antibody against a particular target was added 
to normal sera in increasing concentrations.  In the first experiment, polyclonal mouse sera 
against the human GFOD1 protein was added to normal mouse sera.  In the second experiment, 
human monoclonal antibody against the human gp120 HIV protein was added to normal human 
sera.  Rebecca Halperin also wrote about a similar spiking experiment in her dissertation, and 
found that there was no significant change in binding pattern if a monoclonal antibody was 
applied to the array alone or mixed into sera 73.  She was not investigating entropy at that time, 
and was more interested in peptides that uniquely bind to the antibody. 
Polyclonal sera against the human GFOD1 (glucose fructose oxidase 1) protein was 
added to normal mouse sera at increasing concentrations by Josh Richer.  The polyclonal IgG 
mouse antibody was added to a 1:500 dilution of normal mouse sera in order to obtain the 
following final antibody concentrations: 0.1 nM, 1 nM, 2.5 nM, 5 nM, 10 nM, and 40 nM.  There 
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were two technical replicates for each condition applied to the CIM10Kv2 arrays.  A line graph of 
the entropy vs antibody concentration (“Figure 5 Entropy for increasing concentrations of α-
GFOD1 antibody into normal mouse sera”) reveals that the entropy decreases as the 
concentration increases up to 5 nM and then the entropy starts to increase.  The order of the 
measures with the most significant p-values between normal mouse sera and 5 nM antibody is as 
follows: 95th percentile, 5th percentile, median, mean, entropy, and cv.  The concentration of 5 
nM was chosen as the comparison point because this is the point at which the trend in the curves 
reverses.  Note that in Figure 5, the entropy at 2.5, 5, and 10 nM is about the same when error 
bars are taken into account, but the entropy at lower antibody concentrations (0, 0.1, and 1 nM) is 
quite different.  Note also that the error bars at an antibody concentration of 0, 0.1, and 1 nM do 
not overlap.  These observations suggest that entropy is more sensitive to the addition of 
antibody at lower concentrations, and resolution of the entropy measure decreases at high 
antibody concentrations. 
 
Figure 5 Entropy for increasing concentrations of α-GFOD1 antibody into normal mouse 
sera 
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Increasing concentrations of polyclonal sera against the GFOD1 protein were added into normal 
mouse sera and the entropy of each technical replicate was calculated.  The entropy values at 
each concentration are plotted on a line plot. 
 A second experiment was performed by Heidi Larsen and Bart Legutki in which the 
human B12 monoclonal antibody against the gp120 HIV protein was spiked into a 1:500 dilution 
of normal human sera at increasing concentrations and applied to the CIM10Kv2 arrays.  A very 
wide range of antibody concentrations was tested: 0.00128 nM, 0.0064 nM, 0.032 nM, 0.16 nM, 
0.8 nM, 1 nM, 4 nM, 10 nM, 20 nM, and 100 nM.  Two technical replicates were performed for 
each concentration.  Since the range of dilutions tested is so wide, the data was graphed across 
two separate ranges for the entropy (Figure 6 A and B). 
A) 
 
 
 
 
 
 
 
 
6
6.5
7
7.5
8
8.5
0 0.2 0.4 0.6 0.8 1 1.2
En
tr
o
p
y
Concentration (nM)
 35 
B) 
 
Figure 6 Entropy for increasing concentrations of α–gp120 antibody into normal human 
sera 
Increasing concentrations of antibody against the gp120 HIV protein was spiked into normal 
human sera and applied to the HT330K peptide microarray.  The entropy for each replicate at 
each concentration was determined and a line plot was created covering α-gp120 antibody 
concentrations from 0 to 1 nM in A) and 0 to 100 nM in B). 
The results from increasing concentrations of monoclonal antibody into sera support the 
expectations up to a point, but there were also some surprises.  The value of the entropy 
measure did in fact decrease as the concentration of monoclonal antibody in the sera increased.  
However, after a certain point in both experiments, the entropy began to increase again.  This 
result may have been the result of saturation of target peptides on the array by the monoclonal 
antibody.  After a certain concentration was reached, the monoclonal antibody then began to “spill 
over” and bind to a variety of different features on the array in a more chaotic manner.  This 
hypothesis is explored more fully in the discussion section (“1.4.1.2 Spiking antibody into sera”).  
Ultimately, this controlled experiment provides insight into how the AbStat measures can provide 
information about health, disease, and aged sera states as antibody mixtures become more 
complex or alternatively are dominated by antibodies against a few targets.  For example, in a 
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lymphoma, one antibody with one target begins to increasingly dominate the repertoire, and this 
change will result in decreases in entropy up to a point. 
1.3.2 Mouse vaccines and infections 
Are there changes in the AbStat measurement with artificial mouse vaccines and 
infections?  During an infection or a vaccination, the affinity, avidity and abundance of certain 
antibodies in the bloodstream should change, and this change should be detectable in changes in 
the fluorescence intensity distribution acquired from applying sera with antibodies to a non-natural 
sequence peptide microarray.  The expectation is that the antibody repertoire complexity will 
decrease during a vaccine or infection.  During these events a few antibodies against a few 
specific epitopes will make up an increasing portion of the antibody repertoire, thus reducing the 
total complexity of the repertoire.  This repertoire will produce higher tighter peaks in the 
fluorescence intensity distributions and therefore a lower entropy value. 
There are three experiments to help investigate the issue of mouse vaccines and 
infections: 246 day time course, a multiple vaccine experiment, and a 6 day time course.  The 
246 day time course after a vaccine spans a very long time (more than half a year).  During this 
time the entropy should decrease after a vaccine.  However, as the mice ages, the specificity of 
new antibodies will decrease, and therefore the entropy should increase with time.  This behavior 
is also observed in the “Changes with age” section (“1.3.7 Changes with age”).  In the multiple 
vaccine experiment, different groups of mice are immunized with different vaccines.  The 
expectation is that the entropy of the fluorescence intensity distribution from vaccinated mice 
should be lower than the entropy of the mock vaccinated group.  In the 6 day time course after 
infection the expectation is that entropy would decrease after the mice are vaccinated, unless this 
time interval is too short to observe any difference.  The results from these mouse experiments 
can provide some insight into what might happen during the course of human vaccines and 
infections. 
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1.3.2.1 246 day time course 
Bart Legutki performed an experiment with ten 4-5 week old female BALB/c mice, and 
these mice were vaccinated ("day 0") and challenged with H1N1 A/PR/8/34 influenza 35 days 
later 9.  Serum was collected 0, 14, 28, 51, and 246 days after vaccinations.  The serum was 
applied to CIM10Kv1 non-natural sequence peptide arrays with three technical replicates for each 
timepoint with the exception of day 28 which had two timepoints.  In this experiment, one of the 
key findings was that the immune system of the mice responded to 283 influenza-specific 
peptides after vaccination, and the response to these peptides was present 211 days post-
challenge.  Therefore, the immune response was present over a long period of time 9.  A heatmap 
of the AbStat measures for all of the replicates ranging from day 0 to day 246 is displayed in 
Figure 7.  A line graph of the entropy measure over time is displayed in Figure 8.  The change in 
entropy from day 0 to day 246 is statistically significant with a p-value of 6.79E-3.  During the 
experiment, weights of the mice were collected, and these weights indicated that the mice 
recovered after about 14 to 21 days after infection. 
 
Figure 7 Heatmap of AbStat measures for 246 day mouse time course with 2-3 technical 
replicates for each timepoint. 
Each column corresponds to an AbStat measure and each row corresponds to a replicate mouse 
sera sample after a certain number of days from vaccination with H1N1 A/PR/8/34 influenza.  The 
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mouse samples were applied to the CIM10kv1 peptide microarray.  The relative average value of 
each AbStat measure is represented by a color with blue indicating the lowest relative value and 
red indicating the highest relative value.  This indicates for example that three 0 day samples 
exhibit a lower entropy (blue) than the three 246 day samples (red). 
 
 
Figure 8 Line graph of entropy over time for 246 day mouse time course 
Sera samples from mice after vaccination with H1N1 A/PR/8/34 influenza on day 0 were applied 
the CIM10kv1 peptide microarray.  The mice were challenged with the virus on day 35.  The 
entropy of each technical replicate at each time point was calculated and displayed on a line 
graph. 
 The results of the 246 day challenge were interesting.  The entropy did decrease after 
vaccination after enough days had passed.  Over the long time course the entropy also increased 
as expected.  Therefore, this experiment provided important information about the behavior of the 
antibody repertoire and AbStat measures during the course of a vaccine as well as during the 
normal aging process of a mouse.  Using the AbStat measures it was also possible to distinguish 
between the young and aged timepoints of the mice. 
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1.3.2.2 Multiple mouse immunizations 
Bart Legutki performed an experiment in which different groups of mice received different 
vaccines.  In this experiment, there were a total of four groups: mice infected with the 2006-2007 
influenza vaccine (06_INF_vacc), mice infected with the 2007-2008 influenza vaccine 
(07_INF_vacc), mice infected with influenza (infected), mice injected with formalin fixed PR8 
(killed PR8), and a mock group of mice that received PBS intranasally (mock) 8.   There were 10 
samples in each group with a replicate for a total of 20 peptide array results (gpr files) per group.  
The 2006-2007 and the 2007-2008 vaccine had the same H2N3 strain, same B strain, but a 
different H1N1 strain.  Specifically, the 2006-2007 Fluzone vaccine had the following composition: 
H1N1 A/New Caledonia/20/99, H2N3 A/ Wisconsin/67/2005 and B/Malaysia/2506/20004.  The 
2007-2008 Fluvarin vaccine had the following composition: H1N1 A/Solomon Islands/3/2006, 
H2N3 A/ Wisconsin/67/2005, and B/Malaysia/2506/20004.  The sera was taken from these mice 
on day 38 after treatment, and the sera was later applied to CIM10Kv2 arrays.  The results from 
the experiment revealed that the 2006-2007 vaccine resulted in 60% survival after challenge and 
the 2007-2008 vaccine resulted in 80% survival after challenge 8.  The researchers also found 
that they could identify reactive peptides on the array which distinguished the groups of mice.  
Their analysis revealed that some of the reactive peptides contained epitopes found in the PR8 
virus. 
A graph of the entropy of each group is presented in Figure 9.  The entropy value 
between the mock group and the group which received the 2007-2008 vaccine was statistically 
significant with a p-value of 0.0251, but the entropy value between mock and infected was not 
statistically significant (p-value: 0.530).  Note that the 2007-2008 vaccine was the more effective 
vaccine of the two.  The AbStat measure with the most significant p-value between mock and 
infected was the dynamic range (p-value: 0.0453). 
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Figure 9 Entropy for multiple mouse immunization experiment 
Sera from 5 groups of mice were applied to the CIM10Kv2 array 38 days after an injection with 
the 2006-2007 influenza vaccine, the 2007-2008 influenza vaccine, the influenza PR8 virus, killed 
formalin fixed PR8 virus, or a mock PBS treatment.  There were 10 mice in each group and there 
was an array replicate for each mouse for a total of 20 array results per group.  The entropy of 
each array result was calculated and presented in a bar graph. 
The AbStat measures for the mock and infected group samples were input into a J48graft 
tree and SVM classification algorithm.  A J48graft tree classification algorithm can only correctly 
classify 45% of the instances with a kappa statistic of -0.1 and an ROC area of 0.413.  The SVM 
on the other hand can correctly classify 62.5% of the instances with a kappa statistic of 0.25 and 
an ROC area of 0.625.  The instances were also assigned classes (infected or mock) randomly to 
test whether the SVM performance would remain the same or decrease.  With randomly assigned 
classes, the SVM correctly classified 55% of the instances with a kappa statistic of -0.0496 and 
an ROC area of 0.478. 
 One prediction about this experiment was correct.  There was a vaccine group that did 
have lower entropy than the mock immunized group (Figure 9).  However, the 06_INF_vacc did 
not exhibit lower binding than the mock group.  Perhaps the resolution provided by the array 
platform was not high enough to distinguish between the groups even though a difference was 
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present.  Alternatively perhaps the difference in entropy reflects the fact that the 2006 vaccine did 
not produce an immune response that was as effective as the 2007 vaccine since there was 60% 
survival vs 80% survival.  The more effective 2007 vaccine may have resulted in higher affinity 
antibodies which resulted in a “tighter” fluorescence intensity distribution from the non-natural 
sequence peptide array.  Another interesting result is that the dynamic range of the fluorescence 
intensity of the infected group was considerably lower than the other groups.  Perhaps the 
infected group produced a fairly high tight immune response which resulted in a low dynamic 
range, but the binding within this range may still have been fairly chaotic in a manner which did 
not significantly decrease the entropy value.  Note that there could be competing reactions with 
divergent effects detected in the immune system through the microarray as well.  Overall, these 
results provide support for the idea that vaccines and infections change the overall binding 
observed from an antibody repertoire interacting with a peptide array, and this change is reflected 
in the AbStat measures. 
1.3.2.3 6 day time course 
One group of five female BALB/c mice was infected with the H1N1 A/PR/8/34 influenza 
strain on day 0, and another matching mock group of mice was treated with PBS.  Sera was 
collected each day for six days, and the last sera samples were collected by terminal bleed.  
Samples were applied to the CIM10Kv1 non-natural sequence peptide array with two to three 
technical replicates for each day.   
From this experiment, Bart Legutki noted several key findings in an unpublished 
manuscript.   One finding is that an immune response to the influenza infection in mice can be 
detected very soon after the initial infection.  Twelve peptide features increased in signal within 
the first three days after infection.  He also found that the limit of detection of the non-natural 
sequence peptide microarray is more sensitive than the limit of detection of the standard ELISA 
assay.  A peptide feature could be detected 7 fold above background at a dilution as high as 
1:1,638,400, whereas the limit of detection of the ELISA assay was reached at a dilution of 
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1:409,600.  Once the immune response of mice or humans was raised, this immune response 
could be detected in the immunosignature as far as one month after the infection. 
I used the fluorescence intensity distribution from this mouse influenza experiment to 
obtain values for the AbStat measures.  None of the AbStat measures comparing the mock and 
infected on day 6 were statistically significant.  The best p-value was 0.195 for the mean, and the 
normalized minimum, median, and entropy followed.  A line graph of the entropy for the 6 days is 
presented in the Figure 10. 
 
Figure 10 Entropy for 6 day mouse time course 
Sera from mice were applied to the CIM10Kv1 array each day after injection with the H1N1 
A/PR/8/34 influenza virus or PBS for 6 days.  There were five mice in both groups.  Each sample 
was applied to the array with two to three replicates, and the entropy of each replicate was 
calculated and graphed in a line graph. 
 The results from this experiment demonstrate that it is not possible to distinguish 
between an infected and a mock group of mice using the AbStat measures in only 6 days.  This 
short time-frame may have been too demanding to measure an antibody response that can be 
measured with these broad and global AbStat measures.  If more timepoints had been taken, 
perhaps a difference could have been observed.  Alternatively, if the superior peptide arrays 
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which were developed at a later time had been used, then these arrays may have allowed the 
samples to be distinguished.  These results demonstrate that there are clearly limits on the 
abilities of the AbStat measures to distinguish infected and mock mouse samples if the time after 
infection is too short. 
1.3.3 Human vaccines 
The previous section demonstrated that changes in the AbStat measures can be 
observed when a mouse is vaccinated, but do the same results hold when a human is 
vaccinated?  If the results do hold true, then this means that the AbStat measures can be used to 
detect when there is a sudden and strong immune response in humans.  This issue was explored 
by applying human sera pre and post vaccination to the peptide microarray and analyzing the 
AbStat results.  The expectation is that the entropy of the fluorescence intensity distribution will 
decrease post vaccination after enough days have passed. 
Penny Gwynne collected sera from two individuals identified as individual 84 and 
individual 43 around the time when they received the seasonal flu vaccine.  The Peptide Array 
core under the direction of Zbigniew Cichacz then applied the sera to the CIM10Kv2 non-natural 
sequence peptide arrays.  In the original analysis, the researchers were able to identify specific 
peptides which significantly increased after the vaccination 9.  The fluorescence intensity 
distribution was then characterized.  Two line graphs of the entropy over time are displayed for 
individual 43 for the flu vaccine they received in 2006 and 2009 in Figure 11 A) and B).  A line 
graph of the entropy over time for individual 84 for the flu vaccine they received in 2009 is 
displayed in Figure 11 C. 
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C) 
 
Figure 11 Change in entropy after vaccination 
A human individual was immunized with the influenza vaccine, and sera pre and post 
immunization was applied to the CIM10Kv2 microarray.  The entropy of each replicate was 
calculated and plotted vs time in days in a line graph.  In A) individual 43 was vaccinated in 
December 2006.  In B) individual 43 was immunized in December 2009.  In C) individual 84 was 
immunized in December 2009.  A red square indicates the time of the vaccination. 
 During the month of November in 2011 both individuals had their blood drawn on a near 
daily basis.  Just before this month, both individuals received the 2011/2012 seasonal trivalent 
influenza vaccine.  This sera was applied to the CIM10Kv2 arrays.  The time course for individual 
43 and 84 is presented in Figure 12.  Note that individual 84 reported catching a cold on day 17. 
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Figure 12 Daily one month entropy change 
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Sera from two individuals was applied to the CIM10Kv2 during November 2011 on a near daily 
basis.  The entropy of each replicate was calculated and plotted vs time in days in a line graph.  
The plot in A) represents the entropy results for individual 43, and the plot in B) represents the 
entropy results for individual 84.  The red square indicates the time that the influenza vaccine was 
received. 
 In every circumstance in which the entropy was calculated for a sample more than three 
days after vaccination the entropy decreased.  In the one circumstance when the sample was 
only three days after vaccination, a reduction in entropy could not be observed.  These results 
indicate that a global measure of fluorescence intensities is not capable of detecting a difference 
between pre and post vaccination in only three days.  After three days, the reduction in entropy 
indicates that the antibody repertoire changes significantly enough for changes in the 
fluorescence intensity distribution to be observed.  These results support the concept that the 
AbStat measures could reflect changes in the human immune system. 
1.3.4 Reduction in antibody repertoire complexity with lymphoma 
Are there changes in the AbStat measurement during the course of a lymphoma which 
reduces the complexity of the antibody repertoire?  During the course of a B cell lymphoma one 
particular antibody in the repertoire becomes dominant as one B cell proliferates uncontrollably 
and produces large amounts of the antibody.  Can this change be detected in the fluorescence 
intensity distribution produced from applying the sera to an array of peptides?  The anticipated 
result is that the entropy of the fluorescence intensity distribution will decrease when sera 
associated with a B cell lymphosarcoma (LSA) is applied to the array relative to normal sera.  The 
antibody repertoire for LSA sera will have a higher prevalence of an antibody against one specific 
target.  Therefore, this sera will resemble a monoclonal antibody more than normal sera, and this 
sera will bind to a few features with high intensity which contain peptides with a mimotope similar 
to the cognate epitope of the antibody.  Many of the other features on the array will have very low 
intensity ultimately resulting in a less complex fluorescence intensity distribution and a lower 
entropy value.  
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The experiment was performed by Bart Legutki using sera from dogs with and without a 
B cell lymphosarcoma (LSA).  These sera samples were obtained from The Flint Animal Cancer 
Center at Colorado State University.  There were 24 different male healthy dogs and 15 female 
healthy dogs with an age range from 2 to 15 (median of 6) of the following breeds: Mix Breed 
(19), Golden Retriever (6), Labrador (3), Staffordshire Terrier (2), Australian Cattle Dog (2), 
Australian Shepherd, Dalmatian, Doberman, German Wire Haired Pointer, Std. Poodle, St. 
Bernard, and Rottweiler.  There were 22 male and 16 female B cell lymphosarcoma dogs with an 
age range from 2 to 13 (median of 7.9) of the following breeds: Mix Breed (10), Golden Retriever 
(5), Border Collie (4), German Shepard (2), Rottweiler (2), Scottish Terrier (2), Vizsla (2), Bassett 
Hound, Belgian Melinois, Boxer, Chesapeake Bay Retriever, Collie, Doberman, Labrador, 
Miniature Schnauzer, Sheltie, Staffordshire Terrier, and one non-classified breed.  The sera from 
these dogs was applied to the CIM10Kv2 array.   
The researcher Bart Legutki and his collaborators made several key findings from this 
experiment.  They found that although LSA is due to the clonal expansion of a single B cell 
unique to each dog, that there was also a general immunosignature defined by specific reactive 
peptide features in common among the dogs.  Selected peptide features from a training set of 
dogs was able to predict the health status of a test set of dogs with 97% accuracy (unpublished 
data).  An individual set of peptides unique to each dog was identified as well which consisted of 
approximately 6 to 8 peptides.  The immunosignature at diagnosis was also able to predict which 
dogs would go into remission and relapse within 120 days.  They also found that the median raw 
feature intensity of the B cell LSA dogs was lower than the healthy dogs (p-value of 1E-4).  I 
calculated the entropy of each sample of the two class types and a dot plot is presented in Figure 
13.  The p-value between the two groups is 5.47E-10. 
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Figure 13 Box and dot plot of entropy for normal (N) and lymphosarcoma (LSA) dogs 
Sera from dogs with and without B cell lymphosarcoma were applied to the CIM10Kv2 array.  The 
entropy of each replicate was calculated and the data were plotted in a box and dot plot. 
The data for all of the measures for the two groups was input into a SVM algorithm, and 
the algorithm was able to correctly classify 78.8% of the instances with a Kappa statistic of 0.566 
and ROC area of 0.779.  When the normal or LSA class was randomly assigned to each sample, 
the SVM could only correctly classify 52.3% of the instances with a Kappa statistic of 0.0348 and 
a ROC area of 0.517. 
These results demonstrated that the entropy of the LSA group of dogs was indeed lower 
than the entropy of the normal dogs.  The reason for this is that in a B cell lymphoma one 
antibody comes to predominate the repertoire.  The solution comes to resemble more of a 
monoclonal antibody rather than a complex antibody mixture, and the entropy value is closer to 
that of a monoclonal antibody.  This result was also observed in the section in which a 
monoclonal antibody was artificially spiked into monoclonal sera (“1.3.1.2 Spiking antibody into 
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sera”).  A similar phenomena is also observed with vaccines as was demonstrated with mouse 
vaccines and human vaccines (“1.3.2 Mouse vaccines and infections” and “1.3.3 Human 
vaccines”).  The reason that this is the case is due to the fact that vaccines are also characterized 
by an increase of the number of antibodies against one specific epitope or a few epitopes.  In 
conclusion, these results show that the AbStat measures could be used to monitor dogs for the 
occurrence of B cell lymphomas.  Presumably, the same techniques would work for human sera 
as well. 
1.3.5 Mouse cancer progression 
Are there changes in the AbStat measurements as mice develop cancer?  This question was 
addressed using a wild type mouse and a transgenic mouse which develops mammary tumors.  
The expectation is that the entropy of the wild type control mouse will increase over time with 
age.  However, the entropy of the cancer mouse should increase more as the antibody repertoire 
becomes more chaotic and complex during the course of the chronic battle against cancer.  If 
changes can be detected, then the AbStat measure could be used for the early detection of 
cancer. 
Hu (Tiger) Duan performed the experiments to address this issue with a transgenic mouse 
strain.  The strain of the transgenic mouse was FVB/N neuT which begins to develop 
spontaneous mammary adenocarcinomas around 33 weeks old 74, 75.  One transgenic mouse and 
one wild type mouse were used.  The breeding pairs of transgenic mice were obtained from Dr. 
Joseph Lustgarten from the Mayo Clinic, Phoenix, AZ.  The transgenic mice used for the 
experiment were bred at Arizona State University.  The wild type mice were obtained from 
Jackson Laboratories.  The first tumor in the transgenic mouse was detected after 231 days (33.1 
weeks) with a size of 0.5 mm3.  Sera samples from these mice were applied to CIM10Kv2.  By 
analyzing specific peptides, Tiger Duan was able to identify array features that began to exhibit 
increased fluorescence intensity over time eight weeks before the appearance of the first 
palpable tumor (33.1 weeks).  The broad AbStat measures view the data at a global level without 
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analyzing specific peptides.  A line graph of the entropy over time for the transgenic mouse and 
the wild type mouse is presented in Figure 14. 
A) 
 
B) 
 
Figure 14 Entropy time course for transgenic and wild type mouse 
Sera from a A) transgenic FVB/N neuT mouse and a B) wild type mouse were applied to the 
CIM10Kv2 microarray.  The entropy of each sample was calculated and plotted vs time in weeks 
in a line graph. 
 The chaotic nature of the entropy over time for the transgenic mouse was unexpected.  
The wild type mouse exhibited the steady increase in entropy over time that was expected and 
also observed in the “246 day time course” section after vaccination (“1.3.2.1 246 day time 
course”).  This result provides further evidence that the entropy obtained from the antibody 
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repertoire increases with age.  The transgenic mouse entropy was expected to increase to a 
higher level than the normal mouse, but instead the entropy was rather chaotic with constant 
sharp increases and decreases.  This chaotic entropy timeline may be the result of the immune 
system undergoing constant surges against the tumor.  For one period of time, perhaps many 
antibodies against a single target are produced, and during another period of time perhaps the 
immune system may subside or produce many different antibodies against many different targets.  
These effects may or may not be observable in the standard immunosignature which examines 
specific highly reactive peptides.  If the phenomenon is not observable, than the change in 
entropy may mostly occur in the low intensity range.  If the phenomenon is observable, then the 
fluorescence intensity of the disease specific features may increase and decrease over time.  
Note that the situation of a transgenic mouse may also be different than a spontaneous tumor.  
The Center for Innovations in Medicine plans to investigate this in the future. 
1.3.6 Human disease 
Can the AbStat measurements distinguish between humans with and without disease on 
different non-natural sequence peptide array platforms?  This question is addressed with data 
from several different experiments across two different platforms: the HT330K silicon wafer 
platform, and the CIM10K glass slide platform.  For each experiment, several normal and disease 
samples were applied to the array and the quantitative values of all of the AbStat measures were 
obtained.  These measures were then analyzed to determine whether they could distinguish the 
different groups.  The expectation is that the AbStat measures should provide the ability to 
distinguish between healthy and disease sera because disease sera will contain a different 
number of antibodies, antibody affinities, and antibody avidities.  Therefore, disease sera will bind 
to an array of non-natural sequence peptides in a different manner than normal sera.  More 
resolution between normal and disease sera should be provided by the HT330K chip over the 
CIM10K chip since more peptides are present on the HT330K chip.  If these expectations are 
met, then the AbStat measures will prove useful for monitoring and diagnosing the presence or 
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absence of disease.  At this point, further investigations would be required to determine the exact 
nature of the disease. 
1.3.6.1 HT330K first chip disease dataset 
In order to address the issue of whether or not normal sera can be distinguished from 
disease sera using the broad AbStat measures, sera from patients with infectious diseases and 
sera from normal patients were applied to the HT330K platform type.  The infectious disease 
samples could result in a higher or lower entropy fluorescence intensity distribution than normal 
samples.  If the entropy is lower, this could indicate there is a high focused immune response 
against few targets for a certain type of infection.  If the entropy is higher, then this infectious 
disease may result in more inflammation and a non-specific immune response with antibodies 
against many different targets.  There may also be more antibody binding to the non-natural 
sequence peptide microarray in general during the course of an infection.  
The following diseases were applied to the array: West Nile virus (WNV), syphilis 
(SYPH), malaria (MAL), hepatitis B virus (HBV), dengue (DEN), Bordetella pertussis (BPE), and 
Borrelia (BORR).  The samples were applied to the array and the resulting image files were 
aligned by the Peptide Array Core under the direction of Zbigniew Cichacz.  The samples were 
obtained from SeraCare Life Sciences, Milford, MA. 
Before presenting the results of the AbStat analysis, an analysis based on the traditional 
approach of selecting specific peptides will be presented.  Half of the normal and half of the 
disease samples were randomly selected as training samples, and the other half of the samples 
was used as test data.  The intensity values of the top 100 most significant peptides by p-value 
from a t-test from the training data samples were used as input for one of three machine learning 
algorithms: Naïve Bayes, SVM, or J48graft tree.  After the algorithm was trained, the algorithm 
was used to predict the classification of the test data samples.  This same process was repeated 
with random classification assignments for each sample as disease or normal.  Randomly 
assigned classes should result in a decrease in classification performance.  The results of this 
analysis are presented in Table 1.  All three classification algorithms can correctly classify the 
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samples as disease or normal with about 90% accuracy.  Note that for this specific peptide 
approach the Center for Innovations in Medicine lab often uses Naïve Bayes as the classifier of 
choice, and Muskan Kukreja has demonstrated that this is the fastest algorithm which still results 
in acceptable performance 64.  With this particular dataset consisting of 118 samples with 86 
disease and 32 normal, all of the algorithms completed in less than 1 second with a standard 
desktop computer. 
Table 1 Machine learning statistics for first chip disease dataset using selection of specific 
peptides 
Algorithm Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
Naïve 
Bayes 
87.9 0.679 0.836 
SVM 91.4 0.771 0.863 
J48graft 89.7 0.741 0.871 
Naïve 
Bayes 
Random 
70.7 0.0199 0.528 
SVM 
Random 
60.3 -0.0537 0.475 
J48graft 
Random 
67.2 0.0072 0.503 
 
Three different algorithms were used to predict the class (disease or normal) of samples applied 
to the HT330K microarrays.  Half of the samples were randomly selected as training samples and 
half were randomly selected as test samples.  The top 100 most significant features by p-value 
from a t-test with the training samples only were used to train the algorithms.  The algorithms 
were then used to predict the class of the samples in the test set.  Several machine learning 
statistics are presented in columns.  In a separate analysis, samples were randomly assigned a 
class as disease or normal and the analysis was repeated. 
This specific peptide approach is more susceptible to overtraining than the AbStat 
approach.  For example, if the dataset is not split in half so that features are selected on the 
training data half and used against the test data half, undesirable results occur.  If the top 100 
 55 
most significant peptides  by p-value from a t-test are selected from the whole dataset, and then 
these peptides are input into the Naïve Bayes classifier with 10-fold cross-validation, then the 
result is 93.2% correctly classified instances, 0.822 kappa statistic, and 0.934 ROC area.  If the 
process is repeated with samples with randomly assigned class as disease or normal, then the 
result is 98.3% correctly classified instances, 0.957 kappa statistic, and 0.996 ROC area.  The 
random dataset did not result in worse performance as it should have.  The reason for this 
overtraining is likely that with so many features (330,000) and the presence of some degree of 
noise in the experimental data as well as some degree of similarity among any randomly chosen 
samples for some portion of the 330k peptides, there is bound to be at least a small percentage 
of features which can distinguish between any random grouping of the samples.  Another reason 
for the overtraining with the whole sample set is that the p-value for each peptide is determined 
by comparing all the samples in both groups, whereas the features of the AbStat are not selected 
based on comparing both groups.  Instead, all of the AbStat measures are calculated 
independently for each sample, and then these calculated values are input into the machine 
learning algorithm.  The AbStat method is not as susceptible to overtraining, and performance 
that is no better than random chance results when the classes are randomly assigned to each 
sample, even when the whole dataset is used. 
The AbStat analysis uses only broad global measures, and no specific peptides are 
selected.  A box and dot plot of the entropy of all of the samples is presented in Figure 15.  A 
heatmap of all of the measures for all of the samples is presented in Figure 16.  The significance 
of the measures from a t-test comparing all disease against normal (Figure 17), the SVM weight 
of the measures (Figure 18), the J48graft tree (Figure 19), and machine learning statistics are 
also presented (Table 2).  All of the diseases had a higher entropy average than the entropy 
average of the normal group with the exception of BPE (Figure 15).  The heatmap of all of the 
measures reveals that many of the normal samples cluster together with a low entropy and a 
higher cv, normalized standard deviation, normalized mean, normalized 95th percentile, dynamic 
range, and normalized maximum than the infectious disease samples.  Many of the West Nile 
virus samples also cluster together with values characteristic for that group for the same 
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measures and a very low kurtosis and skew (Figure 16).  The entropy and kurtosis could 
distinguish between disease and normal the best by a t-test, and the max normalized and entropy 
were weighted the most by SVM (Figure 17 and Figure 18).  The J48graft tree reveals that 12 
samples were correctly classified as normal based on the criteria that their entropy was less than 
or equal to 7.63 (Figure 19).  A total of 46 samples were classified as disease if they had a high 
entropy and high cv (entropy>7.63 and cv>1.47), and only 12 of these 46 were misclassified.  The 
machine learning statistics illustrate that the machine learning algorithms can classify better than 
chance with information from the measures (about 80% accuracy for J48graft), but these 
algorithms can classify no better than chance when the class assignments are randomly assigned 
(Table 2). 
 
 
Figure 15 Box and dot plot of entropy for groups in first chip disease dataset 
Sera samples were applied to HT330K microarrays.  The entropy of each replicate was 
calculated and presented in a box and dot plot.  The class of the sample is designated as follows: 
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N = normal, WNV = West Nile virus, SYPH = syphilis, MAL = malaria, HBV = hepatitis B virus, 
DEN = dengue, BPE = Bordetella pertussis, and BORR = Borrelia. 
 
Figure 16 Heatmap of Measures for samples in first chip disease dataset 
 58 
Each column corresponds to an AbStat measure and each row corresponds to a sera sample.  
The relative average value of each AbStat measure for the samples is represented by a color with 
blue indicating the lowest relative value and red indicating the highest relative value.  The class of 
each sample is designated as follows: N = normal, WNV = West Nile virus, SYPH = syphilis, MAL 
= malaria, HBV = hepatitis B virus, DEN = dengue, BPE = Bordetella pertussis, and BORR = 
Borrelia. 
 
 
Figure 17 Statistical significance of measures comparing normal with disease in HT330K 
first chip disease dataset 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  A p-
value from a t-test was then determined for each measure for disease vs normal.  The negative 
logarithm in base 10 of the p-value was then plotted in a bar graph. 
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Figure 18 SVM weight of measures comparing normal with disease in first chip disease 
dataset 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  An 
SVM algorithm with 10-fold cross-validation was then used to predict the class of the samples as 
disease or normal.  The absolute value of the weight of each measure assigned by the SVM was 
then plotted in a bar graph. 
 
 
Figure 19 J48graft tree for first chip disease dataset 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  A 
J48graft tree algorithm with 10-fold cross-validation was then used to predict the class of the 
samples as disease or normal.  The algorithm then selected certain measures with specified 
cutoff points to construct a classification tree to assign a sample to the normal or disease group.  
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Table 2 Machine learning statistics for first chip disease dataset 
Algorithm 
Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
SVM 62.1 0.234 0.616 
J48graft 78.8 0.5706 0.744 
SVM 
Random 
48.8 -0.0351 0.483 
J48graft 
Random 
54.5 0.066 0.504 
 
Two different algorithms with 10-fold cross-validation were used to predict the class (disease or 
normal) of samples applied to the HT330K microarrays.  The attributes of each sample were the 
AbStat measures.  Several machine learning statistics are presented in columns.  In a separate 
analysis, samples were randomly assigned a class as disease or normal and the analysis was 
repeated. 
 These results demonstrate that it is possible to distinguish disease samples from normal 
samples better than chance using the AbStat measures.  A classification accuracy of 
approximately 80% can be obtained with the J48graft algorithm.  Although much better 
classification performance can be obtained by other methods, the value of the AbStat measures 
is that they do not rely on specific features.  Instead, this classification performance is achieved 
from very broad global measures.  Additionally, these measures display similar behavior for both 
disease and age.  This is a fact which may be related to some aspect that connects these two 
different concepts. 
 Note that the AbStat metric can perform just as well using half of the dataset.  Previously, 
I demonstrated that the specific peptide analysis method is more susceptible to overtraining.  
Therefore, instead of performing a t-test with all of the samples, and then using the values of the 
top 100 peptides as input into a classification algorithm with 10-fold cross-validation, a different 
approach had to be taken.  The top 100 peptides from a t-test with half of the samples had to be 
selected, and then these peptides were input into a classification algorithm for training to then 
predict the test samples.  This approach resulted in the decrease in performance expected with 
random class assignments for each sample.  The AbStat did not suffer from this overtraining, 
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primarily because all of the AbStat measures are used, and the measures are not selected by 
comparing them with other samples as with a t-test.  However, one can ask the question, does 
the AbStat perform just as well if data from half of the samples are input into the algorithms and 
then these algorithms are used to classify the other half, instead of using 10-fold cross-validation?  
To answer this question half of the samples were randomly assigned to the training set, input into 
a classification algorithm, and then used to predict the class of the test samples.  The same 
process was repeated with random class assignment samples to see if the expected decrease in 
classification performance was observed.  The results in Table 3 demonstrate that the AbStat 
method does indeed perform just as well with half the sample set as it does with 10-fold cross-
validation.  Note that in this particular dataset there were 86 disease samples and 33 normal 
samples so simply predicting every sample as disease results in 86/(33+86)*100= 72.3% 
correctly classified instances.  Therefore, it is important to look at the kappa statistic and ROC 
area when evaluating the outcomes in Table 3. 
Table 3 Machine learning statistics for first chip disease dataset with half samples as 
training rather than 10-fold cross-validation 
Algorithm Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
Naïve 
Bayes 
82.8 0.551 0.832 
SVM 74.1 0.135 0.551 
J48Graft 86.2 0.626 0.778 
Naïve 
Bayes 
Random 
51.7 0.077 0.534 
SVM 
Random 
72.4 0 0.5 
J48Graft 
Random 
65.5 -0.0221 0.388 
 
Three different algorithms were used to predict the class (disease or normal) of samples applied 
to the HT330K microarrays.  The samples were randomly split into training samples or test 
samples.  The attributes of each sample were the AbStat measures.  Each algorithm was trained 
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with the training set and then tested on the other samples.  Several machine learning statistics 
are presented in columns.  In a separate analysis, samples were randomly assigned a class as 
disease or normal and the analysis was repeated. 
1.3.6.2 HT330K wafer 46 
In the last section, a variety of infectious disease sera samples were applied to the 
peptide array.  In this section two different monoclonal antibodies, pure buffer, and chronic 
diseases were applied to the peptide array.  The chronic diseases were breast cancer and 
multiple myeloma.  The fundamental question addressed was still the same: can AbStat be used 
to distinguish between disease and normal sera?  This dataset may be particularly good for 
addressing this issue since several researchers with hands on experience with the different 
HT330K wafers had the opinion that wafer 46 was one of the highest quality wafers that yielded 
quality data.  The expected results are that the chronic disease samples would have a higher 
entropy than normal, and normal would have an even higher entropy than monoclonal antibodies.  
Normal sera should have a higher entropy than monoclonal antibodies because normal sera is 
composed of a more complicated mixture of antibodies than a single monoclonal antibody even 
though normal sera does not generally have high binding.  The differences in the AbStat 
measures observed should allow for classification between normal and disease sera. 
The experiments were performed by the Peptide Array Core under the direction of 
Zbigniew Cichacz.  Two different monoclonal antibodies (Ab1 and Ab2), buffer alone (B), sera 
from normal donors (N), sera from patients with breast cancer (BC), and sera from patients with 
multiple myeloma (MM) were applied to 330k peptide arrays.  The breast cancer samples were 
obtained from Dr. Adi Gazday from UT Southwestern, Dallas, TX.  The myeloma samples were 
obtained from Dr. Robert Penny from the Multiple Myeloma Research Foundation, Norwalk, CT.  
A specific peptide analysis was performed by splitting the dataset in half, choosing the top 100 
peptides by p-value from a t-test from the training samples, training a naïve Bayes algorithm, and 
testing with the testing samples.  The results were 85% correctly classified instances, 0.634 
kappa statistic, and 0.956 ROC Area.  Higher performance would likely be achieved with a larger 
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dataset since this dataset only had 15 disease samples (5 breast cancer, and 10 multiple 
myeloma). 
The dataset was then subjected to an AbStat analysis.  A box and dot plot of the entropy 
for the groups is presented in Figure 20, and a heatmap of all of the measures for each sample is 
presented in Figure 21.  The statistical significance of each measure when comparing disease 
and normal is presented in Figure 22.  Machine learning was also used to classify samples as 
disease or normal.  The SVM weight of each measure is presented in Figure 23, the J48graft tree 
is presented in Figure 24, and machine learning statistics for actual and random class 
assignments are presented in Table 4.  In Table 4, the random class assignment test was 
performed as follows: the random class assignments were made, the values of the attributes and 
fake class of each sample was input into a machine learning algorithm for training and testing 
with 10-fold cross-validation, and this process was repeated four more times.  The average value 
plus or minus one standard deviation for each machine learning statistic for the random class 
assignment test is presented in the table. 
The box and dot plot of the entropy shows that the chronic disease groups have a 
significantly higher entropy than the normal group (p-value of 0.0167 for breast cancer and p-
value of 0.00186 for multiple myeloma).  The buffer and monoclonal antibody groups on the other 
hand have a lower entropy (Figure 20).  The heatmap of all of the measures with each sample 
shows that samples of the same group generally cluster together (Figure 21).  The multiple 
myeloma samples have a very high relative entropy and a low normalized 5th percentile.  The 
breast cancer samples have a relatively high entropy, mean, median, 5th percentile, min, 
standard deviation, and 95th percentile.  The monoclonal antibodies and the normal samples are 
relatively low for all of these measures, but higher for measures to the right of these in the 
heatmap.  The statistical significance from a t-test reveals that entropy and the normalized 
maximum are the best measures (Figure 22), and the normalized 5th percentile and entropy have 
the greatest SVM weights (Figure 23).  The J48graft tree reveals that 24 samples were classified 
as normal if the entropy was less than or equal to 9.22, and only 2 of these samples were 
misclassified.  The machine learning algorithms demonstrate that these measures allow about 
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80% of the samples to be correctly classified with an SVM, and the algorithms perform no better 
than chance when random class assignments are made (Table 4). 
 
 
Figure 20 Box and dot plot of entropy for groups on wafer 46 
Sera samples were applied to HT330K microarrays.  The entropy of each replicate was 
calculated and presented in a box and dot plot.  The class of the sample is designated as follows: 
N = normal, MM = multiple myeloma, BC = breast cancer, B = buffer, Ab1 = antibody 1 against 
p53 epitope RHSVV, Ab2 = Ab2 against p53 epitope SDLWKL 
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Figure 21 Heatmap of Measures for samples on wafer 46 
Each column corresponds to an AbStat measure and each row corresponds to a sera sample.  
The relative average value of each AbStat measure for the samples is represented by a color with 
blue indicating the lowest relative value and red indicating the highest relative value.  The class of 
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each sample is designated as follows: N = normal, MM = multiple myeloma, BC = breast cancer, 
B = buffer, Ab1 = antibody 1 against p53 epitope RHSVV, Ab2 = antibody 2 against p53 epitope 
SDLWKL. 
 
 
Figure 22 Statistical significance of measures comparing normal with disease for wafer 46 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  A p-
value from a t-test was then determined for each measure for disease vs normal.  The negative 
logarithm in base 10 of the p-value was then plotted in a bar graph. 
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Figure 23 SVM weight of measures comparing normal with disease for wafer 46 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  An 
SVM algorithm with 10-fold cross-validation was then used to predict the class of the samples as 
disease or normal.  The absolute value of the weight of each measure assigned by the SVM was 
then plotted in a bar graph. 
 
 
Figure 24 J48graft tree for wafer 46 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  A 
J48graft tree algorithm with 10-fold cross-validation was then used to predict the class of the 
samples as disease or normal.  The algorithm then selected certain measures with specified 
cutoff points to construct a classification tree to assign a sample to the normal or disease group. 
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Table 4 Machine learning statistics for wafer 46 
Algorithm 
Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
SVM 78.6 0.496 0.73 
J48graft 66.7 0.274 0.559 
SVM 
Random 
62.9 
+/-2.74 
-
0.00742 
+/-0.0928 
0.498 
+/-0.0388 
J48graft 
Random 
57.6 
+/-4.57 
-0.109 
+/-0.102 
0.354 
+/-0.0432 
 
Two different algorithms with 10-fold cross-validation were used to predict the class (disease or 
normal) of samples applied to the HT330K microarrays.  The attributes of each sample were the 
AbStat measures.  Several machine learning statistics are presented in columns.  In a separate 
analysis, samples were randomly assigned a class as disease or normal five different times and 
the analysis was repeated.  The average plus or minus one standard deviation of each machine 
learning statistic is presented. 
 The results of the chronic disease samples applied to the HT330K platform matched the 
expected outcome even though this outcome was opposite that of some infectious diseases and 
vaccines.  The chronic disease samples had a higher entropy than normal samples.  Additionally, 
the monoclonal antibody samples exhibited an even lower entropy than the normal sera samples.  
Although some of the infectious diseases and vaccines exhibited lower entropy in different 
experiments, I expected that chronic disease samples would have a higher entropy.  Infectious 
diseases and vaccines may produce high concentrations of antibodies that bind to a few targets 
resulting in a large and sudden “focused” immune response.  A chronic disease on the other hand 
develops over a long period of time, and the immune response often fails to overcome the 
challenge.  In this situation, the immune system may produce a wide variety of many different 
antibodies against various targets with lower affinity than might be seen with an infectious 
disease.  An infectious disease may mimic the situation of adding monoclonal antibody to sera 
(“1.3.1.2 Spiking antibody into sera”), and a chronic disease may mimic the situation of mixing 
many different antibodies together.  Regardless of whether or not these speculations are correct, 
 69 
the differences among all of the AbStat measures allowed for the correct classification of about 
80% of the normal and disease samples.  These results provide further evidence that the AbStat 
measures provide useful information about human disease states. 
1.3.6.3 CIM10K 
In the last two sections, disease samples were applied to the HT330K platform, but this 
section aims to address the issue of whether or not disease samples can be distinguished with 
the AbStat measure on the CIM10K platform with fewer peptides.  The disease samples would 
still be expected to have a higher entropy than the normal samples, unless the disease typically 
causes a very strong specific immune response.  The CIM10K platform should also still provide 
the resolution necessary to distinguish samples since 10,000 peptides is still a fairly large number 
of peptides as compared to a few hundred, but the CIM10K platform would be expected to 
provide less resolution than the HT330K platform.  Note that not only are there a different number 
of peptides on the two platforms, but a slide of each platform type is manufactured using 
drastically different techniques.  Therefore, positive results would indicate that the AbStat 
measures are robust and can work with peptide arrays produced by a variety of techniques. 
The experiments were performed by the Peptide Array Core under the direction of 
Zbigniew Cichacz.  Sera obtained from Lawrence Livermore National Laboratory from patients 
with West Nile virus (WNV), syphilis (SYPH), hepatitis B virus (HBV), dengue (DEN), Bordetella 
pertussis (BPE), and Borrelia (BORR) were applied to the CIM10Kv2 non-natural sequence 
peptide array.  An analysis using specific peptides was performed by splitting the dataset into a 
training set and a test set.  The top 100 peptides by p-value from a t-test with the normal and 
disease samples in the training set were used as input to a naïve Bayes classifier, and this 
classifier was used to classify the test set samples.  The results were 89.7% correctly classified 
instances, 0.608 kappa statistic, and 0.899 ROC Area. 
I also performed an AbStat analysis.  A box and dot plot of the entropy of the different 
groups (Figure 25), a heatmap of the measures for all of the samples (Figure 26), the statistical 
significance of the measures from a t-test (Figure 27), the SVM weight of the measures (Figure 
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28), the J48graft tree of the measures (Figure 29), and a table of the machine learning statistics 
(Table 5) is presented below.  Every disease group had a higher entropy than the normal group 
with the exception of DEN and BPE (Figure 25).  The heatmap of the measures for all of the 
samples revealed that many of the groups clustered together indicating that some samples within 
a group have similar values for the different measures (Figure 26).  The statistical significance 
from a t-test showed that the 5th percentile, mean, 95th percentile, median, and skew measures 
were the best at distinguishing the groups (Figure 27), and the SVM weights of the measures 
show that the coefficient of variation, standard deviation, 95th percentile, entropy, and skew had 
the most weight (Figure 28).  The J48 graft tree indicates that thirty samples were classified as 
normal if the dynamic range was less than or equal to 12.6 and the 5th percentile was less than or 
equal to 678, and eight of these samples were misclassified.  Additionally, five samples were 
classified as disease if the entropy was greater than 7.70 along with the following criteria: 574<5th 
percentile<=678, and dynamic range>12.6.  One of these samples was misclassified.  The 
machine learning statistics demonstrate that an SVM can classify about 60% of the instances 
correctly, and the classification algorithms perform no better than chance when the class of each 
sample is assigned randomly (Table 5). 
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Figure 25 Box and dot plot of entropy for groups on CIM10K 
Sera samples were applied to CIM10K microarrays.  The entropy of each replicate was calculated 
and presented in a box and dot plot.  The class of the sample is designated as follows: N = 
normal, WNV = West Nile virus, SYPH = syphilis, MAL = malaria, HBV = hepatitis B virus, DEN = 
dengue, BPE = Bordetella pertussis, BORR = Borrelia. 
 72 
 
Figure 26 Heatmap of Measures for samples on CIM10K 
Each column corresponds to an AbStat measure and each row corresponds to a sera sample.  
The relative average value of each AbStat measure for the samples is represented by a color with 
blue indicating the lowest relative value and red indicating the highest relative value.  The class of 
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each sample is designated as follows: N = normal, WNV = West Nile virus, SYPH = syphilis, MAL 
= malaria, HBV = hepatitis B virus, DEN = dengue, BPE = Bordetella pertussis, BORR = Borrelia. 
 
 
Figure 27 Statistical significance of measures comparing normal with disease for CIM10K 
Sera samples were applied to the CIM10K array and the AbStat measures were calculated.  A p-
value from a t-test was then determined for each measure for disease vs normal.  The negative 
logarithm in base 10 of the p-value was then plotted in a bar graph. 
 
Figure 28 SVM weight of measures comparing normal with disease for CIM10K 
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Sera samples were applied to the CIM10K array and the AbStat measures were calculated.  An 
SVM algorithm with 10-fold cross-validation was then used to predict the class of the samples as 
disease or normal.  The absolute value of the weight of each measure assigned by the SVM was 
then plotted in a bar graph. 
 
Figure 29 J48graft tree for CIM10K 
Sera samples were applied to the CIM10K array and the AbStat measures were calculated.  A 
J48graft tree algorithm with 10-fold cross-validation was then used to predict the class of the 
samples as disease or normal.  The algorithm then selected certain measures with specified 
cutoff points to construct a classification tree to assign a sample to the normal or disease group. 
 
Table 5 Machine learning statistics for CIM10K 
Algorithm 
Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
SVM 59.6 0.192 0.596 
J48graft 57.7 0.154 0.592 
SVM 
Random 
51.9 0.0299 0.515 
J48graft 
Random 
48.1 -0.0385 0.469 
 
Two different algorithms with 10-fold cross-validation were used to predict the class (disease or 
normal) of samples applied to the CIM10K microarrays.  The attributes of each sample were the 
AbStat measures.  Several machine learning statistics are presented in columns.  In a separate 
analysis, samples were randomly assigned a class as disease or normal and the analysis was 
repeated. 
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 The AbStat measures were able to distinguish normal and disease samples better than 
chance with a classification accuracy of about 60%.  This classification was less accurate than 
the classification accuracy that was obtained from both HT330K datasets which was about 80%.  
The increased number of peptides, and superior technology used to produce the HT330K slides 
likely allowed for the increased classification performance.  Nevertheless, the AbStat measures 
were robust enough to perform better than chance on a variety of platforms.  The performance of 
the AbStat measures could possibly be increased further with more peptides and enhanced 
manufacturing techniques that produce higher quality slides. 
1.3.6.4 Alzheimer’s disease 
Can the AbStat measurement distinguish between aged humans with Alzheimer’s and 
aged human controls?  The characteristic of the Alzheimer’s disease is quite different from the 
previous diseases analyzed up to this point.  Alzheimer’s affects the brain and there is a blood 
brain barrier which separates the brain from the rest of the bloodstream.  Many researchers also 
do not associate Alzheimer’s with the immune system as they do for many cancers and infectious 
diseases.  Nevertheless, there is evidence that the immune system interacts with Alzheimer’s and 
even produce antibodies that target antigens associated with the disease 76.  If the AbStat 
measures could distinguish between normal and Alzheimer’s, then this could provide another tool 
for monitoring and diagnosing the disease.  The expectation is that the AbStat measures should 
be able to distinguish normal and disease samples if there are enough antibodies with varying 
affinities and avidities that are different from normal samples which can be detected on a global 
level with the peptide array. 
The Alzheimer’s experiments were performed by Lucas Restrepo.  Sera from patients 
with Alzheimer’s disease (AD) and sera from patients classified as “non-cognitive impairment” 
(NC) were applied to the CIM10Kv2 arrays.  All of the samples were either obtained from a brain-
bank program at Banner’s Sun Health Research Institute (Phoenix, AZ) or UT Southwest Medical 
Center (Dallas, TX) 76.  The NC patients are individuals of approximately the same age as the AD 
patients, but the NC patients have not been diagnosed with Alzheimer’s disease.  Lucas Restrepo 
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analyzed this data and found that he was able to correctly classify 75% of 8 samples in one 
experiment, and 100% of 24 samples in another experiment using a technique based on the 
selection of specific array features 76.  I performed another peptide specific analysis as well with 
98 Alzheimer’s samples and 98 normal samples.  The samples were randomly split in half into a 
training set and a test set.  The top 100 peptides from a t-test with the training set were used as 
input into classification algorithms.  These classification algorithms were used to predict the class 
of the test set.  The same process was repeated using random class assignments.  The results in 
Table 6 show that using a specific peptide analysis does result in a better classification 
performance with the real sample IDs than can be achieved with random class IDs. 
Table 6 Machine learning statistics for Alzheimer's disease with specific peptide analysis 
Algorithm Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
Naïve 
Bayes 
62.2 0.245 0.646 
SVM 61.2 0.225 0.612 
J48graft 58.2 0.163 0.588 
Naïve 
Bayes 
Random 
59.2 0.157 0.574 
SVM 
Random 
55.1 0.125 0.564 
J48Graft 
Random 
47.9 -0.0382 0.482 
 
Three different algorithms were used to predict the class (disease or normal) of samples applied 
to the CIM10Kv2 microarrays.  Half of the samples were randomly selected as training samples 
and half were randomly selected as test samples.  The top 100 most significant features by p-
value from a t-test between disease and normal with the training samples only were used to train 
the algorithms.  The algorithms were then used to predict the class of the test set.  Several 
machine learning statistics are presented in columns.  In a separate analysis, samples were 
randomly assigned a class as disease or normal and the analysis was repeated. 
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Using the AbStat measures, which do not select specific array features, I analyzed this 
Alzheimer’s dataset in the same manner as the previous human disease datasets to answer the 
question of whether the classes could be distinguished.  A box and dot plot of the entropy for the 
NC and AD group (Figure 30), the statistical significance of the measures from a t-test (Figure 
31), and the machine learning statistics are presented (Table 7).  The p-values obtained for this 
dataset (Figure 31) were not as significant as those obtained for the other human disease 
datasets (Figure 17, Figure 22, and Figure 27).  The machine learning algorithms were also 
incapable of classifying the samples any better than expected by chance (Table 7). 
 
Figure 30 Box and dot plot of entropy for groups for Alzheimer's disease 
Sera samples were applied to CIM10K microarrays.  The entropy of each replicate was calculated 
and presented in a box and dot plot.  The class of the sample is designated as follows: AD = 
Alzheimer’s disease, NC = non-cognitive impairment control 
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Figure 31 Statistical significance of measures comparing normal with Alzheimer's disease 
Sera samples from Alzheimer’s patients or controls were applied to the CIM10K array and the 
AbStat measures were calculated.  A p-value from a t-test was then determined for each measure 
for Alzheimer’s vs non-cognitive impairment control.  The negative logarithm in base 10 of the p-
value was then plotted in a bar graph. 
Table 7 Machine learning statistics for Alzheimer’s disease 
Algorithm 
Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
SVM 55.2 0.104 0.552 
J48graft 47.4 -0.0521 0.472 
 
Two different algorithms with 10-fold cross-validation were used to predict the class (Alzheimer’s 
disease or non-cognitive impairment control) of samples applied to the CIM10K microarrays.  The 
attributes of each sample were the AbStat measures.  Several machine learning statistics are 
presented in columns. 
 The AbStat measures were not able to distinguish between the controls and the 
Alzheimer’s samples any better than chance.  The entropy values were also not significantly 
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higher with the Alzheimer’s samples as compared to the controls.  This result certainly does not 
imply that the immune system is not involved in Alzheimer’s disease.  There can still be 
antibodies against selected peptides on the array without providing enough of a global shift in 
fluorescence intensity for the AbStat measures to detect.  Nevertheless, this dataset illustrates 
some of the limitations of the AbStat measures since normal immunosignaturing analysis 
techniques are capable of distinguishing the samples.  Note that the fact that both the Alzheimer’s 
samples and the normal samples were from elderly individuals may have complicated the AbStat 
analysis since the AbStat is affected by age. 
1.3.7 Changes with age 
Can the AbStat measurement be used to distinguish between young and aged 
organisms?  Since there are changes in the antibody repertoire with age, the AbStat measures 
may be able to capture this change.  Additionally, there may be some similarities in many 
different individual aged samples vs young samples.  For example, there is a general trend of 
loss of antibody specificity and affinity with age, and this change in the antibody repertoire should 
be detectable with the AbStat measures.  One would expect the entropy of the antibody repertoire 
to increase with age.  A validation of this prediction would connect the aging process to an 
increase in non-specific binding of the antibody repertoire, and provide a means to quantitatively 
monitor increases and decreases in health. 
1.3.7.1 Changes with age in mice 
Before investigating human sera, young and aged mice were compared.  Although mice 
only live a little over 2 years, they still undergo a gradual decline of health and die of old age.  The 
anticipated result is that aged mice would have higher entropy fluorescence intensity distributions 
than young mice. 
Bart Legutki applied sera from seven young mice and ten aged mice to the 10k arrays.  
The aged mice were one year and two months old.  The young mice were 6-8 weeks old.  All of 
the mice were infected with 1*10^4 pfu (plaque forming units) of live attenuated PR8 influenza 
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virus, and blood was collected 40 days after infection.  All of the young samples were pooled 
together, and all of the aged samples were pooled together.  These two samples were applied to 
the 10k arrays with four replicates each.  The average entropy was higher for the aged group 
than the young group (Figure 32).  The young and aged samples also cluster together in a 
heatmap, and the aged samples have generally higher values for most of the measures (Figure 
33).  The most significant measures that distinguish the two groups in a t-test were the 
normalized mean and normalized 95th percentile (Figure 34).  These trends reflect the broader 
fluorescence intensity distribution in the aged samples compared to the young samples, as 
illustrated with one aged and one young example sample (Figure 35).  The sample number is too 
small to apply any machine learning techniques. 
 
Figure 32 Box and dot plot of entropy for young and aged mice 
Four replicates of a pool of seven young mice (6-8 weeks old) and four replicates of a pool of ten 
aged mice (one year and two months old) were applied to the array and the entropy from each 
slide was determined. 
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Figure 33 Heatmap of measures for young and aged mice 
Four replicates of a pool of seven young mice (6-8 weeks old) and four replicates of a pool of ten 
aged mice (one year and two months old) were applied to the array and the AbStat values from 
each slide was determined.  The relative average value of each AbStat measure for the samples 
is represented by a color with blue indicating the lowest relative value and red indicating the 
highest relative value. 
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Figure 34 Statistical significance of measures comparing young and aged mice 
Sera samples were applied to the CIM10K array and the AbStat measures were calculated.  A p-
value from a t-test was then determined for each measure for young vs aged.  The negative 
logarithm in base 10 of the p-value was then plotted in a bar graph. 
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A) 
 
 
B) 
 
Figure 35 Young and aged mouse fluorescence intensity histograms 
Sera from a A) young and B) aged mouse was applied to a CIM10K microarray separately.  The 
fluorescence intensity values of all 10,000 features was then plotted in a histogram.  The interval 
on the x-axis scale is 1,000 from an intensity of 0 to 6,000, and the interval changes (indicated by 
the vertical line separating the two parts of the graph) to 10,000 from an intensity of 6,000 to 
70,000. 
 The results matched the expectations since aged mice did have a higher entropy 
fluorescence intensity distribution than young mice.  The shape of the distribution is high and tight 
for the young mice, and the distribution is broader and flatter for aged mice with more outliers 
spread throughout the intensity range.  This result demonstrates that the AbStat can be used to 
distinguish young and aged mouse sera samples. 
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1.3.7.2 Changes with age in humans 
In the previous section, young and aged mouse samples were compared, and in this 
section young and aged human samples are compared.  The aged samples could have a higher 
entropy than the young samples as was observed with the mice samples. 
All of the normal samples with recorded ages in the 10k experiment (“1.3.6.3 CIM10K”) 
and from HT330K wafers 20, 22, 25, and 46 were used to analyze the effects of age on the 
fluorescence intensity distribution in humans.  The experiments were performed by the Peptide 
Array Core under the direction of Zbigniew Cichacz.  Many normal samples were collected from 
volunteers of many ages and nationalities throughout the Biodesign Institute.  Across the datasets 
from the four wafers and the CIM10K experiment previously mentioned there were 99 samples.  
A sample was placed into the "Young” category if the age was less than or equal to 25 years old, 
and a sample was placed into the "Aged" category if the age was greater than or equal to 50 
years old.  Note that an analysis based on the selection of specific peptides for this entire dataset 
cannot be performed because there are samples from the CIM10K and the HT330K platform 
which have different peptides.  This same issue does not exclude an analysis with the AbStat 
measure since this measure does not depend on the selection of specific peptides.   
The average entropy of the aged group was higher than the average entropy of the 
young group (p-value of 2.44E-5) as presented in Figure 36.  If linear regression is performed to 
fit a line to the collection of samples with age and entropy values, the resulting line has a slight 
upward angle of entropy with age with a slope of 0.0278, a y-intercept of 6.728, and an r^2 of 
0.0958.  Note that the total range of entropy in this dataset is larger than some of the other 
datasets, and this may be a characteristic unique to the individuals who donated blood.  Most of 
this sera came from individuals who work at the Biodesign Institute, and there are many students 
and professors who have not been diagnosed with serious illnesses in this dataset.  There can 
also be differences in the non-natural sequence peptide arrays that were produced when 
compared with other experiments, and this variation could result in more or less overall binding.  
Median normalizing the data from different batches would not assist one to make multi-batch 
comparisons with the entropy measure since the value of the entropy measure would not change.  
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Therefore, a different form of normalization or using the raw entropy values would be the 
necessary strategy to implement when making comparisons with the entropy measure. 
A heatmap reveals that most of the aged samples cluster together with high entropy 
values (Figure 37).  Subsets of normals also group together since there is a fairly large group of 
normals with relatively low values for all of the measures with the exception of the normalized 
maximum, normalized 5th percentile, kurtosis, and skew.  The most statistically significant 
measures from a t-test were skew, entropy, and kurtosis (Figure 38). 
Machine learning was performed on a subset of the dataset discussed previously and 
presented in Figure 36.  This subset consisted of an equal number of young and aged samples.  
The young samples to include were chosen randomly.  The measures with the greatest SVM 
weight were the entropy and normalized entropy (Figure 39).  Note that the normalized entropy 
was included for this dataset since some of the samples were run on 10k arrays and some other 
samples were run on 330k arrays.  The J48graft tree algorithm created a tree without even using 
the entropy measure (Figure 40), but the J48graft tree method was only able to correctly classify 
58.7% of the instances; whereas the SVM algorithm could correctly classify 82.6% of the 
instances (Table 8).  The SVM algorithm could not classify as well when samples were randomly 
assigned to the young or aged groups.  A classification accuracy of 65.2% was achieved in this 
situation. 
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Figure 36 Box and dot plot of entropy for young and aged humans 
Sera samples were applied to HT330K microarrays.  The entropy of each replicate was 
calculated and presented in a box and dot plot.  Young was classified as less than or equal to 25 
years old, and aged was classified as greater than or equal to 50 years old. 
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Figure 37 Heatmap of measures for young and aged humans 
Each column corresponds to an AbStat measure and each row corresponds to a sera sample.  
The relative average value of each AbStat measure for the samples is represented by a color with 
blue indicating the lowest relative value and red indicating the highest relative value.  The legend 
on the left indicates blue for young and red for aged.  Each column corresponds to one of the 
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AbStat measures.  Young was classified as less than or equal to 25 years old, and aged was 
classified as greater than or equal to 50 years old. 
 
  
Figure 38 Statistical significance of measures comparing young and aged humans 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  A p-
value from a t-test was then determined for each measure for young vs aged.  The negative 
logarithm in base 10 of the p-value was then plotted in a bar graph. 
  
Figure 39 SVM weight of measures comparing young and aged humans 
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Sera samples were applied to the HT330K array and the AbStat measures were calculated.  An 
SVM algorithm with 10-fold cross-validation was then used to predict the class of the samples as 
young or aged.  The absolute value of the weight of each measure assigned by the SVM was 
then plotted in a bar graph. 
 
Figure 40 J48graft tree of young and aged humans 
Sera samples were applied to the HT330K array and the AbStat measures were calculated.  A 
J48graft tree algorithm with 10-fold cross-validation was then used to predict the class of the 
samples as young or aged.  The algorithm then selected certain measures with specified cutoff 
points to construct a classification tree to assign a sample to the normal or disease group. 
Table 8 Machine learning statistics for young and aged humans 
Algorithm 
Correctly 
Classified 
Instances 
Kappa Statistic ROC Area 
SVM 82.6 0.652 0.826 
J48graft 58.7 0.174 0.56 
SVM Random 65.2 0.304 0.652 
J48graft Random 63 0.261 0.597 
 
Two different algorithms with 10-fold cross-validation were used to predict the class (young or 
aged) of samples applied to the HT330K microarrays.  The attributes of each sample were the 
AbStat measures.  Several machine learning statistics are presented in columns.  In a separate 
analysis, samples were randomly assigned a class as young or aged and the analysis was 
repeated. 
 In order to provide further evidence that age was the attribute of these individuals which 
allowed the measures to distinguish between young and aged, two different nationalities were 
compared.  One would not expect healthy individuals around the same age from different 
countries to have dramatically different antibody numbers, affinities, or avidities.  Eight Chinese 
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samples and twelve Indian samples from donors under the age of 40 were compared.  The 
machine learning algorithms were unable to distinguish between Chinese and Indian (Table 9). 
Table 9 Machine learning statistics for Chinese and Indian nationality 
Algorithm 
Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
SVM 52.4 -0.117 0.447 
J48graft 52.4 -0.117 0.519 
 
Two different algorithms with 10-fold cross-validation were used to predict the class (Chinese or 
Indian) of samples applied to the HT330K microarrays.  The attributes of each sample were the 
AbStat measures.  Several machine learning statistics are presented in columns. 
 All of these results support the idea that the global behavior of the antibody repertoire 
interacting with an array of peptide features changes with age, and this change can be detected 
with the AbStat measures.  Approximately 80% of the young and aged samples could be correctly 
classified using the AbStat, and classification accuracy may improve with more advanced peptide 
arrays manufactured in the future.  Note that it could also be interesting to apply pools of aged 
sera and pools of young sera to the array and test the classification performance of the AbStat 
with this data.  In general, the aged samples result in higher entropy fluorescence intensity 
distributions.  These findings could provide insight into the nature of the aging process as well as 
provide a method for monitoring health with age.  
1.3.7.3 Specific peptide analysis with aged humans 
A specific peptide analysis with the previous dataset could not be performed because this 
dataset combined human normal samples from the HT330K platform as well as the CIM10K 
platform in order to obtain a larger sample size for the classification algorithms.  The reason a 
specific peptide analysis cannot be performed with this data is because the identity and number 
of peptides on the two different platforms are different and a t-test among the samples for a given 
peptide cannot be performed.  Therefore, another analysis is presented here using only samples 
from the HT330K platform on wafers 20, 22, and 25.  Half of the samples were assigned to the 
 91 
training set, and half of the samples were assigned to the test set.  The top 100 peptides by p-
value from a t-test with the training samples were input into a classification algorithm.  Once 
trained, the algorithm was used to predict the class of the test samples.  The process was then 
repeated using samples with random class assignments.  Additionally, in a separate test, the 
values of the AbStat measures for the training samples were input into a classification algorithm, 
and then the algorithm was used to predict the class of the test samples with the AbStat 
measures.  The results of this analysis are presented in Table 10 for the real class assignments 
and in Table 11 for the random class assignments for each sample which should result in a much 
lower classification performance.  The classification performance of the specific peptide method 
vs the AbStat method was about the same, with the specific peptide method exhibiting slightly 
better performance. 
Table 10 Machine learning statistics for young and aged humans for specific peptide and 
AbStat method comparison 
Algorithm Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC 
Area 
Naïve Bayes 
Specific Peptide 
76.7 0.493 0.844 
SVM 
Specific Peptide 
86.7 0.683 0.841 
J48Graft 
Specific Peptide 
54.5 0.085 0.544 
Naïve Bayes 
AbStat 
73.3 0.366 0.683 
SVM  
AbStat 
66.7 0.333 0.824 
J48Graft  
AbStat 
76.7 0.493 0.77 
 
Three different algorithms were used to predict the class (young or aged) of samples applied to 
the HT330K microarrays.  Half of the samples were randomly selected as training samples and 
the other half was designated as the test set.  The top 100 most significant features by p-value 
from a t-test with the training samples only were used to train the algorithms.  The algorithms 
were then used to predict the class of the test set.  Several machine learning statistics are 
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presented in columns.  In a separate analysis, the process was repeated with the AbStat 
measures rather than from the features with the best p-value. 
Table 11 Machine learning statistics for young and aged humans for specific peptide and 
AbStat method comparison with random class assignments 
Algorithm Correctly 
Classified 
Instances 
Kappa 
Statistic 
ROC Area 
Naïve Bayes 
Specific Peptide 
63.3 -0.122 0.44 
SVM 
Specific Peptide 
66.7 -0.0638 0.476 
J48Graft 
Specific Peptide 
57.6 0.087 0.542 
Naïve Bayes 
AbStat  
50 -0.154 0.421 
SVM 
AbStat 
70 0.211 0.55 
J48Graft 
AbStat 
70 0 0.5 
 
Samples were randomly assigned to the young or aged class.  Then three different algorithms 
were used to predict the class (young or aged) of samples applied to the HT330K microarrays.  
Half of the samples were randomly selected as training samples and the other half was 
designated as the test set.  The top 100 most significant features by p-value from a t-test with the 
training samples only were used to train the algorithms.  The algorithms were then used to predict 
the class of the test set.  Several machine learning statistics are presented in columns.  In a 
separate analysis, the process was repeated with the AbStat measures rather than from the 
features with the best p-value. 
1.3.8 Rank of Measures 
Which metrics of the AbStat measures provide the most information about healthy and 
disease states?  The measures were evaluated in four different ways: 1. The rank of the measure 
by p-value acquired from comparing disease with normal (Figure 41); 2. The rank of the measure 
by p-value multiplied by the p-value acquired from comparing disease with normal (Figure 42); 3.  
The rank of the absolute value of the SVM weight for the measure acquired from comparing 
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disease with normal (Figure 43); 4.  The rank of the absolute value of the SVM weight multiplied 
by the reciprocal SVM weight acquired from comparing disease with normal (Figure 44).  The 
reciprocal was used so that smaller values would indicate the best rank as in the other three 
methods of ranking.  The log of this value was taken since the values spanned a very large 
range.  Four datasets were used to calculate the rank values: the first 330k dataset (“1.3.6.1 
HT330K first chip disease dataset”); the 330k dataset from wafer 46 (“1.3.6.2 HT330K wafer 46”); 
the 10k dataset (“1.3.6.3 CIM10K”); and the human age dataset (“1.3.7.2 Changes with age in 
humans”).  These results indicate that entropy is one of the best measures for distinguishing 
disease and normal samples followed by measures such as skew, kurtosis, cv, and dynamic 
range. 
 
Figure 41 Sum of rank of measures by p-value 
The sum of the rank of the AbStat measures by p-value acquired from comparing disease with 
normal from four different datasets was plotted in a bar graph. 
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Figure 42 Sum of rank of measures multiplied by the p-value 
The sum of the rank of the AbStat measures by the p-value acquired from comparing disease 
with normal multiplied by the actual value of the p-value from four different datasets was plotted in 
a bar graph. 
 
 
Figure 43 Sum of SVM Rank of measures determined by greatest absolute value SVM 
weight 
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The sum of the rank of the AbStat measures by absolute value SVM weight obtained from 
classifying disease and normal samples from four different datasets was plotted in a bar graph. 
 
 
Figure 44 Sum of the log of the SVM rank multiplied by the reciprocal of the absolute value 
of the SVM weight 
The sum of the log of the rank of the AbStat measures by absolute value SVM weight obtained 
from classifying disease and normal samples multiplied by the actual SVM weight from four 
different datasets was plotted in a bar graph. 
1.3.9 Range of entropy 
What is the typical range of entropy in healthy and disease states?  A box and dot plot 
with the mean plus or minus one or two standard deviations for normal and disease samples is 
presented in Figure 45.  This plot was constructed using data from four different datasets: the 1st 
330k (“1.3.6.1 HT330K first chip disease dataset”); the wafer 46 330k (“1.3.6.2 HT330K wafer 
46”); CIM10K (“1.3.6.3 CIM10K”); and the young/aged dataset (“1.3.7.2 Changes with age in 
humans”).  The plot shows that the average entropy of disease samples is higher than the 
average entropy of normal samples.  The plot also shows that there are many more data points at 
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the highest range that are disease samples, and there are many more data points at the lowest 
range that are normal samples.  With this dataset, the total range of the normal samples is so 
large that it includes the range for the disease samples. 
 
Figure 45 Box and dot plot of entropy values for normal and disease or aged states across 
four different datasets. 
The blue solid line is the mean entropy for normal, the blue dashed line is the mean +/- 1 
standard deviation, and the blue dotted line is the mean +/- 2 standard deviations.  The red solid 
line is the mean for disease/age, the red dashed line is the mean+/-1 standard deviation, and the 
red dotted line is the mean +/- 2 standard deviations. 
1.3.10 Quantitative analysis of the entropy measure 
This section aims to identify how changes in the numerical analysis of the entropy 
measure affect the final outcome.  From such an analysis, one may identify which parts of the 
fluorescence intensity distribution are most important for the entropy measure.  One may also 
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identify possible ways to perform the entropy calculation to enhance the power of the entropy 
metric to distinguish between healthy and disease groups. 
1.3.10.1 Changes in entropy measure with removal of peptides 
What is the characteristic of the peptides which contribute the most to the entropy 
measurement of the AbStat?  In order to investigate this question, the 5 breast cancer samples 
and 24 normal samples from wafer 46 (“1.3.6.2 HT330K wafer 46”) were compared.  Different 
types of peptides were removed, the entropy was calculated for each sample with these removed 
peptides, and then a t-test between the two groups was performed.  The results of this analysis 
are presented in (“Figure 46 P-value vs peptides removed”).  In this figure, random peptides were 
removed five different times, and the standard deviation of the p-value for these five different 
times is plotted on the graph as error bars.  However, the error bars are so small that they are not 
visible until about only 10,000 peptides are remaining.  The graph has multiple axes so that the 
data can be viewed from different perspectives.  On the y-axis the –log10 p-value is plotted so 
that more significant p-values are higher on the graph.  The actual p-values at these positions are 
also displayed on the second y-axis so that one can quickly determine if a value is less than a p-
value of 0.05 or another value.  The log10 of the number of peptides removed is plotted on the x-
axis, and the log10 is used since there is such a wide range of peptides removed.  The second x-
axis displays the actual number of peptides that were removed at each evaluation, and the third 
x-axis displays the number of peptides remaining, rather than removed, from the original 330k 
distribution.  Note that as the random peptides were removed, the average entropy of the breast 
cancer groups (groups is plural because there were 5 different trials of random peptide selection) 
at each step was higher than the average entropy of the normal groups until there are only 1,000 
peptides, at which point the inequality flips. 
In addition to the random removal of peptides, peptides that were the most significant 
based on a t-test for the feature intensities for the two groups were also removed.  These are the 
peptides that constituted the immunosignature of the disease of interest.  Note that the average 
entropy of the breast cancer group is always higher than the average entropy of the normal group 
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at each step until there are only 50 peptides left at which point the inequality flips.  In another 
analysis, the highest signal peptides for each sample were removed.  Each sample was sorted by 
its own highest intensity.  Therefore, in the highest intensity analysis, the same peptides were not 
removed from each sample at each step.  The average entropy of the breast cancer group is 
higher than the average entropy of the normal group at each step until there are only 50 peptides 
left, at which point the inequality flips. 
Some additional graphs provide more information about Figure 46 A.  In this graph, there 
are many data points that lie in the region of the graph where there are few peptides remaining.  
Due to the scale, these data points are not well separated.   A graph for 5,000 peptides remaining 
or less is also presented in Figure 46 B.  The value of the most significant p-value in the peptide 
distribution at every point as the peptides were removed, rather than the p-value from a t-test 
between two groups with entropy values, is presented in Figure 47. 
A) 
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B) 
 
Figure 46 P-value vs peptides removed 
A) Highest intensity, disease specific (based on p-value), or random peptide features were 
removed, the entropy was calculated for each sample with these removed peptides, and then a t-
test between the two groups of breast cancer vs normal was performed.  The y-axis displays the 
p-value from the test as well as the negative logarithm of the p-value.  The x-axis displays the 
logarithm of the number of peptides removed, the number of peptides removed, and the number 
of peptides remaining.  B)  The same data is plotted from 5,000 to 20 peptides remaining only. 
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Figure 47 P-value of most significant peptide vs significant peptides removed 
The value of the most significant p-value peptide from a t-test between normal and disease (no 
entropy values were a part of this calculation) was plotted in a line graph as the most significant 
peptides were removed. 
 More details about the highest fluorescence intensity features can be investigated.  One 
might be curious about the value of the highest fluorescence intensity at each step as the highest 
fluorescence intensity peptides are removed.  In Figure 46 the p-value becomes much more 
significant between the normal and breast cancer groups when only 1,000 peptides remain 
(329,173 peptides removed) after the highest intensity peptides have been removed.  What is the 
fluorescence intensity of the highest intensity peptide for each sample at this point?  The heatmap 
in Figure 48 A shows the value of the highest fluorescence intensity peptide for each sample as 
the highest fluorescence intensity peptides are removed.  The heatmap in Figure 48 B shows the 
same data with a color bar scale from 0-2000 only instead of 0-70,000.  In this figure, the highest 
fluorescence intensity value for each sample lies around 1,000 when there are only 1,000 
features remaining.  This information might suggest that calculating the entropy with fluorescence 
intensities less than about 2,000 could be beneficial in certain circumstances.  The “noise” or 
distribution of fluorescence intensities in this low fluorescence intensity range appears to be 
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different in normal and disease samples, and the evidence for this is provided in the p-value 
graph in Figure 46. 
A) 
 
B) 
 
Figure 48 Heatmap of highest intensities as highest intensity features are removed 
The columns contain the samples with BC for breast cancer and N for normal.  The rows indicate 
the number of highest intensity features removed.  The color of each square corresponds to the 
intensity value of the highest intensity feature remaining for the given sample.  In A) the color bar 
ranges from 0-70,000 and in B) the color bar ranges from 0-2,000 for the same data. 
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Another analysis was performed in which the least significant peptides were removed.  
The entropy of each sample was obtained, and a t-test between the breast cancer and normal 
group was performed.  A graph of the p-value between the two groups as the least significant 
peptides were removed is displayed in Figure 49.  The entropy of the breast cancer group is 
higher at each step until there are 100,000 peptides remaining, at which point the inequality flips.  
From there, the average entropy of the breast cancer group is lower than the average entropy of 
the normal group at each step until there are only 1,000 peptides remaining, at which point the 
inequality flips.  The actual p-value of the least significant peptide as least significant peptides 
were removed is plotted in Figure 50. 
 
Figure 49 P-value vs least significant peptides removed 
The least disease specific (based on p-value) peptide features were removed, the entropy was 
calculated for each sample with these removed peptides, and then a t-test between the two 
groups of breast cancer vs normal was performed.  The y-axis displays the p-value from the test 
as well as the negative logarithm of the p-value.  The x-axis displays the logarithm of the number 
of peptides removed, the number of peptides removed, and the number of peptides remaining. 
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Figure 50 P-value of least significant peptide vs peptides removed 
The value of the least significant p-value peptide from a t-test between normal and disease (no 
entropy values were a part of this calculation) was plotted in a line graph as the least significant 
peptides were removed. 
How did the distinguishing power of the entropy measure change as the lowest intensity 
peptides were removed?  The lowest intensity peptides were removed from each sample 
individually.  Therefore, the identity of the peptides removed in each sample could be slightly 
different.  The entropy of each sample was obtained, and a t-test between the breast cancer and 
normal group was performed.  A graph of the p-value between the two groups as the lowest 
intensity peptides were removed is displayed in Figure 51.  The entropy of the breast cancer 
group is higher at each step until there are 100,000 peptides remaining, at which point the 
inequality flips.  The inequality is somewhat sporadic after this point.  The entropy of the normal 
group is then higher when there are 10,000 peptides remaining, higher when there are 5,000 
peptides remaining, lower when there are 1,000 peptides remaining, higher when there are 500 
peptides remaining, and lower when there are 100 peptides remaining.  The p-value does not 
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change much until about only 100,000 peptides remain after removing the lowest intensity 
peptides.  Nevertheless this indicates that the 230,173 lowest intensity peptides are important for 
the entropy measure.  In fact, low intensity peptides appear to be more important than high 
intensity peptides since removing these peptides decreases the significance of the p-value and 
taking away high intensity peptides can increase the significance of the p-value as shown in 
Figure 46.   
 
Figure 51 P-value vs lowest intensity peptides removed 
The lowest intensity peptide features were removed, the entropy was calculated for each sample 
with these removed peptides, and then a t-test between the two groups of breast cancer vs 
normal was performed.  The y-axis displays the p-value from the test as well as the negative 
logarithm of the p-value.  The x-axis displays the logarithm of the number of peptides removed, 
the number of peptides removed, and the number of peptides remaining. 
1.3.10.2 Change in entropy with change in bin size 
When calculating entropy, it is necessary to set the size of the bins.  How does the ability 
of the entropy metric to distinguish between disease and healthy groups change with changes in 
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bin size?  In order to investigate this question, the 5 breast cancer samples and 24 normal 
samples from wafer 46 (1.3.6.2 HT330K wafer 46) were compared.  The bin size was adjusted 
from 1 to 60,000 (the max fluorescence intensity is 65,535), the entropy was calculated for each 
sample at each bin size, and a p-value from a t-test with the normal donor and breast cancer 
groups was acquired.  The results are presented in Figure 52.  Note that throughout this 
dissertation, if the bin size was not specified, then the smallest bin size of 1 was used.  These 
results demonstrate that the p-value generally increases (becomes less significant) with 
increasing bin size with some exceptions like the exception at a bin size of 5,000 (Figure 52 B).  
Note that at every bin size, the average entropy of the breast cancer group was higher than the 
average entropy of the normal group. 
A) 
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B) 
 
C) 
 
Figure 52 P-value vs bin size 
The bin size was adjusted and the entropy of each sample was calculated.  A p-value from a t-
test between breast cancer and normal with the entropy values was then performed.  The p-value 
vs bin size was plotted on a line graph.  The bin size was adjusted from 1 to 500 in A), 500 to 
60,000 in B), and 1,000 to 10,000 in C). 
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 The slight drop in p-value at a bin size of 5,000 was somewhat surprising (Figure 52 B).  
The p-values at more bin sizes near a bin size of 5,000 were acquired to increase the resolution 
of the curve near this area.  This data is presented in Figure 52 C.  This curve shows that there is 
a drop in p-value after a bin size of 3,000, and the lowest p-value is near a bin size of 4,000.  
Note that the p-value at a bin size of 4,000 is not dramatically different than the p-value at a bin 
size of 5,000. 
1.4 Discussion 
The AbStat measures provide indicators for a wide variety of different immunological 
situations.  I first demonstrated that the entropy measure of three different antibodies was 
different and correlated with the affinity of these antibodies for their cognate epitopes.  Next I 
investigated the behavior of the AbStat measures as the concentration of a monoclonal antibody 
spiked into sera was increased, and I found that the entropy decreased up to a certain point in 
two different experiments.  Next I investigated the behavior of the AbStat with mouse vaccines 
and infections and found that entropy decreased after vaccination, while also increasing in 
general over long periods of time.  Human vaccines also showed that the entropy decreased after 
vaccination if more than three days had passed.  Dog lymphoma samples revealed that the 
entropy decreases when one single antibody begins to comprise a larger portion of the antibody 
repertoire, and these findings supported the results from the controlled antibody spiking 
experiments.  A cancer mouse was also compared to a normal mouse.  The normal mouse 
exhibited a steady increase in entropy over time, but the entropy of the cancer mouse over time 
was much more sporadic.  Human infectious disease, chronic disease, and normal samples were 
investigated and I demonstrated that the AbStat measures can be used to correctly classify the 
samples with about 80% accuracy with the HT330K platform, but only 60% accuracy with the 
CIM10K platform.  The entropy was generally higher for the disease samples.  Alzheimer’s 
samples could not be distinguished from the controls.  Finally, I demonstrated that the AbStat 
measures were capable of distinguishing young mice from aged mice as well as young humans 
from aged humans with a higher entropy in the aged state. 
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I also used the data from these experiments to rank the most important measures of the 
AbStat, and the entropy measure turns out to be the most distinguishing measure.  A more 
detailed analysis of this entropy measure reveals that it is more affected by peptides with certain 
characteristics such as high intensity or statistical significance than randomly selected peptides.  
Ultimately, the concept of using entropy and other broad measures of a distribution to assess the 
vitality of a complex adaptive system is not restricted to antibodies and non-natural sequence 
peptides.  The potential of the AbStat for the immune system though is that it can aid with 
diagnosis of health and disease states, and the concept may also lead to strategies to mitigate 
the development of disease states such as old age. 
1.4.1 AbStat changes with artificial antibody experiments 
Three different controlled antibody experiments were performed in order to understand 
the relationship of the AbStat measures with certain types of antibody mixtures: 1. Antibodies with 
a range of recorded affinities for their targets were applied to the array; and 2. Increasing 
concentrations of antibody against a single target were spiked into sera.  The knowledge gained 
from these experiments allowed for better understanding and prediction of the AbStat behavior 
with different health states. 
1.4.1.1 Monoclonal affinities and AbStat measures 
The different types of measures exhibit different behaviors across the range of affinities 
tested.  An affinity is quantified by the Kd value which measures the strength of the interaction 
between an antibody and its cognate epitope.  Although the cognate epitope may not be present 
in any of the non-natural peptides on the microarray, an antibody with a high affinity for its 
cognate epitope will also have a higher affinity for mimotopes present in some of the peptides on 
the array.  The following measures increase as the Kd increases and the monoclonal antibody 
binds less tightly to its specific cognate epitope: entropy, mean, median, 5th percentile, 95th 
percentile, 95th percentile normalized, dynamic range, standard deviation, and min.  The 
following measures decrease as the Kd increases: minimum normalized, standard deviation 
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normalized, mean normalized, 5th percentile normalized, cv, kurtosis, and skew.  The maximum 
did not follow a trend in one direction.   
What is a possible explanation for the trends observed?  In general an antibody with a 
low Kd will bind tightly to peptides with sequences similar to the target, and the intensities of the 
interactions may be in a very similar range.  This will produce a “spike” in the fluorescence 
intensity distribution.  The entropy of such a distribution will be lower than a broad distribution, 
and the mean and median may remain on the lower end if there are only a few specific high 
signals.  This logic would also apply to the 95th percentile, 5th percentile, and dynamic range 
which is actually the ratio of the 95th percentile to the 5th percentile.  An antibody with a high Kd 
for the target, on the other hand, will not bind tightly to peptides with sequences similar to the 
target.  These antibodies may bind more broadly to many different peptides on the array in a 
more chaotic manner producing many different intensity values thus leading to a higher entropy 
and an overall higher mean, median, and dynamic range.  Note that the kurtosis and skew often 
exhibit the opposite behavior of entropy, and many of the other measures which decrease as the 
Kd increases are measures calculated after the fluorescence intensity distribution has been 
median normalized. 
The observations can be concisely summarized by stating that high affinity antibodies 
(low Kd) will result in fluorescence intensity distributions with tight peaks (“Figure 3 Histogram and 
box plot for <0.1 nM Kd antibody”), and  low affinity antibodies (high Kd) will result in fluorescence 
intensity distributions with broad peaks (“Figure 4 Histogram and box plot for 80 nM Kd 
antibody”).  A high affinity antibody will bind tightly to a few peptides and ultimately result in a high 
fluorescence intensity for these array features.  The rest of the fluorescence intensity distribution 
will form a tight high peak in the range with almost no intensity value (values close to zero).  A low 
affinity antibody on the other hand will bind chaotically with mostly weak binding to many different 
peptides forming a shorter broader peak in the lower intensity range with moderate binding in the 
mid and high intensity ranges.  Note that the reason high affinity antibodies can bind tightly to a 
few specific sequences is due to the fact that high affinity antibodies are affinity matured 
antibodies representing the immune system’s mature, late response to an antigen.  The summary 
 110 
measures used can distinguish between narrow and broad fluorescence intensity distribution 
shapes and summarize the observation in a single quantitative number.  Although all of the 
different measures are calculated in a different manner, most of them will have general trends for 
narrow or broad distributions. 
1.4.1.2 Spiking antibody into sera 
Two separate experiments in which antibody was spiked into normal sera at increasing 
concentrations resulted in similar trends.  In both experiments, both the entropy and mean from 
raw intensity values decreased as increasing concentrations of antibody against a single target 
were added (“1.3.1.2 Spiking antibody into sera”).  Then once a certain point was reached the 
trend reversed and both the mean and entropy increased.  An explanation for the decrease in 
entropy as more target specific antibody is added is that the antibody will bind to a few peptides 
with sequences similar to the target epitope with roughly the same intensity.  Therefore, a “spike” 
in the fluorescence intensity distribution may appear which would lead to a lower calculated 
entropy.  After a certain concentration is reached, however, the antibody will have already bound 
to all of the peptides on the array with sequences similar to the target epitope.  Once this 
saturation point is reached, the antibody may “spill over” and bind to many other peptides with a 
variety of intensities which would lead to a broader fluorescence intensity distribution profile and 
therefore a higher calculated entropy value.  These observations suggest that a solution which 
behaves more like a monoclonal antibody will have a lower entropy unless the monoclonal 
antibodies have completely saturated the array.  A corollary is that the entropy may show a 
concentration curve dependent on the ratio of peptides to antibodies. 
Also note that although the entropy and the mean followed similar trends, they are 
different measures and one or the other may provide more or less resolution between samples 
depending on the situation.  For example, when comparing the 1 nM concentration to the 10 nM 
concentration in “Figure 6 Entropy for increasing concentrations of α–gp120 antibody into normal 
human sera”, the entropy provides a more significant difference between the two groups than the 
mean (p-value of 0.0253 compared to 0.140).  Also note that while the mean will change 
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depending on whether or not the data has been median normalized, the value of the entropy will 
remain unchanged.  This is a particularly important feature when trying to compare data across 
different array types. 
How reasonable is the explanation that the trend of the entropy reversed due to 
saturation of the target peptides?  A few very approximate calculations can be used to address 
this question.  For the sake of simplicity, the system of the peptide microarray is modeled by 
pretending that the target peptides of the antibody are present at a homogenous concentration in 
the chamber rather than just at spots on the slide surface.  We can use the Kd equation to 
determine the Kd of the antibody if the system has reached saturation so that all of the target 
peptides are bound by antibody.  The entropy trend in “Figure 5 Entropy for increasing 
concentrations of α-GFOD1 antibody into normal mouse sera” for the GFOD antibody may 
indicate that saturation has been reached at about 5 nM since the trend reverses at this point.  
Note that the Kd values of antibodies typically range from 1 pM to 10 µM.  If the system is 
saturated and 95% of the target peptides have been bound by antibody when the concentration of 
free antibody is approximately 5 nM, then the Kd value would be 0.3 nM which lies within the 
normal range of Kd values for antibodies (Equation 6).  If 95% of the  target peptides have been 
bound at an antibody concentration of  approximately 1 nM, as Figure 6 may suggest for the 
gp120 antibody, then the Kd value would be 50 pM.   These approximate calculations support the 
idea that the entropy may start to increase once the target peptides have been saturated.  
Beyond this antibody concentration, the additional antibodies may bind with less specificity and 
even bind somewhat randomly to the remaining peptides on the array. 
 
Equation 6 Dissociation constant calculation for saturation at 5 nM 
In this calculation [A] can be considered to be the concentration of free antibody, [B] is the 
concentration of free peptide, and [AB] is the concentration of peptide bound to antibody.   When 
95% of the free peptide is bound by antibody, the concentration of free peptide is 0.05 multiplied 
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by the original concentration of peptide, and the concentration of antibody bound by peptide is 
0.95 multiplied by the original concentration of peptide. 
These approximate Kd calculations can be compared with the Kd values determined from 
a one to one binding model.  The software Graphpad Prism can implement a one to one binding 
model to perform non-linear regression to fit the equation y = Bmax*X/(Kd+X) where y is the 
specific binding, Bmax is the maximum specific binding, X is the concentration of ligand, and the Kd 
is the equilibrium binding constant defined as the ligand concentration needed to achieve half-
maximum binding.  The input in this case is the fluorescence intensity value of a peptide at 
various concentrations of antibody.  In order to use this model the top 10 peptides by intensity 
were chosen.  Note that a peptide was not chosen if the intensity was at the maximum value for 
all concentrations.  The Kd value was then calculated for each peptide, and the calculated Kd 
values from peptides with an r2>0.90 for the non-linear regression were averaged.  The resulting 
Kd for the GFOD antibody is 61.9 nM, and the resulting Kd for the gp120 antibody is 15.9 nM.  
The approximated Kd from the entropy described previously was 0.3 nM for the GFOD antibody 
and 0.05 nM for the gp120 antibody.  Although the Kd values from these two different methods of 
approximation differ, the order of Kd values for the two different antibodies remains the same, 
and both methods yield Kd values within the normal range observed for antibodies. 
 In summary, entropy appears to decrease as increasing concentrations of antibody 
against a single target are added.  However, once the concentration is high enough, the entropy 
reverses and begins to increase.  The point at which the trend in entropy reverses may be near 
the concentration of antibody at which the targets have been bound and the array is saturated.  At 
this point, antibody may “spill over” and bind to many other peptides somewhat non-specifically.  
A few approximate methods for determining the Kd from this data support this hypothesis since 
the Kd values obtained are within a normal antibody Kd range.  Note that the relationship of the 
entropy to the antibody concentration may be non-linear since the “spill over” antibody binding 
may be driven by avidity, which may be a more diffuse process than a process driven by affinity. 
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1.4.1.3 Summary of AbStat changes with artificial antibody experiments 
These controlled antibody experiments reveal trends in the AbStat measures for certain 
types of solutions.  In these examples, solutions that behave more like a monoclonal antibody 
have low values (with the exception of kurtosis and skew which will be high), and solutions that 
are complex with low affinity antibodies will have high values.  This conclusion is derived from two 
types of experiments.  In the first type of experiment antibodies with high or low affinities were 
applied to the array, and the data revealed that measures which often followed entropy increase 
for low affinity antibodies.  A second type of experiment involved antibody spiking experiments.  
Two examples of antibody spiked into normal sera revealed that measures that follow the entropy 
decreased as monoclonal antibody was added up until a certain point, and then at concentrations 
greater than this point the trend reversed indicating that the array may be fully saturated.  The 
lessons learned from these experiments indicate that if there is a disease that raises a few high 
affinity antibodies or alternatively results in a complex mixture of many different antibodies, then 
the AbStat measures such as entropy will be significantly different enough from normal sera to 
detect a change. 
Note that it is extremely important to point out that not all of the measures are always 
positively or negatively correlated with entropy.  In these tightly controlled artificial antibody 
experiments, this was mostly the case.  However, there are certainly situations in which this 
would not be the case.  For example, one could have a very low entropy, but a very high mean, 
which was not observed in these experiments.  This situation would occur when there is a very 
high tight narrow peak at a very high intensity value.  Each measure characterizes the peptide 
distribution in a unique way and they do not all positively follow or negatively follow one another in 
all circumstances.  The results from the human disease data demonstrates this (“1.3.6 Human 
disease”).  Three measures which do appear to be quite connected are entropy, kurtosis, and 
skew.  When the entropy is low, kurtosis and skew are usually high; when the entropy is high, 
kurtosis and skew are usually low. 
The observations from these controlled artificial antibody experiments aid in 
understanding the state of human sera.  Diseases which make the sera appear more like a 
 114 
monoclonal antibody should decrease the entropy measure.  For example, in a B cell lymphoma 
a great portion of the antibody repertoire consists of one single antibody from a B cell that is 
proliferating out of control and producing large amounts of one antibody.  Vaccines may also 
result in a similar observation since a vaccine will induce the immune system to produce large 
amounts of antibody against a single well defined target in a short amount of time.  Diseases in 
which there is a large amount of inflammation and many non-specific and specific antibodies 
against many different targets would have complex antibody mixtures with many low affinity 
antibodies.  These types of diseases may result in a high entropy value.  Diseases that could fall 
into this category are chronic diseases such as cancer, and autoimmune diseases.  The aging 
process may also fall into this category as overall inflammation (non-specific immune responses) 
and autoimmunity increases.  Even without an increase in inflammation and autoimmunity, the 
aging process might lead to an increase in the complexity of the antibody repertoire as more 
antibodies are produced against more targets over time. 
There are detectable and quantifiable changes in the overall antibody repertoire when 
transitioning from different types of health and disease states.  These controlled antibody 
experiments provide insight into the correlation between different types of antibody mixtures and 
several quantitative measures.  This insight can be further applied to understand actual sera in 
various health states. 
1.4.2 Mouse vaccines and infection 
There were three separate experiments in which mice were vaccinated against or 
infected with an infectious pathogen: 246 day time course experiment, a multiple mouse 
immunization experiment, and a 6 day time course.  The 6 day time course may have been too 
short to detect many changes in the AbStat.  However, the 246 day time course spanned a 
considerable portion of the mouse lifespan and the AbStat exhibited some clear trends over this 
long period of time.  The multiple mouse immunization experiment revealed differences in 
measures of the AbStat for the different groups.  These experiments provided some initial insight 
before examining human vaccine data. 
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1.4.2.1 246 day time course 
In the 246 day time course many of the AbStat measures change in a consistent way over 
several time points.  For example, the entropy measure increases as the mouse age increases 
(Figure 8).  The normalized standard deviation and normalized 95th percentile start high and 
decrease with age, while the mean, median, and ninety fifth percentile start low, but then increase 
with age (Figure 7).  Therefore, there are clear changes that occur in the overall binding of the 
array, and these changes can be detected without focusing on specific peptides which may have 
a mimotope with a known antigen.  For this particular experiment, it is unclear whether these 
changes are due to the vaccine and challenge, the aging process alone, or a combination of both 
since there is not a mock group to compare the experimental group with. 
1.4.2.2 Multiple mouse immunizations 
The multiple mouse immunization experiment had data for one time point 37 days after 
treatment which consisted of one of two immunizations, a killed PR8 injection, an infection, or a 
mock treatment.  The group with the greatest entropy was the infected group, and the group with 
the lowest entropy was the 2007-2008 vaccinated group.  For this experiment, the dynamic range 
was the measure that was able to distinguish between some of the groups the very best since the 
dynamic range had the best p-value for mock vs infected, and the SVM algorithm assigned the 
greatest weight to the 5th percentile normalized and dynamic range measures.  The dynamic 
range was lower in the infected group than the normal group which indicates that there was a 
narrower range of intensities produced by antibodies binding to non-natural sequence peptides 
for the infected group.  Overall, a SVM algorithm was able to make more accurate predictions of 
mock vs infected with the real data rather than data with random assignments.  This increase in 
prediction accuracy indicates that it is possible to detect changes in the immune system from 
broad measures which summarize all of the data from antibodies interacting with an array of non-
natural sequence peptides. 
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1.4.2.3 6 day time course 
Significant differences in the AbStat measures for the mock vs infected groups could not be 
detected after 6 days of infection with this mouse experiment.  The timeframe may have been too 
short.  Another possibility may be that differences would be able to be detected on newer arrays 
with 330k peptides instead of 10k peptides.  Our lab has also performed experiments on several 
versions of 10k slides over the years, and this experiment was performed on the earliest version 
of 10k arrays. 
1.4.3 Human vaccines 
The results from the human vaccines indicate that in general the entropy decreases shortly 
following vaccination.  A decrease in entropy after vaccination was observed in individual 43 for 
the 2006 vaccination and in individual 84 for the 2009 vaccination (“Figure 11 Change in entropy 
after vaccination”).  A decrease in entropy was not observed for individual 43 in 2009 3 days after 
the vaccination.  This was the shortest time point observed after vaccination, and the data may 
have been collected too soon to observe a difference in entropy.  In the one month trial, both 
individuals generally exhibit a decrease in entropy after vaccination, which then later increases 
back again (“Figure 12 Daily one month entropy change”).  Individual 84 reported catching a cold 
on day 17, and there was a very dramatic drop in the entropy on day 27, which was just 10 days 
later.  The entropy stayed low for one more day before returning back to the previous level.  Note 
that no blood was drawn on days 23-26 due to the individual's illness.  These observations 
indicate that changes in the overall fluorescence intensity distribution can capture the event of an 
individual catching a cold. 
The observed decrease in entropy following vaccination is likely due to an increasing 
predominance of antibodies in the antibody repertoire against a single target present in the 
vaccine.  The notion that the global AbStat measures could detect a change in the antibody 
repertoire makes some sense in relation to the amount of antibody a human body can produce to 
protect itself from an infection.  The exact amount of antibody required for protection varies from 
disease to disease, but the amount of antibody against a target can often be as much as 0.1 mg 
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77, and the Center for Innovations of Medicine has always identified a unique set of peptides for 
each disease 1, 9.  Note that after a vaccine there will be a decrease in entropy, but a higher 
mean.  This higher mean is likely due to more peptides binding to the antibodies produced 
against the vaccine target. 
1.4.4 Reduction in antibody repertoire complexity with lymphoma 
During the course of a lymphoma, a single B cell proliferates uncontrollably and can produce 
a large amount of the single type of antibody which it produces.  The rate at which a single B cell 
can produce antibodies is astounding, with 5,000-20,000 antibodies secreted per minute 1.  The B 
cell itself divides about every 70 hr, which would ultimately lead to an amplification of 1011 for a 
specific antibody in just one week.  Altogether there are about 4*1016 IgG antibody molecules in 
one milliliter of blood 78.  Therefore, the complexity of the antibody repertoire is reduced as an 
antibody that binds to one target makes up an increasingly larger proportion of the repertoire.  
Note also that researchers in the Center for Innovations in Medicine have also previously 
demonstrated that an individual lymphoma signature can be detected for each dog as well as a 
general immunosignature in common among the dogs.  The unique individual immunosignature 
consists of approximately 6 to 8 peptides (unpublished data).  Therefore, the antibodies from the 
cancer B cell clone can be detected on the non-natural sequence peptide array.  These facts 
provide an explanation for the ability of the AbStat metrics to detect a change in the dogs with a 
lymphosarcoma.  The reduction in antibody repertoire complexity manifests itself as a reduction in 
entropy in the fluorescence intensity distribution acquired from application of the sera to a non-
natural sequence peptide array (Figure 13).  This reduction in entropy is caused by a narrower 
fluorescence intensity distribution, and this result is consistent with the results from spiking 
increasing concentrations of a single monoclonal into normal sera (“1.3.1.2 Spiking antibody into 
sera”). 
The results from applying the SVM algorithm to the data indicates that there truly are unique 
characteristics associated with the fluorescence intensity distribution that help classify a sample 
as either normal or LSA.  The SVM could correctly classify with an accuracy of 78.8%, but when 
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the classes were randomly assigned, the SVM could only correctly classify 52.3% of the samples 
which is the performance one would expect if one were to randomly guess the class of each 
sample.  Note that the measure with the best p-value is not necessarily the measure with the 
highest SVM weight.  For example, with this dataset entropy had the 2nd best p-value but the 8th 
highest absolute value SVM weight.  Overall these results demonstrate that these measures can 
be used to classify a dog sample as normal or LSA with approximately 80% accuracy. 
1.4.5 Mouse cancer progression 
The behavior of the entropy of the fluorescence intensity distribution over time for the 
transgenic mouse and the normal mouse was dramatically different.  The entropy of the 
transgenic mouse was somewhat sporadic as it continually increased for a short time, decreased 
for a short time, and then repeated (“Figure 14 Entropy time course for transgenic and wild type 
mouse”).  For example the entropy increased from about week 15 to week 19, decreased from 
week 19 to 21, increased from week 24 to 27, decreased from 27 to 29, increased from 29 to 33, 
decreased from 33 to 39, increased from 39 to 41, and decreased from week 41 to 43.  The 
entropy of the wild type mouse on the other hand constantly increases from week 15 to week 33 
after which the value of the entropy basically reaches a plateau relative to the other points (Figure 
14).  One possible explanation for this behavior is that the immune system of the transgenic 
mouse is constantly battling the cancer and changing.  At one time the antibody repertoire might 
consist of a large amount of antibody against a single target, and at another time there may be 
more general inflammation and many different antibodies with varying affinities against different 
targets.  The wild type mouse on the other hand may just have a slow increase of general 
inflammation or simply just an increase in the number of antibodies with time resulting in a steady 
increase in entropy.  The constant change in entropy observed in the transgenic mice as opposed 
to the steady increase in entropy of the normal mice may provide a method for detecting cancer 
early.  Constant changes in the entropy value may indicate that a cancer is developing.  
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1.4.6 Human disease data 
Samples from patients diagnosed with diseases could be classified with an accuracy 
better than chance based on the AbStat measures as sample attributes.  The HT330K human 
disease samples could be classified based on the values of the measures with an accuracy of 
approximately 80%, the CIM10K samples could be classified with an accuracy of approximately 
60%, and the Alzheimer’s dataset could be classified no better than chance.  This performance 
was not achieved when the class of each sample (disease or normal) was randomly assigned.  
Therefore, there are differences in the measures that are unique to disease which distinguish 
disease from normal samples.  The poor performance obtained with the Alzheimer’s dataset 
indicates that there is not enough resolution provided by these measures to distinguish between 
Alzheimer’s patients and non-cognitive impairment controls of approximately the same age.  As 
stated in the Alzheimer’s results section (“1.3.6.4 Alzheimer’s disease”), a classification accuracy 
of about 75% was achieved by using methods which select specific peptides instead of the global 
measure methods of the AbStat.  Therefore, AbStat is not appropriate for all scenarios. 
On the other hand, one of the interesting aspects of the classification of human diseases 
with the AbStat is that specific peptides with a high or low intensity for each disease were not 
identified.  In certain situations, this could be an advantage since the classification is not 
dependent on the presence of peptides with specific sequences.  Instead, the overall 
characteristics of the fluorescence intensity distribution summarized into single quantitative 
values were able to provide enough information for the classification performance observed.  
These characteristics were able to classify a sample as disease over a very wide range of 
diseases from a variety of different infectious diseases to a variety of different chronic diseases.  
Therefore, there appears to be a fundamental pattern in the antibody repertoire that applies to a 
very wide spectrum of disease states that is not present in normal states. 
1.4.7 Changes with age 
Does the antibody repertoire contain information about an organism’s age?  Can this 
information be captured and quantified?  Differences in the fluorescence intensity distribution 
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resulting from the application of young or aged sera to a non-natural sequence peptide array are 
present.  These differences were detected in both mice and humans.  Using quantitative 
measures of this fluorescence intensity distribution from humans, it is possible to classify a 
sample as young (≤25 yo) or aged (≥50 yo) with about 80% accuracy.  The algorithms can 
classify no better than chance when samples are assigned a class (young or aged) randomly.  
Note that the changes that occur with age are similar to the changes that occur with disease 
since both groups exhibit an increase in entropy. 
What are other metrics of aging, and how is the entropy calculated from the data of 
antibodies reacting with a non-natural sequence peptide microarray a useful metric for aging?  
Everyone has a general notion of what “aging” is, but there can be disagreement about precise 
definitions.  Chronological age can be precisely quantitated, but chronological age and biological 
age are two very different things.  Aging can be generally viewed as the decline of health with 
increasing chronological age, as well as increased vulnerability to death 79.  Some definitions of 
health include “the capacity to adapt to changing external and internal circumstances”, “wellbeing 
and not merely the absence of disease” from the World Health Organization, the opposite of 
“disorder of structure or function in an organism” from the Oxford dictionary for the definition of 
disease, and “the capacity to love and work” from Sigmund Freud 80.  As people age and health 
declines, many physiological process go awry: wound healing rates decrease 81, lean muscle 
body mass decreases, muscle strength decreases, progressive demineralization leads to decline 
of bone strength, neurodegeneration occurs, balance decreases, reaction times decrease, 
memory declines, sensory (vision, hearing, taste) abilities decrease, resting metabolic rate 
decreases, and homeostasis pathways consisting of hormones and inflammatory molecules 
provide less resistance to stress 80.  Leonard Hayflick stated “The fundamental aging process is 
not a disease but it increases vulnerability to disease” 82.  In recent decades, researchers have 
gained the ability to associate quantitative levels of molecular markers with age such as telomere 
length 83, 84, DNA methylation 59, damaged proteins 82, 85-87, hormones 88, 89, and markers 
associated with the following: genomic instability, epigenetic alterations, deregulated nutrient 
sensing, mitochondrial dysfunction, cellular senescence, and stem cell exhaustion 79.  The role of 
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the AbStat and the entropy measure among data from all of these other biological features and 
processes is to provide a metric of aging and health that is specifically related to the humoral 
immune system.  Information from these metrics can be used not only to monitor “aging”, but to 
monitor health, and make changes to slow down the decline of health or even maintain or 
enhance health. 
One interesting characteristic of the machine learning results with the age data was that 
the SVM weighted the entropy measure the most (Figure 39), but the J48graft tree algorithm did 
not (Figure 40).  The SVM algorithm achieved higher performance: 82.6% correctly classified by 
SVM, and 58.7% correctly classified by J48graft (Table 8).  Also note that the SVM algorithm 
provides further evidence that age is the attribute that distinguishes fluorescence intensity 
distributions of the individuals since the algorithm was unable to correctly classify samples of two 
different nationalities: Chinese or Indian (Table 9).  Another interesting aspect of this analysis was 
that the normalized entropy was not weighted by the SVM more than the entropy.  Therefore, 
even though the samples were applied to arrays with a very different number of features, the 
SVM still weighted the entropy without normalization as the most important feature. 
1.4.8 Rank and range of measures 
The AbStat measures were ranked in four different ways.  The entropy measure was 
ranked as the best measure with three of these ranking methods.  With the fourth ranking 
method, entropy was ranked as the 3rd best measure.  The following ranks after the 1st position 
are different depending on whether the rank is based on the p-value or the SVM weight.  The 
entropy, normalized maximum, skew, and kurtosis perform well in p-value based ranks, and the 
entropy, dynamic range, and normalized minimum perform well by SVM rank.  Therefore, the 
entropy, dynamic range, normalized minimum, normalized maximum, skew, and kurtosis are the 
measures which provide the most information when distinguishing normal, disease, and aged 
states. 
The range of normal entropy values is around 7.80 +/-1.  The disease entropy values 
have less variation and the values range from around 8.10 +/-0.60.  Therefore, the disease/aged 
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range is enclosed within the normal range.  The knowledge acquired from these datasets 
indicates that the higher the entropy, the more likely it is that a sample is actually a disease/aged 
sample or progressing towards this state.  A normal sample with a very low entropy below the 
mean minus one standard deviation could exhibit this value due to a variety of different situations: 
1. the individual is healthy and normal; 2. the individual has recently been vaccinated; 3. the 
individual has an acute infection such as a common cold; 4. the individual has a serious illness for 
which they are producing large amounts of high affinity antibodies against a single target; or 5. 
the individual has a lymphoma which is causing a few B cells to produce a large amount of 
antibody against a single target.  In the cases 2-5, the expectation would be that the entropy 
would be low while the mean, on the other hand, would be higher than normal since antibodies 
would bind to a few peptides with high intensity.  Therefore, the mean is another important 
measure to monitor with time. 
1.4.9 Quantitative analysis of the entropy measure 
Several conclusions can be made from the results of the quantitative analysis of the 
entropy measure presented in “1.3.10 Quantitative analysis of the entropy measure”.  A quick 
summary is that disease specific peptides are more important to the entropy measure than 
randomly selected peptides.  The “maxed out” fluorescence intensity peptides with the highest 
possible intensity dilute the entropy calculation.  The distribution of low intensity peptides is very 
important for the entropy measure, particularly since the majority of the distribution consists of low 
intensity peptides.  Another conclusion is that the sensitivity of the entropy metric generally 
decreases with increasing bin size, but there are exceptions.  A more thorough discussion is 
presented in the subsections below. 
1.4.9.1 Analysis of important peptides 
Analysis was performed to identify the types of peptides in the distribution which 
contributed the most to the ability of the entropy measure to distinguish between healthy and 
disease groups (“1.3.10.1 Changes in entropy measure with removal of peptides”).  The data 
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used for the analysis consisted of 5 breast cancer samples and 24 normal samples.  The entropy 
of each sample was calculated, and a t-test was performed with the two groups.  Before the 
entropy was calculated, however, various numbers of peptides of a given type were removed.  If 
non-natural peptides which bound specifically to disease sera were more important than 
randomly selected peptides, then fewer specific peptides could be removed before the 
significance of the p-value started to decrease.  Here specific peptides referred to peptides that 
had the most significant p-value in a t-test with the intensities of that peptide in breast cancer and 
normal samples.  The results showed that specific peptides are indeed more important than 
random peptides since the p-value with entropy between the two groups started to become less 
significant after about 5,000 peptides have been removed (“Figure 46 P-value vs peptides 
removed”).  With random peptides, on the other hand, about 230,173 peptides must be removed 
before the p-value starts to become less significant.  A targeted removal of peptides that are most 
different from breast cancer and normal caused the entropy measure to lose the ability to 
distinguish between the groups more than removal of random peptides. 
What does this result mean relative to standard immunosignaturing techniques?  In the 
Center for Innovations of Medicine, the standard immunosignaturing technique involves 
performing a t-test for each peptide in all of the samples, and selecting the peptides which are 
specific to the disease with a p-value more significant than a certain cutoff value.  These peptides 
are then used with a classification algorithm such as naïve Bayes to classify samples as normal 
or disease samples.  The number of peptides selected to be input into a classification algorithm is 
typically in the range of about fifty to a few hundred peptides.  However, this entropy analysis 
demonstrated that the distinguishing power of the entropy measure for normal and disease 
samples did not drop off until about 5,000 specific peptides had been removed as stated 
previously.  Perhaps it would be far too extreme to state that these 5,000 peptides are “disease 
specific”.  However, this result may mean that these 5,000 peptides are more similar to 
mimotopes of the disease than other randomly chosen peptides, but not that these peptides 
actually are mimotopes.  Let’s assign some hypothetical numbers to illustrate the point.  The top 
20 peptides may have a similarity score of 90% to a cognate epitope of the disease, whereas a 
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peptide that ranks as the 4,500th most specific peptide may have a similarity score of 15% to the 
same cognate epitope.  Alternatively, these 5,000 peptides may not have any similarity to disease 
specific epitopes at all, but rather they may exhibit non-specific avidity interactions with the 
antibody repertoire of a disease sample.  These avidity effects may not be manifest by other 
randomly selected peptides on the array due to their level of non-specific binding or general 
characteristics such as hydrophobicity or hydrophilicity.  In conclusion, there appears to be more 
information present than can be captured from selecting highly specific array features alone. 
What is the actual p-value of the most significant peptide when the p-value with the 
entropy between the groups begins to become less significant?  The p-value with the entropy 
becomes less significant than a p-value of 0.1 after 100,000 peptides have been removed.  At this 
point the p-value of the most significant peptide is about 0.15 (Figure 47).  Therefore, in this 
dataset, peptides with a p-value more significant than 0.15 seem to contribute the most to the 
ability of entropy to distinguish between groups. 
Removal of the highest intensity peptides yielded some interesting results as well 
(“Figure 46 P-value vs peptides removed”).  Here different peptides were removed from each 
sample since the peptides were removed in order of highest intensity unique to each sample.  
Naturally, there will be some similarities.  Many of the top 1,000 peptides in one sample will be in 
the top 1,000 peptides of another sample, but there will not be a 100% overlap due to natural 
variation.  In the analysis, when the top 5,000 peptides were removed, the p-value actually 
becomes more significant than when all of the peptides were present.  This result makes sense 
because many of the top several thousand peptides were maxed out at 65,535 in this dataset.  
Therefore, these peptides which had exactly the same value in both groups was diluting the 
calculations so that there was less of a difference in entropy between the two groups.  Once 
these maxed out peptides are removed, then the p-value becomes more significant than it was 
with the full 330k distribution.  Next the p-value between groups with entropy becomes extremely 
significant with the remaining very low intensity peptides.  This makes sense since a fairly large 
group of peptides will have intensity values near zero, and the distribution of these near-zero 
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peptides will have a different shape in normal and breast cancer samples.  Figure 46 shows the 
graph zoomed into the portion with 5,000 or less peptides remaining. 
In another analysis, the least significant peptides, rather than the most significant, were 
removed from the distribution.  In this experiment, the p-value of the entropy between the groups 
becomes more significant after the 100,000 least significant peptides have been removed, and 
then the p-value drops off to become less significant (Figure 49).  The increase in significance 
observed was not as great as the significance obtained when removing the highest intensity 
peptides.  What is the actual value of the p-value of the least significant peptide when there is an 
increase in significance with entropy?  The p-value of the least significant peptide when 100,000 
least significant peptides have been removed is about 0.25 (Figure 50).  Therefore, removing 
peptides with a p-value greater than 0.25 improved the ability of entropy to distinguish between 
the two groups. 
In summary, peptides that are different by a t-test with fluorescence intensity contribute 
the most to the ability of the entropy to distinguish between the two groups.  The highest maxed 
out peptides do not contribute much to the ability of entropy to distinguish.  Also, the shape of the 
group of peptides in the very low range is very important for the ability of entropy to distinguish 
between groups. 
Many questions can be asked from these results.  Would the set of low peptides that 
allow entropy to distinguish well be mostly the same or different for different diseases such as 
breast cancer and lung cancer or syphilis?  If another breast cancer dataset was analyzed would 
the low peptides be mostly the same or different than the original breast cancer dataset?  In other 
words, is this distribution of low peptides caused by a type of specific low binding unique to a 
disease or set of diseases, or is this distribution of low peptides mostly random.  If it is random, 
then non-specific antibodies may be binding randomly to peptides on the array based on their 
location at the time and whether they happen to interact with a certain peptide somewhat due to 
chance.  Technical replicates are usually performed in the lab and high correlation coefficients 
above 0.95 are frequently obtained.  This means that a peptide with a given intensity in one 
replicate will have a very similar value in another replicate.  Therefore, it would not be appropriate 
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to describe the binding to the array as “random”.  However, there may be more or less variation in 
certain intensity ranges.  For example, array features with a high fluorescence intensity may often 
be due to binding with high affinity antibodies, and the standard deviation of the fluorescence 
intensity of these array features may be small e.g. 20 intensity units.  Binding to array features in 
the lower intensity range (<1,000) may be due to lower affinity antibodies and the standard 
deviation of the fluorescence intensity of an array feature in this range may be higher e.g. 150 
since the binding could be more random and chaotic in this range.  In this situation, technical 
replicates could still have a very high correlation coefficient, but the degree of variability in the 
signals could be different in different intensity ranges. 
1.4.9.2 Change in entropy with change in bin size 
One of the main parameters of an entropy calculation is the bin size.  The analysis in 
section “1.3.10.2 Change in entropy with change in bin size” demonstrates that in general the 
best bin size is the smallest bin size.  This makes sense since smaller bin sizes will allow for 
increased resolution.  As the bin size was increased, the ability of the entropy metric to 
distinguish between disease and normal samples decreased.  However, there were some 
exceptions since the p-value did become more significant near a bin size of 5,000.  The 
distributions between disease and normal exhibited the largest difference when a bin size of 
5,000 was used with this particular dataset, but different datasets may have a different optimal bin 
size.  A bin size of 5,000 is likely optimal because the majority of the distribution at the low 
intensity range would fit into or not fit into the first bin depending on whether the sample was 
normal or disease.  A quantitative examination of this dataset supports this conjecture.  In the five 
breast cancer samples present in this dataset, 46.7 +/-18.1% of the features have a fluorescence 
intensity less than 5,000.  However, an analysis of five randomly selected normal samples 
reveals that 69.7 +/-4.87% of the features have a fluorescence intensity less than 5,000 due to a 
distribution with a high tight peak less than 5,000.  Therefore, choosing a bin size of 5,000 places 
most of the feature intensities in the normal samples in the first bin, and splits the feature 
intensities in the breast cancer samples to a greater degree.  This leads to a difference in 
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calculated entropy.  Interestingly, the total range of p-values did not change dramatically with the 
wide range of different bin sizes tested.  The p-values ranged from 0.0195 to 0.117, which is a 
smaller range than one might have anticipated. 
1.4.10 Limitations of AbStat 
The AbStat measures clearly have limitations since some samples could not be 
distinguished from normal.  For example, the Alzheimer’s samples could not be distinguished 
from the controls, but these samples could be distinguished when using other classification 
techniques (“1.3.6.4 Alzheimer’s disease”).  For many other diseases there was also very poor 
separation from normal.  For example, most of the Bordetella pertussis (BPE) samples fall within 
a normal range (Figure 15).  The classification accuracy of the AbStat measures is also typically 
low even though it is better than chance, in the range of 60-80%.  Higher accuracy can be 
obtained with analysis methods that focus on specific peptides.  Note, however, that the 
classification accuracy of the broad global measures that compose the AbStat improved when 
analyzing samples on the HT330K platform as opposed to the CIM10K platform.  This result 
suggests that with more peptides and higher quality slides made possible with more advanced 
technology, the power of the AbStat measures may improve with time. 
Another clear limitation of the AbStat is that it cannot aid a researcher in identifying 
specific antibody targets.  The measures used in the AbStat are broad global measures that take 
all of the fluorescence intensities and compress them into one single numerical value.  All amino 
acid sequence information associated with an array feature is discarded.  Therefore, it would not 
be possible to use mimotopes on the array to trace back and identify the cognate epitopes of the 
antibodies in the sample.  These mimotopes and epitopes are critical for biological discoveries, 
diagnosis, and vaccine development.  Although the AbStat measures cannot be used to study 
biological sequence information, they should be applied to scenarios that they do provide 
information for: monitoring overall health states associated with disease and age, studying the 
overall characteristics of an antibody mixture, and making enlightening connections between 
diseases.  More detail on the value of AbStat is provided in the next section. 
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1.4.11 Value of AbStat compared to other classification methods 
What is the value of the AbStat measures when compared to other classification 
methods?  In the Center for Innovations in Medicine the typical procedure for classifying samples 
is to perform a t-test for all of the features comparing the intensity of each feature to the intensity 
of that same feature obtained with other samples.  Features which yield a p-value that is more 
significant than the cutoff value are then used as the features to input into a classification 
algorithm such as naïve Bayes to determine whether a sample can be classified as normal or as 
a certain disease.  The p-value cutoff point used to select the significant disease specific features 
is often the reciprocal of the number of features.  This process usually results in significantly 
better classification performance than can be obtained with the AbStat.  Note, however, that the 
specific peptide analysis approach is also more susceptible to overtraining as presented in the 
“1.3.6.1 HT330K first chip disease dataset” section.  Therefore, it is important to use caution with 
this approach, and analyze the data with appropriate training and test data.  Nevertheless, since it 
is possible to obtain better classification performance with specific peptide analysis methods, one 
can ask the question: What is the use of AbStat when more accurate classification methods 
exists? 
The benefits of AbStat are found not with its classification ability alone, but rather with 
many other features which other methods do not provide.  First, the AbStat measures are broad 
global measures which do not rely on selecting specific features from the rest of the features.  
Using other methods, if certain disease specific peptides were removed or not originally included 
on an array, then classification performance may decrease significantly.  However, the 
classification performance of the AbStat measures would likely remain about the same as long as 
enough non-natural sequence peptides selected from random space were included.  Additionally, 
many of the AbStat measures are unaffected by normalization, whereas other classification 
methods would not work as well without normalization.  Since there can be disagreement about 
which normalization techniques are most suitable for various situations, the fact that 
normalization does not even affect some of the AbStat measures could be perceived as an 
advantage in certain situations. 
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The AbStat methods can also detect differences between young and aged sera.  The 
overall specificity of the antibody repertoire seems to change with age and these changes are 
reflected in the AbStat measurement.  These AbStat measurements may ultimately allow 
individuals to mitigate the effects of age as they learn which factors exacerbate or ameliorate 
changes in the AbStat measurements such as entropy. 
Another benefit of the AbStat measures is that they connect several different health 
states together, and some of these connections may not have been previously apparent.  For 
example, the entropy measure of the AbStat increases to higher than normal levels for both 
chronic diseases and old age.  The general public would probably often associate chronic 
disease and old age with poor health, but the AbStat provides another quantitative means of 
directly comparing these two states of health.  This association also suggests that in both cases 
the antibody repertoire may become more complex and “chaotic”, and this can reveal something 
fundamental about both states.  As another example, the entropy measure of the AbStat 
decreases for both vaccines and lymphomas which produce large quantities of a single antibody.  
Before this finding, one might not see much of a similarity between these two different states.  
However, the AbStat measure can find some clear commonalities between these two seemingly 
unrelated states.  The vaccine and lymphoma states are conceptually connected by the fact that 
they both undergo a decrease in repertoire complexity by increasing the proportion of a particular 
antibody against a specific epitope or a few epitopes.  Therefore, the AbStat measures can help 
reveal truths and connections which were not previously obvious. 
Not only can the AbStat make connections between different health states, but the 
AbStat can also make connections between different fields of study.  One of the critical measures 
of the AbStat is entropy which is used in the field of physics and thermodynamics as well as 
information theory.  Therefore, now entropy can be used in biology, physics, and information 
theory, and the knowledge gained from the other fields may be useful in biology as well.  For 
example, in physics and information theory entropy can reflect the degree of randomness in a 
system, and this could be true in biology as well.  Additionally, in thermodynamics, entropy must 
always increase as the universe moves towards disorder, and scientists and philosophers have 
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claimed that this provides the universe the arrow of time in which we operate 90.  The entropy 
measure of the AbStat also demonstrates that the entropy of the antibody repertoire interacting 
with an array of peptides also increases with time/age.  Many individuals  often have the general 
notion that the entropy of biological systems increases with age 27, but the AbStat entropy 
provides some quantitative evidence for this impression.  Therefore, the AbStat is important 
because it ties several fields together, and this measure may lay the groundwork for future 
discoveries and insights. 
1.4.12 Use and possible future applications 
1.4.12.1 Overview of use and possible future applications 
Since these AbStat measures have proved useful for identifying interesting immune 
states associated with chronic disease, infectious disease, vaccine, and age, individuals may be 
interested in monitoring their AbStat constantly over time.  By constantly monitoring this 
information, one might be able to catch the progression of disease early and take action to 
mitigate the effects of disease.  Researchers with access to large databases of this data can also 
identify new trends which can be used to inform the public to make healthy decisions.  Basically, 
the AbStat can provide people with another metric that allows them to evaluate their fitness more 
quickly and make adjustments as they deem fit for optimum health.  This metric could accompany 
many others in the emerging Quantified Self revolution 91. 
In the scenario that people are constantly monitoring their AbStat measures it would be 
useful to have a simple method for conveying the AbStat information to the individual who may 
not be an expert on these topics.  Two different approaches could be suitable for this task.  One 
approach is to simply plot one of the most informative measures, entropy vs time with lines for the 
population mean +/- one standard deviation so that the individual can compare their state with the 
population norm.  The individual may also just prefer to view their entropy in relation to other 
people of their age group or even only their own past data.  The key here is to keep it simple, and 
to allow the individual to obtain more information if they desire.  The second approach is basically 
the same as the first.  However, instead of plotting entropy on the y axis, the distance to the SVM 
 131 
boundary would be plotted.  As the data throughout this document was analyzed, all of the 
measures were input into an SVM, and the SVM used some training data in order to draw a linear 
boundary in a high dimensional space which can separate as many samples of two different 
classes as possible.  Therefore, the distance to the SVM boundary would incorporate information 
from all of the measures rather than entropy alone, and the information acquired from the training 
data would also inherently be included.  The larger a positive value was the more likely it would 
be that an individual is in a disease state, and the larger a negative value was the more likely it 
would be that an individual is in a normal state. 
AbStat could also be used to quantitatively characterize monoclonal antibodies.  The 
results in “1.3.1.1 Monoclonal affinities and AbStat Measures” indicate that there is a relationship 
between monoclonal antibody affinity and entropy.  Lower affinity antibodies appear to bind more 
non-specifically to the array.  Companies which produce monoclonal antibodies often do not 
describe the specificity of an antibody, and often don’t even determine the dissociation constant 
for the affinity.  However, Dr. Johnston had the idea that the entropy measure obtained from 
reacting a monoclonal antibody with a microarray of non-natural sequence peptides could be 
used to quantify the specificity of an antibody.  This could result in higher quality antibodies as 
companies produce antibodies to optimize this metric.  Note that there may be a relationship 
between affinity and specificity because of the rigidity of the structure of an antibody.  Antibodies 
with little specificity for one unique target (termed polyreactive antibodies) often have more 
flexibility in their structure 92.  On the other hand, an antibody with high specificity and high affinity 
may have a more rigid structure which does not allow the antibody to bind many other sequences 
that are not similar to the cognate epitope 53, 93. 
The concepts, metrics, and data analysis presented in this document could have much 
wider implications than a new metric for the immune system.  In particular the entropy measure 
may prove interesting in other situations, but may be aided by other measures such as the mean 
just as it was in this document.  Anytime one can obtain a distribution of numbers, one could test 
the entropy which would essentially be the same as asking how easily a random number 
generator could reproduce the frequency of values observed.  This would test how random a 
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distribution is.  Entropy has already been used to demonstrate that the entropy of the alternative 
splicing distribution is higher in cancer cells than normal cells 30, 94.  Entropy has also been used 
in many other situations as reviewed in the “1.1.4 Entropy with previous biological data” section.  
Using quantitative values to characterize the shape of a distribution, and then using those values 
to assess the vitality or stability of a system, is not limited to biology either.  For example, the 
statistician George Zipf made the argument that certain levels of heterogeneity in the income 
distribution of a country can precede revolutions 95. 
There are many other datasets which one could apply this type of analysis to.  For 
example, the AbStat of mass spectrometry data of all of the proteins in a cell may be different 
between healthy and disease cells since diseased cells may have different numbers and types of 
proteins, and this difference may be quantifiable in the entropy measure.  An analysis of brain 
scan data in which the number of connections of each neuron was determined could allow one to 
calculate the entropy of the neuron degree distribution, where degree refers to the number of 
connections of each neuron.  Individuals diagnosed with Alzheimer’s disease or insanity may 
have distinctly different entropy values than individuals who have not been diagnosed with 
Alzheimer’s disease or insanity, just as schizophrenic patients exhibited abnormally low entropy 
fMRI data compared to normal patients 38. 
Once one begins to apply the entropy calculation to assess the vitality of systems 
represented as networks, such as the brain, the situation could become extremely fascinating for 
two reasons: 1. Many systems can be represented as networks from genetic networks, protein 
networks, metabolic networks, social networks, airplane networks, software since any software 
can represented as a network, etc.;  and 2.  There is a great deal of existing network science that 
can be applied to understand such networks.  Theoretically, one could apply the entropy 
calculation to all of these networks and associate certain entropy values with well-functioning 
versions of these networks and certain entropy values with poor functioning versions of these 
networks.  So is the node degree entropy of a real-world network lower than a random version of 
the same network?  The answer to this question is yes.  A quick calculation of the entropy of a 
real world network, which turns out to be a small-world scale-free network 96, such as the network 
 133 
of airport connections in the United States 97 revealed that this network had an entropy value of 
5.03 whereas a random version of the same network had a value of 5.76 (personal calculation).  
These type of real world networks are “small” because the average distance between any two 
nodes is small.  These networks are “scale-free” because the basic shape of the network looks 
about the same at small or large scales so there is no scale.  Note, however, that quite different 
results are obtained with the node degree entropy for networks that are not scale-free such as 
road and power-grid networks which are exponential networks rather than scale-free networks.  
Scale-free networks have a node degree distribution that obeys a power law where very few 
nodes have a very high number of connections, and exponential networks have a node degree 
distribution that obeys a Poisson distribution in which most of the nodes have the average 
number of connections.  
The lowest node degree entropy for a network occurs when the network forms a ring so that 
every single node has exactly the same number of connections (two connections), but this 
network certainly does not have the form that actual real world networks exhibit.  These real world 
networks are also ordered and non-random.  A ring network is also extremely inefficient at 
passing messages to different nodes since the average shortest path is very high (one must pass 
through every single node to reach a node half-way around the ring).  Networks that represent 
living systems fall into the category of small-world scale-free networks as mentioned previously, 
and these networks have a definite complexity and organization to them that is not random.  
Perhaps the best metric or version of an entropy metric for a network would be one that is low for 
very simple “boring” networks such as a ring, low for random networks, and high for a small-world 
scale-free network.  Other methods for calculating the entropy of a network as opposed to node 
degree entropy have already been investigated such as search information entropy, target 
entropy, and road entropy 98, 99.  Other network measures such as the average shortest path 
length and the clustering coefficient may also be very important.  A metric which is the highest for 
a very well organized efficient network, may send an alarm when the network changes and the 
value for this metric drops off indicating that the network has become more chaotic or less 
optimal.  This event may indicate that the complex adaptive system which the network 
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represents, whether it be a human brain or a system of airport connections or even software, is 
beginning to lose its proper function.  The essential idea here is that one can obtain a distribution 
of numbers that measure something about a complex system, calculate a value from that 
distribution, and then have knowledge about the vitality of that system. 
Once one knows how healthy or sick a system is, what good is this information?  The primary 
use of this information is to then take action to mitigate damage to the system and to get it 
functioning optimally.  For example, one could predict from the results in this document, that if 
one were to immunize an aged person and a young person against the same target that neither 
of their immune systems had ever seen, then the resulting entropy of the fluorescence intensity 
distribution would be higher for the aged individual.  The explanation would be that the aged 
individual has an immune system that does not function as optimally, and the aged individual 
produces antibodies with a lower affinity to the target.  These less specific antibodies then bind 
more randomly (not completely randomly by any means) to a variety of different peptides with 
varying intensities which results in a higher entropy.   
However, what if there were actions one could take to mitigate the increase in entropy in 
older individuals?  How could this be done?  The immune system is a complex adaptive system 
with similarities to many other complex adaptive systems such as a brain or a collection of muscle 
cells.  These systems stagnate when there is nothing to adapt to.  However, when they are 
constantly challenged, a brain or a muscle will respond to that challenge and maintain better 
performance for future challenges.  Perhaps the immune system could benefit from constant 
training or challenge as well.  Perhaps an aged individual who is vaccinated against targets 
throughout their lifetime will be able to produce more specific antibodies than an aged individual 
who has an immune system that is rarely used.  Whether or not these speculations are true, the 
entropy of the peptide distribution provides a quantitative way to test these predictions.   
If training or exercising the immune system is beneficial, another fascinating topic to 
investigate is what is the nature of the optimal training?  For any complex adaptive system, the 
challenge needs to be at an appropriate level for the ability of the system to currently handle that 
challenge.  Additionally, the challenges need to vary with an appropriate frequency and level.  
 135 
Someone does not lift the heaviest weight in a weight room if they have never lifted a weight 
before.  Additionally, people training with weights do not lift the heaviest weight they can possibly 
lift at all times every day and do nothing else; they often perform some type of warm-up and/or 
cool-down, and often don’t lift the heaviest weight they can every day.  Challenging a system too 
harshly will damage it, and challenging a system too little will lead to stagnation so that the 
system will be unprepared for future challenges.  What are the mathematical truths that underlie 
the optimal training and maintenance of a complex adaptive immune system, and how can these 
concepts be applied to the immune system?  Although the answers to these questions are 
unknown, the entropy of the fluorescence intensity distribution provides a method for quantitating 
the results of any experiments to address such questions. 
1.4.12.2 Immune system training hypothesis with mouse experiment 
 Let’s discuss a simple experiment one could perform to test the hypothesis that 
exercising and stimulating the immune system will slow the progression of AbStat entropy.  One 
could immunize one group of mice frequently over the lifetime of a mouse, and then the sera of 
these mice could be applied to the peptide microarrays to determine the increase in entropy 
overtime.  This entropy time course would then be compared to a control group of mice which 
only received PBS (phosphate buffered saline) injections.  At the end of the time course, both 
groups would be immunized with an antigen neither group had ever been exposed to.  If 
stimulating and exercising the immune system truly does result in a more “fit” immune system 
capable of producing higher affinity antibodies to new targets, then the expectation is that the 
frequently immunized group would exhibit a lower entropy than the control group after both 
groups were immunized with a new antigen.  Such a result would imply that frequent 
immunization would be a method for slowing down the decline of immune system health with age.  
This result would support other studies which demonstrate that exercising muscles or memory 
can slow the deterioration of these systems with age.  Note that exploring the frequency of 
immunization, quantity of antigen, and diversity of antigens immunized could also be interesting 
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as well.  How much is too much and how much is too little in regard to obtaining the goal of 
improved immune function? 
1.4.12.3 Immune system training hypothesis with rural and non-rural individuals 
Another strategy for testing the immune system training hypothesis would be to compare 
the AbStat from immune systems of individuals from rural areas and individuals from large 
industrialized cities.  The phenomena that individuals from industrialized countries develop more 
allergies than those from developing countries has led to the hygiene hypothesis.  The hygiene 
hypothesis states that the industrialized country individuals were not exposed to infectious 
agents, parasites, and microorganisms during childhood, and therefore their immune systems did 
not develop properly 100-102.  In addition to an increase in allergies often associated with a Th2 
immune response, there is also an increase of Th1 immune response autoimmune diseases in 
industrialized nations 103.  The exact cause of this phenomena is still debated, but the fact that 
there are fewer of these types of immunological disorders in developing nations is a statistical 
fact.  Therefore, perhaps the AbStat approach can detect a difference in the immune systems of 
rural and non-rural individuals.  This strategy for testing the immune training hypothesis has 
advantages over the mouse immunization approach since it is not known whether frequently 
immunizing a mouse can enhance the immune system, but it is already known that individuals 
from rural areas have fewer allergies and autoimmune disorders on average.  In fact, with the 
mouse approach, frequent immunizations may actually be harmful, since this non-natural 
intervention may cause the immune system to become imbalanced in some way. 
The AbStat measures may be able to classify individuals from rural or non-rural areas.  
One might predict that the rural individuals typically have a lower AbStat entropy than the non-
rural individuals since lower AbStat entropy is typically correlated with absence of disease, with 
several exceptions (shortly after a vaccine, the occurrence of a cold, and a lymphoma).  To be 
more precise, one might expect rural individuals to have a low AbStat entropy as well as a low 
AbStat mean compared to non-rural individuals.  AbStat numbers that are more associated with 
normal healthy states may be found more often in rural individuals than non-rural individuals, and 
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these better AbStat numbers may result from the increased immune system training that the rural 
individuals had been exposed to. 
1.4.12.4 AbStat and overall health hypothesis 
One hypothesis could be that the AbStat entropy of individuals that are extremely healthy 
may be lower than the AbStat entropy of individuals who have just not been diagnosed with a 
disease.  If this hypothesis were true, then the public would have a reason to monitor their AbStat 
because they would know that it would be one more metric of their general health.  Not only 
would it be one more metric of general health, but it would also be one specifically associated 
with the immune system which people often do not monitor currently.  Throughout this 
dissertation, “normal” individuals were simply not diagnosed with a disease, but it is natural to 
assume that there is a whole spectrum of health and disease states.  Some “normal” people may 
be significantly healthier than other “normal” people.  Additionally, general metrics of health may 
also often be correlated with the health of various specific systems since the whole body is 
connected together, and the health of one system will often impact the health of another.  
Therefore, it could be very interesting to correlate the AbStat measures with various other metrics 
of general health such as body mass index, resting heart rate, blood pressure, VO2 max, etc.  
Another measure could be a score of health from a panel based on photographs of individuals.  
Although this method may seem unscientific and not quantitative at first, at least one study has 
already found that the perceived age of twins from photographs correlated significantly with time 
of death, physical functioning, cognitive functioning, and leukocyte telomere length 104.  The 
prediction with AbStat entropy is that the entropy would be lower for healthy individuals compared 
to less healthy individuals of the same age.  Health would be correlated with various metrics of 
general health.  Such a finding would provide a motivation to monitor and adjust one’s AbStat. 
Note that it may be necessary to immunize individuals in the study against a foreign 
antigen to create a strong immune response.  Individuals with better overall health may have 
healthier immune systems, and they may produce higher affinity antibodies against new targets 
than less healthy individuals.  Although there could be a difference between the two groups 
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without immunization, the difference may be too small to detect with statistical significance.  I 
believe that this sub-hypothesis may hold true for the immune system training hypothesis with 
rural and non-rural individuals as well. 
1.4.13 Conclusion of use and possible future applications 
 This discussion can be concluded by revisiting the practical applications of AbStat.  The 
immediate use of the AbStat could be for frequent monitoring of health and for 
classification/diagnosis purposes.  Individuals could obtain their AbStat on a regular basis, and 
choose how they want to interpret the information themselves given the normal range of entropy 
for all other individuals tested.  A simple line graph could display their entropy over time, and they 
could correlate this with personal events in their own lives such as “This timepoint is when I 
started this new exercise routine”, “This timepoint is when I received an immunization”, and “This 
timepoint is when I caught a cold”.  Alternatively, they might observe a strange sudden drop in 
their entropy which is not correlated with any life event that they are aware of.  This information 
could prompt them to see a doctor, and further investigation might lead to the diagnosis of an 
illness which can be treated more effectively since it was noticed early.  Another practical 
application of the AbStat is to use it as a metric in tests of future hypotheses such as the immune 
training hypothesis mentioned previously.  Therefore, the practical value of AbStat lies in 
monitoring, diagnosis/classification, and as a metric used for testing new hypothesis about the 
immune system. 
1.5 Conclusion 
A group of measures of a fluorescence intensity distribution produced from reacting antibody 
containing sera with a non-natural sequence peptide array result in an AbStat that can distinguish 
healthy and disease as well as young and aged states.  One of the key measures of the AbStat is 
entropy, which has been used to determine how random a system is since the 1800s.  Scientists 
used this calculation in the field of thermodynamics to measure the chaotic state of particles, they 
used it to measure the chaotic state of information, and now it is being used to measure the 
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chaotic state of the humoral immune system.  The quantitative results from measuring the chaotic 
state of the immune system has now been associated with the level of health of both mice and 
humans.  Chronic disease, infectious disease, the common cold, and vaccines are all events that 
the AbStat can detect.  The results obtained with AbStat can be used for practical purposes such 
as diagnosis and monitoring for many different diseases, and the ultimate results may be actions 
people take to maintain health.  The AbStat and the entropy measure have yielded interesting 
philosophical questions and practical applications. 
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 2: PLATFORM FOR SCREENING CDNA LIBRARIES 
2.1 Introduction 
2.1.1 The need for better approaches against cancer 
Cancer is the second leading cause of death worldwide 105.  Conventional treatments for 
cancer such as surgery, chemotherapy, and radiation have harsh side effects and usually slow 
progression but do not cure disease.  There is now a newer class of treatments comprised of 
monoclonal antibodies such as Herceptin, which recognizes the breast tumor-associated antigen 
HER2/neu 106, and Rituximab which binds the lymphoma associated antigen CD20 107.  These 
immunotherapies have the significant benefit of being far more specific than conventional 
approaches, but the disadvantage of their high cost and requirement for continuous re-
administration.  Additionally, only HER2+ or CD20+ tumors are responsive to these single 
surface-marker targeted treatments.  Only 20% of breast cancers are HER2+ 108, and the most 
aggressive cancers are actually HER2- 109.  Furthermore, even receptor positive tumors are 
responsive initially, but can develop escape mechanisms, and patient tumors recur. 
An even less conventional and recently emerging approach to treating cancer is 
vaccination. Vaccines are typically considered for battling infectious pathogens, not one’s own 
cells. However, at least in theory the immune system could be capable of learning to recognize 
the patterns that set tumor cells apart from normal self-cells. Not only does a cancer vaccine 
theoretically make sense, but cancer vaccines have been demonstrated to work in animal 
models. For example, vaccination of rats with a tumor-associated antigen formulation significantly 
delayed growth of chemically induced tumors 110.  Injecting rats with lysates from whole tumor 
cells was also able to provide some level of tumor growth protection 111.  Human self-tumor 
mixtures in which tumor lysates are prepared from patients’ own tumor are also being tested in 
clinical trials 112.  While self-tumor mixtures hold potential, preparing these tumor mixtures from 
tumor-bearing patients is often not feasible relative to both disease timeframes and costs. In 
addition, effectiveness is compromised by the very fact that disease must be sufficiently 
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progressed such that a tumor can be detected and extracted. A more attractive cancer vaccine 
that is economically and technically more practical might consist of a subunit vaccine containing 
tumor-specific antigens to be administered prior to tumor development.  Note that the feasibility of 
component vaccines, instead of whole pathogen vaccines, has been demonstrated 113-116.  In 
order to develop an effective subunit cancer vaccine, prior knowledge of tumor antigens is 
needed. 
2.1.2 Methods for discovering tumor antigens 
Identifying tumor specific antigens can be tackled using a variety of methods. One could 
sequence the DNA of cancer and normal cells to search for genomic differences 117.  
Alternatively, a researcher could examine the RNA transcripts to look for gene expression 
differences 118.  Another method is to actually use the immune system of the patient to discern 
antigenic differences. Researchers have demonstrated that both T and B cell based immune 
responses are generated against tumors 119, 120.  The presence of lymphocytes in a tumor is 
associated with a better patient outcome 121, 122, 123, 124.  While many of these immune responses 
are cell based, there are also a great diversity of humoral responses to tumors. Antibodies 
produced against tumor proteins make robust biomarkers since antibodies can persist in the body 
longer than a tumor protein biomarker, and antibodies are continuously amplified in the presence 
of continued immunogen. Significantly, tumor specific antibodies can even be elicited before 
disease symptoms are manifest. 
Many experimental methods to probe tumor proteins with antibodies have been 
developed.  Before the advent of high throughput methods, researchers could only probe a few 
antigens at a time using assays such as 1D SDS/PAGE and ELISA.  Later on in 1995, the 
serological analysis of recombinant cDNA expression (SEREX) libraries was developed 125.  
Briefly, the method involved producing a tumor cDNA expression library, lysing clones on a 
nitrocellulose membrane filter, and then probing this membrane with autologous sera.  Using this 
approach a large number of antibody and recombinant tumor protein interactions can be assayed 
at one time as compared with the single antigen assays.  Nevertheless the SEREX method does 
have some disadvantages such as the fact the proteins must be capable of being expressed in 
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bacteria, proteins with the most transcripts in the tumor cell may be detected most frequently 
while tumor associated antigens of low abundance may be missed, and there will be antibodies to 
non-tumor associated antigens. Most vexing has been the poor reproducibility of the process and 
the time consuming and labor-intensive protocol (Figure 53). 
 
Figure 53 Example SEREX nitrocellulose membrane 
This 245X245 mm nitrocellulose membrane was pressed against a plate of colonies, the colonies 
were lysed, and then the membrane was probed with sera by myself.  One can imagine that 
tracing back from an antibody-lysate spot signal to the original colony on an agar plate would be 
difficult since the colonies are not arrayed out in a set pattern. 
Microarrays overcome some of the limitations of SEREX.  For example, recombinant 
proteins are systematically organized onto a small slide at addressable locations, rather than 
spread out randomly across a large membrane.  The slide printing arrangement allows for a small 
sample amount to be sufficient. The microarray may be printed with known or unknown proteins.  
The biased approach contains known proteins.  For example, Invitrogen manufactures a 
ProtoArray containing approximately 9,000 proteins which researchers can probe with sera 4.  
The disadvantage of this method is that new immunogens, such as undiscovered mutated 
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proteins that may not be present in current databases, cannot be discovered.  Alternatively, 
recombinant phage or cDNA library cell lysate can be spotted onto a slide.  This method allows 
for the discovery of previously unknown proteins since any protein expressed by the original 
tumor can be in the library. The benefits of this microarray approach include its compatibility with 
high-throughput protocols, reproducibility, small reaction surface, even sera distribution across 
the surface, high dynamic range of signal intensities, and the quantity of data that one experiment 
can produce 126.  The disadvantages currently involve the cost, and the fact that so much data are 
produced that more sophisticated data analysis software must be used to interpret the results. 
Serological proteome analysis (SERPA) is another method for probing tumor proteins 
with antibody containing sera 127.  In this method, 2D electrophoresis is first performed to 
fractionate the lysate’s tumor proteins. A western blot is then performed to detect binding events 
between sera from the tumor-bearing host and the tumor proteins. Tumor proteins of interest are 
then extracted from the gel and the identity of the protein is determined by mass spectrometry.  
This method does not require the construction of a cDNA library. Post-translational modifications 
can potentially be detected and heterologous expression is not needed since the tumor proteins 
are directly assessed. Unfortunately, this method suffers from limiting amounts of material, poor 
reproducibility, and the low resolution of 2D electrophoresis. 
2.1.3 Known cancer immunogens 
The experimental methods described above have discovered >2,500 tumor proteins, 
some of which may be immunogenic. Many of these proteins are stored in the Cancer Immunome 
Database 128.  An analysis of these proteins reveals that there are many different categories of 
non-normal proteins recognized by the immune system of a tumor-bearing host. Well-studied 
tumor antigens include cancer testis (CT) antigens, heat shock proteins 129, and oncoproteins 
such as HER-2/Neu and p53. These have been identified as normal cell antigens that are 
overexpressed in tumor cells 130.  Viral antigens such as antigens from the human papillomavirus 
131, and cell differentiation antigens such as RAB38, and NY-BR-1 have also been identified 94. 
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Other categories of tumor antigens are the result of frameshift mutations due to microsatellite 
regions in the genome such as the CDX2 antigen in colon cancer 119. 
2.1.4 Ideal cancer vaccine  
Although many cancer immunogens have been discovered, other criteria need to be 
satisfied if they are to be useful components of a cancer vaccine. Even if tumor specific antigens 
do exist in each individual tumor, these antigens would not prove very useful targets for a vaccine 
unless they occurred with a relatively high prevalence within the human population. If every 
tumor-specific antigen was unique to each tumor, then a separate vaccine would need to be 
discovered and developed for each patient.  Not only is this impractical, but this is also not 
possible if the goal is to make a prophylactic vaccine. If antigens could be identified that were 
commonly found among cancer patients, then vaccines could be economically and effectively 
developed to treat them.  Supporting this possibility, common mutations in oncogenes p53 and 
Ras have been found 132, 133.  In addition, the ideal cancer vaccine should be comprised of 
multiple antigens so as to prevent immune escape that can occur as tumors continually evolve to 
evade the detection of the immune system. Note that the challenges of immune escape are 
mitigated in earlier stages of cancer and for prophylactic vaccines since there will be fewer tumor 
cells at these stages. Even though many tumor antigens have been discovered, the requirements 
for using these to treat cancer are high, and the current list may not be sufficient for the 
development of an effective vaccine. There may still be many critical proteins left to discover 
which will aid in the understanding of cancer as well as the development of a cancer vaccine. 
2.1.5 Developing platform for screening pooled tumor cDNA library lysates 
In the presented research, a platform was developed for high throughput screening of a 
tumor cDNA library with sera from a tumor-bearing mouse.  The platform consists of screening 
3,000 lysate-pools, isolated from a tumor-cDNA library, and arrayed onto a nitrocellulose slide. 
During the development of this platform many parameters had to be tested and optimized such as 
the protein production process in 96 well plates, the slide surface, and the incubation time with 
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sera.  The platform was also tested using sera to a known protein along with lysate containing 
that protein.  As an additional test, the efficacy of the method was verified by determining that 
sera to a known protein bound to that protein as it naturally occurred within the tumor cDNA 
library.  In the presented research, a microarray of pooled tumor cDNA library lysates was used to 
screen tumor antigens.  This high-throughput approach would not have been practical at the time 
when some tumor antigen screening methods such as SEREX were first developed since this 
new approach makes use of automated equipment for handling large numbers of PCR plates, 
small nitrocellulose slides, high resolution scanners, and accurate printing machinery.   
2.2 Materials and Methods 
2.2.1 Procedures with BALB/c mice 
Fifteen four-week old female BALB/c mice were purchased from Jackson laboratories 
and divided into three groups: a non-treated group, a tumor challenged group, and a Structural 
Maintenance Chromosome 1A frameshift (SMC1Afs) protein immunized group.  Sera was 
collected weekly from each group starting at five weeks of age.  Seven thousand 4T1 cells in 100 
μL PBS were injected subcutaneously (s.c.) into the flank of the mice when they were six weeks 
old.  The tumor volume was measured daily after the tumor was palpable, and mice were 
euthanized when the tumor volume exceeded 2,000 mm3 as calculated by the formula L2*W/2.  
Splenocytes and tumor tissue were collected after euthanasia in accordance with the protocols 
outlined in Current Protocols in Immunology 134, 135 (Figure 54).  Splenocytes were used to 
construct a phage library which is work not presented in this chapter. Tumor tissues were used to 
construct a tumor cDNA library. Murine experiments were conducted under a protocol approved 
by the Arizona State University Institutional Animal Care and Use Committee. 
 
Figure 54 Timeline for tumor group 
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Timeline for the five mice injected with tumor cells.  “0d” refers to 0 days.  The spleen and tumor 
was collected from mouse 5 on day 18 since the tumor of this mouse exceeded the allowed 
volume.  The tumors of the remaining mice were collected on day 25 post injection. 
Mice in the SMC1Afs designated group were immunized with a SMC1Afs DNA 
expression construct followed by the corresponding protein, in a prime-boost regimen.  The 
subsequently harvested serum was used as a positive control for reactivity against the SMC1Afs 
protein in the next set of experiments.  Five female six week old mice were genetically immunized 
with 1 μg SMC1-pCMVi plasmid and 1 μg CpG2395 adjuvant using a gene gun for delivery at day 
zero, day one, and day 15.  Two protein boosts were performed: i) with 5 μg 17 amino acid 
SMC1Afs fused N terminally to GST at day 34, and ii) with Alum and 5 μg of a SMC1Afs 17 
amino acid peptide at day 57 (Figure 55). All mice were euthanized at day 73; sera and 
splenocytes were collected. 
 
Figure 55 Timeline for SMC1fs group 
Five female BALB/c mice were immunized with SMC1-pCMVi plasmid on day 0 (mice were 42 
days old), day one, and day 15.  Two protein boosts were performed on day 34 and 57.  Mice 
were euthanized and sera and splenocytes were collected on day 73. 
2.2.2 Construction of tumor cDNA library 
A tumor cDNA library was constructed from the tumor tissue from the tumor bearing 
BALB/c mice. RNA was extracted from 100–1,000 mg of tumor tissue from mice using TRIzol 
(Cat No 15596-018) from Invitrogen according to the manufacturer’s instructions.   
The In-Fusion SMARTer cDNA Library Construction Kit (Cat No of 634929) from 
Clontech was used to construct the cDNA library from the obtained RNA. The first strand cDNA 
synthesis was performed according to the manual instructions.  Briefly the initial reaction 
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consisted of 4 μg of RNA mixed with the poly T 3' SMART CDS Primer IIA oligo and ddH2O, 
incubated at 72°C 3 min, and then incubated at 42°C 2 min. The following components were 
added to the mixture and incubated 42°C 90 min: 5X First-Strand buffer, DTT, dNTP, SMARTer 
IIA Oligonucleotide, RNase Inhibitor, and SMARTscribe Reverse Transcriptase. For the second 
strand synthesis several different numbers of cycles were used in different reactions. The 
reaction consisted of first-strand cDNA, ddH2O, 10X Advantage 2 PCR buffer, 50X dNTP mix, 5 
PCR Primer IIA, and 50X Advantage 2 Polymerase Mix. The PCR reaction was performed with 
the following conditions: 95°C 1 min, (95°C 15 sec, 65°C 30 sec, 68°C 6 min) Xcycles. The 
sample which yielded a moderately bright smear spanning from about 0.1 to 4 kb with a few 
prominent bands for abundant transcripts was selected for further reactions, and this sample 
corresponded with a cycle number of 21. The ds cDNA was purified to remove many small side 
reaction products. The purification was performed with CHROMA SPIN DEPC-1,000 Columns 
from Clontech which exclude molecules larger than the pore size from the resin so that they pass 
through the column quickly. An ethanol precipitation was performed to purify the DNA further from 
primers and small products. 
An In-Fusion reaction was performed to clone the cDNA products into the pSMART2IF 
vector. An In-Fusion reaction fuses DNA fragments that contain the same 15 base pairs at their 
ends using the In-Fusion enzyme. In this library the sequence of overlapping 15 bp was identical 
at both sides of the insertion site into the plasmid. Therefore, sequences from the library could 
insert into the plasmid in the forward or reverse orientations. Additionally, translation of the 
sequence to protein in the bacterial clone starts from the Lac promoter in the plasmid, and 
therefore the frame of the tumor library sequence expressed may be different than the wild type 
frame. The In-Fusion reaction was performed by combining 5X In-Fusion reaction buffer, 
pSMART2IF linearized vector, cDNA, In-Fusion enzyme, and ddH2O and then incubating at 15 
min 37°C followed by 15 min 50°C.  This In-Fusion product was ethanol precipitated and 
electroporated into DH010B T1 electrocompetent cells from Invitrogen (Cat No 12033-015). 
These transformed cells were then induced to produce protein corresponding to the cDNA 
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sequence inserted into their plasmid. Note that the final protein lysate that was used for screening 
was produced in several different batches of transformation and expression.   
2.2.3 Automated colony counting 
Transformed colonies on numerous plates were counted using ImageJ software from the 
NIH 136.  Images of the plates were obtained using the Universal Hood II from BIO-RAD 
Laboratories. The colony counting was performed by adjusting the brightness and contrast, 
setting the image to an 8 bit image type, applying a threshold so that only the colonies remained 
on the image, and using the analyze particles function to obtain a cell count (Figure 56). 
 
Figure 56 Automated colony counting with ImageJ 
Colony counting was performed by converting the image to an 8 bit image type (left image), 
applying an intensity threshold (middle image), and counting the number of particles (right image) 
with ImageJ software. 
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2.2.4 Protein production and lysate printing 
 
Figure 57 Logistics of printing 
A typical transformation efficiency of bacteria with plasmid was 5*10^6 cfu/ug.  This culture was 
diluted and separated into wells within 96 well plates at a concentration of 1,000 colonies per 
well.  Lysate from the bacteria could be transferred to 384 well plates to be spotted onto 
nitrocellulose slides for a total of 3,000 spots corresponding to approximately 1,000 unique 
bacterial clones per spot.  Alternatively, bacteria could be spread onto LB plates and grown.  
These bacteria could be lysed and the lysate could be transferred to a nitrocellulose membrane.  
Proteins from lysate could be probed with sera containing antibodies or probed with phage 
antibody libraries. 
The proteins of the tumor library sequences were produced in pooled cultures in 96 well 
plates.  For the library with about 3,000 lysate features, 32 96-well plates containing bacteria 
cultures were used (Figure 57).  The transfer of liquid cultures and reagents for these plates was 
performed with the Biomek FX Laboratory Automation Workstation from Beckman Coulter (Figure 
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58).  Briefly, the transformed cultures were incubated overnight at 37°C at 250 rpm.  These plates 
were incubated in stacks in a HiGro shaker from DIGILAB to make handling the numerous plates 
more convenient (Figure 59).  After the overnight incubation, the culture was diluted 1 to 100 in 
fresh LB with Carbenicillin at a final concentration of 50 ug/mL and grown to an OD600 of 0.5. 
Then, IPTG was added to a final concentration of 1 mM to each well in the 96 well plates to 
induce the production of protein.  The cultures were incubated at 37°C for 4 h.  Cultures were 
harvested by centrifuging at about 4,000 rcf for 10 min, discarding the supernatant, and 
resuspending in 100 μL of lysis buffer. The lysis buffer consisted of PBS, 1% Triton X-100 
detergent, 1 mM PMSF protease inhibitor, and Complete Protease Inhibitor Cocktail from Roche 
(1 tablet per 10 mL solution).  Lysozyme was added to the culture at a final concentration of 0.05 
ug/µl. Plates were incubated for 15 min at room temperature with moderate shaking. The plates 
were then subjected to three freeze/thaw cycles to break up the cell membrane.  DNase and 
MgCl2 were added to the solutions for a final concentration of 0.02 ug/mL and 1.1 mM MgCl2 
respectively.  Plates were incubated for 1 h at 4°C with moderate shaking.  Soluble protein was 
isolated by centrifuging at 4,000 rcf for 20 min, and the supernatant was transferred to a new 
plate.  EDTA was added at a final concentration of 1 mM to prevent contaminating growth, and 
glycerol was added at a final concentration of 2% to help maintain the integrity of the protein 
throughout future freeze/thaw cycles.  A portion of the solution in each well was transferred from 
a 96 well plate to a 384 well plate to allow for printing. 
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Figure 58 Biomek FX Laboratory Automation Workstation to automate liquid handling 
The Biomek FX is a workstation capable of automating the transfer of liquid cultures and 
reagents.  In this image the "arm" has obtained pipette tips from the light blue case on the left, 
collected liquid from the container on the far bottom right, and then dispensed this liquid into the 
96 well plate in the middle. 
 
 
Figure 59 HiGro shaker for shaking multiple plates 
Four towers of the HiGro shaker are displayed.  Each tower can contain a stack of 96 well plates 
for shaking and incubating at the set level. 
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Positive control lysate pools were included on the first library array containing 3E6 
clones.  These positive control lysates were from clones containing the pGEX-SMC1fs-27mer 
plasmid, and these clones produced 17 amino acids of frameshift SMC1Afs sequence and 10 
amino acids of wild-type SMC1A sequence fused to GST. Antibodies from mice immunized with 
this protein were later tested against this protein. Negative control lysates from transformants 
containing the pUC19 plasmid were also included in the library. 
 The soluble protein lysate was printed onto slides with the NanoPrint 60 microarray 
printer from Arrayit Technologies.  The final protocol made use of ONCYTE SuperNova 
Nitrocellulose Film-Slides slides from Grace Biolabs (Cat No GBL705177) (Figure 60) with 500 
μm spacing between spots.  Any printed slides were used for an experiment with sera one day 
after the print run to allow for enough time for the lysates to completely dry, but not allow for 
enough time for the proteins to degrade significantly. The lysate plates were stored at −80°C 
when not in use. 
 
Figure 60 ONCYTE SuperNova Nitrocellulose Film-Slide 
Proteins within lysate were spotted onto ONCYTE supernova nitrocellulose slides with the 
NanoPrint 60 microarray printer.   Each slide can contain 3,000 spots with 500 µM spacing 
between spots. 
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2.2.5 Test prints with SMC1Afs dilution series 
Many lysate test print runs were performed to develop a method which would allow for non-
smeared spot morphology on a slide surface and also allow for the antibody detection of dilute 
samples of the cognate protein.  This section will very briefly present the various slide surfaces 
and conditions that were tested during the evolution of an effective protocol.  The ultimate goal 
was to demonstrate that a protein can be detected at low concentrations in a lysate pool.  
Demonstrating this capability was important since the library would contain pooled lysate from 
many different cDNA-library clones. 
2.2.5.1 Initial Aminosilane and CodeLink Slide Test 
For other projects, researchers in our lab print non-natural sequence peptides on 
aminosilane-coated glass slides.  The slide is coated with sulfo-SMCC linker.  This molecule 
binds to the free amines on the slide surface at one of its ends and makes available an NHS ester 
to bind a cysteine on a protein or non-natural sequence peptide on the other end through its 
maleimide group (Thermo Fisher Scientific Cat No 22122).  Since these slides were abundant in 
our lab and compatible with all of our instruments, it was natural for us to attempt to print the cell 
lysate onto these slides. 
In addition to printing lysate onto the aminosilane slides, I also wanted to test another 
slide surface and selected CodeLink Amine-binding slides (Surmodics Cat No DN01-0025).  
These slides have a polymer coating along with a reactive group that binds to amines.  Ideally the 
polymer coating would help trap cell lysate proteins, and prevent smearing of lysate spots on the 
slide. 
A lysate dilution series was printed onto both of these slide types.  Lysate from bacteria 
induced to produce the SMC1fs peptide fused to GST (GST_SMC1fs) from the pGEX-SMC1fs-
27mer plasmid was diluted into negative control lysate from non-induced bacteria containing the 
pUC19 plasmid.  The following lysate spot dilutions were printed onto the array in triplicate in the 
same order that one reads: 1X, 0.5X, 0.1X, 0.001X, 0X, Blank, GST_SMC1fs purified, and GST 
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purified where 1X indicates undiluted GST_SMC1fs lysate, 0.1X indicates a 1/10 dilution of 
GST_SMC1fs lysate, and 0X indicates pure negative control lysate with no SMC1fs. 
Sera were applied to both of these slide types in a similar manner.  First the slides were 
non-specifically blocked.  The aminosilane slides were blocked with BSA for 1 hr at 37 °C.  The 
CodeLink slides were blocked for 30 min with CodeLink ethanolamine blocking buffer which was 
composed of 0.1 M Tris and 50 mM ethanolamine at pH 9, and then 30 min with BSA containing 
buffer.  The slides were then washed and 5 nM purified rabbit α-hSMC1fs 17mer antibody was 
applied to 4 slides while a 1:500 dilution of rabbit α-hSMC1fs 27mer sera was applied to 6 slides 
for 1 hr 37 °C.  The slides were washed and 5 nM biotinylated goat α-Rabbit IgG (Bethyl) was 
applied as the secondary reagent for 1 hr 37 °C.  The slides were then washed and 5 nM 
streptavidin AF647 was applied as the tertiary reagent for 1 hr 37 °C.  This method resulted in 
smeared lysate spots as illustrated in Figure 64a in the results section. 
2.2.5.2 Denatured lysate 
Next I tried to denature the proteins in the lysate to determine whether this would cause 
less smearing on the slide.  SDS was added to the lysate at a final concentration of 1%, and this 
solution was incubated at 50 °C for 1 hr.  The procedure for applying the sera was very similar to 
the procedure described in the previous section.  The denatured lysate still smeared across the 
slide as presented in Figure 64b in the results section. 
2.2.5.3 HEPES and glycerol buffer 
Since glycerol is a viscous substance, I hypothesized that adding glycerol to the lysate 
would prevent smearing across the slide.  I also tested HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer instead of glycerol as well.  Two aminosilane slides and two 
CodeLink slides were tested.  Each slide contained a block of denatured HEPES lysate, non-
denatured HEPES, denatured glycerol, and non-denatured glycerol.  The final concentration of 
HEPEs in the lysate was 7 mM with 1 mM EDTA, and the final concentration of glycerol was 5% 
glycerol.  The primary reagent was 1:500 rabbit α-SMC1fs-17mer; the secondary reagent was 5 
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nM biotinylated goat α-rabbit IgG; and the tertiary reagent was 5 nM streptavidin AF647.  Some of 
the most extreme smearing observed was found with these buffers as seen in Figure 64c in the 
results section. 
2.2.5.4 PEI polymer slides 
Another researcher by the name of Valeriy Domenyuk in our lab was using custom PEI 
(polyethylenimine) polymer slides with whole cells 137, and I decided to test these slides with cell 
lysate.  These slides are glass slides coated with epoxysilane connected to a hyper-branched PEI 
polymer.  Other than the change of the slide surface, the rest of the procedure remained 
essentially the same as in the previous section.  This slide surface still resulted in smearing as 
demonstrated in Figure 64d in the results section. 
2.2.5.5 Nitrocellulose slides 
Nitrocellulose slides were the next slide type tested.  Nitrocellulose slides have a 3D 
porous structure that proteins can become trapped in, and this is the same type of material that 
other protein assays such as dot blots and Western blots are performed with.  Lysate was printed 
and sera was applied to this material the same way as described in the previous sections.  With 
this slide type very good morphology with no smearing on the slide was obtained as illustrated in 
Figure 64e in the results section. 
2.2.5.6 Fresh SMC1fs lysate on nitrocellulose slides 
The nitrocellulose slides resulted in great morphology, but only the positive control 
protein was detected above background signal.  I hypothesized that the diluted SMC1fs may have 
been too old at this point, and I might obtain better results with the nitrocellulose slides and fresh 
SMC1fs lysate.  All of the other conditions remained the same.  This did result in better detection 
of the diluted SMC1fs lysate by the α-hSMC1fs-17mer antibody, but the fresh lysate did smear 
more and the spots were too close as visualized in Figure 64f in the results section. 
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2.2.5.7 Nitrocellulose with 800 µM spacing 
The fresh lysate had larger spots, and adjacent spots ran into each other.  Therefore, 
another print run using farther spacing between each spot at 800 µM was performed.  This did 
result in well-spaced lysate features (Figure 64g). 
2.2.5.8 Concentrated primary with nitrocellulose 
In an attempt to detect lower dilutions of SMC1fs lysate, the concentration of primary 
serum was increased.  Instead of using a 1:500 dilution of serum, a 1:20 dilution was used.  The 
incubation time for the primary sera was also increased from 1 hr to 2 hr.  The features were 
printed with 800 µM spacing as before.  The primary sera used in this experiment was BALB Nat 
α-mSMC1-27mer, the secondary was a 1:100 dilution of goat α-mouse IgG (Bethyl), and the 
tertiary was 5 nM AF647. 
2.2.5.9 Nitrocellulose with overnight primary 
The concentrated sera resulted in better detection of the SMC1fs dilutions, but there was 
too much high uneven signal across the slide.  This condition would not be good for a real library 
print run with many features across the entire slide.  Therefore, I tried using the standard dilution 
of primary serum (1:500) with an overnight incubation (16 hr) instead of 1 hr or 2 hr at a lower 
temperature of 23 °C instead of 37 °C (Figure 64i). 
2.2.5.10 Nitrocellulose with Super G Blocking Buffer and 2hr incubation 
Next I tried using an alternative to the BSA blocking buffer: Super G Blocking Buffer.  
These slides were also incubated for 2 hr at 37 °C with the primary sera. 
2.2.5.11 Nitrocellulose blocking buffer and incubation time test 
One last test print was performed to directly compare the different blocking buffers and 
incubation times.  Both the Super G Blocking Buffer and the BSA based blocking buffer were 
used.  An incubation time of 1 hr at 37 °C and an incubation time at 16 hr 23 °C were also tested.  
The primary serum dilution was 1:500. 
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2.2.6 PCR Screen 
Pools were screened for the presence of particular frameshift transcripts using a 
touchdown PCR protocol.  All of the transcripts screened were chimeric transcripts in mice that 
have been previously identified by our lab 138.  The reaction was setup as follows: 5 µl 10X 
DyNAzyme buffer, 1 µl 25 mM dNTP each, 1 µl 10 µM forward primer, 1 µl 10 µM reverse primer, 
1 µl template, 40.5 µl PCR grade H20, and 0.5 µl DyNAzyme II DNA polymerase (Thermo 
Scientific Cat no F-503S).  Ten cycles of touchdown PCR followed by 40 normal cycles were 
performed as follows: (95 °C 30s, (61-cy) °C 30s, 72 °C 30s)X10cy, (95 °C 30s, 50 °C 30s, 72 °C 
30s)X40, 72 °C 5m, 4 °C hold.  Therefore, with this protocol the first cycle would use an 
annealing temperature of 60 °C, the second would use an annealing temperature of 59 °C, etc.  
The primers used for the different transcripts are listed in Table 12.  For some of the transcripts 
investigated, a primer which bound directly to base pairs across the fusion site was used 
(designated with the letters “fus”) in addition to primers on either end of the chimeric fusion site 
(“F” and “R”). 
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Table 12 Primers used for PCR screen 
Primer Sequence Length (bp) 
Annealing 
Temperature 
(°C) 
TR_E20151F TGGTGAGCTACCCTAAGCTG 20 53.7 
TR_E20151R ACAGCCGTCTTCTGAGTTTG 20 51.7 
TR_E20131F ACCTTTCAACAGGCTCACAG 20 51.7 
TR_E20131R TTCATGCAATACCACCAATG 20 47.6 
TR_E20026F GTGTTCTTTCATGTCCCTGC 20 51.7 
TR_E20026R CCTTCCTTCTTTTCCCTTTG 20 49.6 
TR_E10176F AGCACATCTCTCTGCTGGTC 20 53.7 
TR_E10176R TGGACTGACCTTTCATCCTC 20 51.7 
TR_E10142F GACCATTCTGGAGTGTCGAG 20 53.7 
TR_E10142R CTCTTCTGCAGAGAACCAGC 20 53.7 
TR_E10028F CTGGACCATGAGGTGAAGAC 20 53.7 
TR_E10028R TCTCCAGACTCTCCAGGTTG 20 53.7 
Thap2F CATCAGCTTCCACAGGTTTC 20 51.7 
Thap2R CGATGGTTAAGATGAATCCG 20 49.6 
Thap_fus CAGGCCGAAAGTTACCAGAGAC 22 56.6 
SMC1-mou-R GAGCTGTCCTCTCCTTG 17 49.3 
SMC1-mou-F CTGTCATGGGTTTCCTG 17 46.9 
Smc_fus CACTGCACCCAGAGCCATTG 20 55.8 
Slain2F CCTGCCCTTAATAGGTTTTCTCC 23 55.2 
Slain2R CTTTCCAACTGTCATCTTTCATGC 24 53.9 
Slain2_fus TGGCAATGATTGGCTGAAGCC 21 54.2 
Rbm14F CAATGTCGATGGGGCGGATA 20 53.7 
Rbm14R CCACACCGATAGCAACCACT 20 53.7 
Rbm14_fus GACAAGAGCCTACCACGTCAC 21 56.2 
 
List of primers used to screen for the presence of chimeric transcripts in the tumor cDNA library.  
These transcripts have been previously identified in mice in our lab. 
2.2.7 Application of sera to tumor library lysates 
The nitrocellulose slides were first locked into the Tecan HS 4800 Pro Microarray 
Hybridization Station from Tecan.  Two slides were used for each condition: tumor sera, naïve 
sera, and sera from SMC1Afs immunized mice.  The slides were first washed for 30 sec with Tris-
Buffered Saline and Tween 20 (TBST), blocked with Super G blocking buffer, incubated at 23 °C 
for 1 h, and washed for 30 sec with TBST.  Primary sera at a 500 fold dilution in a 200 μL volume 
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of incubation buffer consisting of BSA, Tween 20, and PBS was then applied to the nitrocellulose 
slides.  This sera was from the tumor bearing, naïve, or SMC1Afs immunized mice described in 
the "Procedures with BALB/c mice" section.  The slides were incubated at 23 °C for 16 h, washed 
for 30 sec with TBST, and then 5 nM of AF647 goat α-mouse IgG H+L antibody from Bethyl was 
added. The slides were incubated at 23 °C 1 h, washed 30 sec with TBST, washed 30 sec with 
ddH2O, and then dried with nitrogen for 5 min.  The slides were scanned in the Tecan Power 
Scanner at 10 μm resolution to produce 16 bit images with intensity values for each pixel ranging 
from 0–65,535. The analysis of the data is described in the "Data Analysis" section. 
2.2.8 Data analysis 
High intensity spots in the images of the scanned slides were correlated with the identity 
of specific lysate pools or lysates containing single clones by aligning the spots with labeled 
circles in a gal file.  This process was performed with GenePix software (Molecular Devices, 
Santa Clara, CA).  The resulting intensity values for each lysate were then analyzed in Microsoft 
Excel (version 15.0.4551.1003) 69 to perform T-tests to determine the p-value for a lysate with 
tumor sera or naïve sera.  The fold change between naïve and tumor was also determined.  The 
QVALUE program for the R statistics software (version 2.15.0) 68 was also used to determine the 
false discovery rate (fdr) distribution of the intensities from a tumor library lysate screen 139.  All of 
the default settings were used to calculate the false discovery rates. Graphs and figures were 
created using GraphPad Prism 4 for Windows (GraphPad Software, www.graphpad.com) and 
Inkscape 0.48 for Windows (www.inkscape.org). 
2.3 Results 
2.3.1 Complexity of cDNA library 
From the 15 colonies that were sequenced after the construction of the tumor cDNA library, 
an estimate of the complexity of the transcripts represented in the library was calculated.  Several 
of the sequences were very short products (three sequences), and nine of the remaining 12 insert 
sequences were oriented in the forward orientation relative to the Lac promoter of the bacterial 
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expression plasmid.  One of these nine sequences was a duplicate, such that eight from this 
sampling of 15 library components were found to be unique probes for screening the binding 
reactivities of test and control sera. 
2.3.2 Troubleshooting protein production in 96 well plate 
The protocol I followed in order to produce protein in 96 well plates was adapted from the 
protocols referred to in Current Protocols in Molecular Biology Unit 16.5 140.  The final protocol I 
consistently used is described in the “2.2.4 Protein production and lysate printing” section.  
However, before arriving at this protocol, I had some trouble producing proteins in the 96 well 
plate format.  I observed very low amounts of the induced protein and high amounts of a 
mysterious 14 kD protein.  The 14 kD band was detected in pGEX-SMC1fs-27mer plasmid type 
solution (induced and non-induced) and pET32b plasmid type solution (both induced and non-
induced) when probed with antibody against SMC1fs or thioredoxin (Figure 61).  The 14 kD 
protein was also observed in a Coomassie stain during which no antibodies are used (Figure 62).   
John-Charles Rodenberry, Dr. Sykes, and I later discovered that this band was caused by 
the addition of too much lysozyme during the protein production protocol to degrade the bacterial 
cell wall.  During the protocol to produce protein, bacteria are grown overnight, diluted, induced to 
produce protein with IPTG, allowed to produce protein for several hours, centrifuged, 
resuspended in lysis buffer, and then lysozyme is added.  The solution is then subjected to 
freeze/thaw cycles, DNA is degraded with DNase, the solution is centrifuged, and the soluble 
protein in the supernatant is stored.  When developing the protocol I had to modify the procedure 
we used in the lab for producing protein in large flasks rather than 96 well plate wells.  For the 
protocol with a large flask, 2 mg of lysozyme is added per 1 mL resuspension solution.  For the 
plate, I was adding 0.4 mg per 1 mL resuspension solution.  However, the original protocol with a 
large flask was actually adding 0.05 mg lysozyme per 1 mL of original culture before the bacteria 
solution was diluted or centrifuged.  Therefore, I was adding too much lysozyme.  Once the 
correct amount of lysozyme (0.05 mg lysozyme per 1 mL of original culture) was used, a strong 
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SMC1fs band could be detected in a western blot with only a faint 14 kD lysozyme band in the 
background (Figure 63). 
 
 
Figure 61 Western blot for production of protein in plate format with 14.3 kD Lysozyme 
band 
E. coli containing different plasmids were lysed, and the lysate was probed with antibody against 
SMC1fs or thioredoxin.  The “0 P” plasmid refers to the negative control E. coli with no plasmid, 
“GEX I” refers to the pGEX-SMC1fs-27mer plasmid with E. coli that were induced to produce 
protein with IPTG, “GEX 0I” refers to the pGEX-SMC1fs-27mer plasmid without induction, “32 I” 
refers to the pET32b plasmid with induction, and “32 0I” refers to pET32b with no induction. 
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Figure 62 Coomassie stain for protein production in plate format with 14.3 kD band 
E. coli containing different plasmids were lysed, and the lysate was subjected to a Coomassie 
stain to visualize protein bands.  The “0 P” plasmid refers to the negative control E. coli with no 
plasmid, “GEX I” refers to the pGEX-SMC1fs-27mer plasmid with E. coli that were induced to 
produce protein with IPTG, “GEX 0I” refers to the pGEX-SMC1fs-27mer plasmid without 
induction, “32 I” refers to the pET32b plasmid with induction, and “32 0I” refers to pET32b with no 
induction. 
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Figure 63 Western blot of protein production in plate format with appropriate lysozyme 
concentration 
E. coli containing either the pGEX-SMC1fs or the pET32b plasmid were induced to produce 
protein with IPTG.  Lysate from this E. coli was then used in a western blot probed with antibody 
against SMC1fs (left), rabbit IgG (middle), or mouse IgG (right).  The molecular weight of GST-
SMC1fs is 29.2 kD, and the expected size of lysozyme is 14 kD.  During the production of the 
protein 0.05 mg of lysozyme per 1 mL of original E. coli culture was used. 
2.3.3 Test prints with SMC1Afs dilution series 
Before arriving at the final protocol used for the tumor cDNA library lysate slides, many 
different slide surfaces, incubation conditions, and reagent concentrations were tested (Figure 64 
and Figure 65).  The final protocol optimized tumor lysate spot morphology without smearing one 
lysate pool into another (Figure 66).  I determined that a test antibody can recognize its cognate 
antigen when diluted up to 1,000 fold into control lysate with a fold change of 1.66 and a p-value 
of 0.01.  An experiment in which α-SMC1Afs antibody was applied to the three million component 
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tumor library array demonstrated that the SMC1Afs containing lysate pools were selectively 
recognized (Figure 67 and Figure 68). 
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Figure 64 Test prints 
a) Lysate morphology on CodeLink and Aminosilane slides.  b)  Denatured lysate on CodeLink 
and Aminosilane slides.  c)  Denatured and non-denatured lysate with HEPES and glycerol buffer 
on CodeLink and Aminosilane slides (HP = HEPES, GC = Glycerol, D = denatured, ND = non-
denatured).  d)  Denatured and non-denatured lysate on PEI polymer slides.  e) Lysate printed 
onto nitrocellulose slide.  f)  Fresh SMC1fs lysate printed onto nitrocellulose slides.  g)  Lysate 
printed onto nitrocellulose slides with farther 800 µM spacing.  h)  Concentrated 1:20 primary sera 
applied to nitrocellulose slide.  i) Overnight primary incubation with nitrocellulose slides.  j)  Super 
G blocking buffer used instead of BSA blocking buffer. k) Bar graph of intensity values detected in 
each dilution of SMC1fs lysate with Super G blocking buffer. 
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a) 
 
b) 
 
Figure 65 Test of blocking buffer and incubation condition 
a) Bar graphs of detected intensity of features in an SMC1fs lysate dilution series on 
nitrocellulose (nitro) slides with Super G Blocking Buffer or BSA blocking buffer, and an overnight 
(Ovnt) 16 hr 23 °C incubation or 1 hr 37 °C incubation.  b) Ratio of 0.001X/0X signal for the 
different conditions. 
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Figure 66 Array scan of slide surface.  
Lysates from a 4T1 tumor cDNA expression library printed onto nitrocellulose slides. (A) Library 
probed with naïve mouse serum. (B) Library probed with serum from 4T1 tumor-bearing mouse.  
Nitrocellulose slides were spotted with 3,000 pools of bacterially expressed tumor cDNA library 
clones, and probed with the indicated sera. Specific lysate binding was detected with an α-mouse 
IgG secondary antibody conjugated to AF647 and then scanned (Tecan Power Scanner) at 647 
nm. An image of one slide with naive sera and one slide with tumor sera is presented. Each one 
of the 3,000 pools is comprised of 1,000 original 4T1 tumor cDNA library transformants. 
 168 
 
Figure 67 Bar graph of detected intensity of controls 
Intensity of lysate containing either SMC1Afs peptide or negative control β-galactosidase protein.  
The intensities were detected after either sera against SMC1Afs or sera from a naïve mouse 
were applied to the 3 million component tumor lysate library. SMC, SMC1Afs; Neg, negative 
control β-galactosidase; S, sera; and L, lysate. 
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Figure 68 Tumor library array probed with SMC1fs sera 
The positive and negative control lysate spots on the array are labeled with a date that the lysate 
was produced, a label indicating whether the lysate is a pUC19 or SMC1fs spot, and information 
about the PCR plate that the lysate came from (the plate number, the row number, and the 
column number). 
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2.3.4 PCR Screen 
A PCR was performed to detect whether certain pools in the library contained certain 
frameshift transcripts and chimeric transcripts which our lab has investigated over time.  Our lab 
has sera against the bottom four transcripts in Figure 69A.  The pools which the selected 
frameshift or chimeric transcripts were detected in are displayed in Figure 69A.  Each pool in this 
screen of 41 pools consists of approximately 96 subpools.  Pool 16 of the 41 pools was selected 
for further screening for the SMC1fs and Slain2 transcripts (Figure 69B).  This pool was chosen 
because it had both transcripts and the bands on a PCR gel looked distinct.  Note that only one 
pool from this screen contains the SMC1fs transcript in the forward orientation relative to the lac 
promoter in the bacterial expression plasmid, and this pool was pool number 87 in Figure 69B. 
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Figure 69 PCR Screens of Pools in Tumor cDNA Library 
Pools in the tumor cDNA library were screened for the presence of specific transcripts using 
PCR.  A) 41 pools each consisting of approximately 96 subpools of the 3,000 pool library 
representing 3 million clones were screened for the presence of 10 chimeric transcripts.  B) Pool 
16 from the screen in A was screened further to determine whether the 96 subpools contained 
the SMC1fs transcript or the Slain2 transcript. 
2.3.5 Application of sera to tumor library 
Sera from mice immunized with SMC1fs and sera from the tumor-bearing mice from 
which the tumor cDNA library was constructed were applied to the 3,000 pool tumor cDNA library 
lysate array.  From the PCR screen described in the “2.2.6 PCR Screen” section, I knew which 
pools in the library contained the SMC1fs transcript.  Three pools on the array corresponded to 
the SMC1fs positive control pools containing lysate from bacteria with the pGEX-SMC1fs-27mer 
plasmid.  One pool is known to contain the SMC1fs transcript in the forward orientation relative to 
the lac promoter in the plasmid. 
After applying sera to the tumor cDNA library lysate array, an intensity value for each 
pool was obtained.  These intensity values were compared to the intensity values for each pool 
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obtained after applying naïve sera, and the p-value and fold change of each pool probed with 
naïve vs SMC1fs sera, or naïve vs tumor sera was obtained.  A figure showing where each of 
these pools lie on a p-value and fold change scatterplot is presented with SMC1fs sera (Figure 
70A) and tumor sera (Figure 70B). 
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Figure 70 Reactivity of SMC1fs lysate with sera on 3K array 
Sera were applied to the 3K lysate array and compared with naïve sera.  A scatterplot of the p-
value obtained in comparison with naïve sera and the fold change in comparison with naïve sera 
is displayed.  A) Results obtained from SMC1fs applied to the array.  B) Results obtained from 
tumor sera applied to the array. 
2.4 Discussion 
2.4.1 Library transcript representation  
The complexity of the sequences contained in the constructed cDNA library indicated that 
53.3% of the sequences were not truncated products and were correctly oriented for expression.  
While informative, this number is likely an overestimate caused by the small sampling size.  
Namely, more than half of the clones in the sampled set were in the correct orientation (11/15 = 
73% in correct orientation).  Unless there is some fortuitous bias that I am unaware, 50% should 
be forward oriented and 50% should be reverse oriented).  If more clones were sequenced, the 
calculated expressed-clone complexity would presumably approach the expected.  This can be 
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approximated as (1/2)*11/15 = 37% since 11/15 of the transcripts were unique non-truncated 
sequences, and approximately 50% of these sequences would be expected to insert into the 
plasmid in the correct orientation.  Of these 37% only 33% would be anticipated to be in the same 
frame as the original transcript and therefore approximately 12% of the clones in the library would 
be expected to express products faithful to the original tumor RNA products. 
The nitrocellulose slides are printed with E. coli cell lysate from this tumor cDNA library.  
There are 3,000 features total.  Each feature represents proteins translated from approximately 
1,000 original transformants.  Therefore, the total number of components present on a single 
microarray is ~3 million.  This number includes transcripts that were inserted backward or out-of-
frame.  After taking these artifacts into account, I estimate a total of 3.6E5 unique transcripts are 
properly translated and presented on the microarray.  There are between 20,000 and 50,000 
transcripts in a mammalian cell, depending on how one defines a unique transcript, and not 
taking into account post-translational modifications or rare splice variants.  Most of the 
mammalian transcripts  (94%) occur between one and five times 141, and about 25% are present 
in one or fewer copies per cell 142.  Given 3,000,000 clones, each mammalian transcript would be 
represented in our library 3E6/50,000 = 60 times on average.  However, since only 12% of the 
library would correspond to the original RNA transcript sequence, each transcript would be 
expected to be represented approximately 60*0.12 = 7.2 times on average.  I expect that there 
are certain transcripts for which this would not be true, given that some transcripts are extremely 
high copy and would appear more than 7.2 times presenting an opportunity to create a noise 
threshold.  However, given a 7.2-fold minimum representation for low-copy transcripts, I expect 
sufficient sensitivity to detect single-copy events.  A spike-in dilution experiment indicated our 
sensitivity is greater than one copy per 1,000 clone pool (feature). 
2.4.2 Experiment conditions 
Different slide surfaces, incubation conditions, and reagent concentrations were tested 
during the development of the protocol.  A brief description of these tests will be provided. Many 
slide surfaces were used before consistently using the nitrocellulose slide surfaces used for the 
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screens presented in the Materials and Methods and Results section.  I first tried to use CodeLink 
and Aminosilane slides, but the printed cell lysate features would smear across the slide.  I then 
tried to denature the lysate by incubating with a final concentration of 1% SDS detergent at 50 °C 
for 1 hr, but this strategy was not effective at preventing smearing.  A 1/10 dilution of SMC1fs into 
pUC19 lysate could not be detected above background.  Next I tried using HEPES and glycerol 
buffer, but this actually resulted in the most smearing of any of the print runs.  Note that there was 
high humidity around this time, and this may have adversely affected the print run as well.  I then 
tried printing onto a different slide type: PEI polymer slides.  No improvement was obtained.  The 
final slide type tested was composed of nitrocellulose, and this material yielded very good cell 
lysate spot morphology.  However, the SMC1fs dilution series did not show any signal. Perhaps 
the SMC1fs lysate which had been stored at -80 °C and frozen and thawed several times was too 
old at this point in time. 
Once I identified that the nitrocellulose material worked very well to prevent smearing, I 
tried to increase our ability to detect the diluted protein.  Fresh SMC1fs lysate was prepared and 
another experiment was performed.  Only the 1X and 0.5X lysate spots were detected above 
background, and this fresh lysate also exhibited more smearing than the older lysate.  Another 
print run with 800 µM spacing instead of 500 µM was performed to prevent adjacent spots from 
running into one another.  In order to detect the lower dilutions of SMC1fs protein, the 
concentration of the primary sera was increased from 1:500 to 1:20.  Lower dilutions were 
detected, but there was too much bright uneven intensity across the slide which would have 
caused problems for screening an entire library with many features.  I then tried using the 
standard primary sera dilution of 1:500, but I increased the incubation time from 1 hr to 16 hr and 
lowered the temperature to 23 °C.  This did allow for the detection of the 1/100 lysate spot, but 
the 1/1,000 dilution was still not detectable.   
Next I tried using the Super G Blocking Buffer instead of the BSA blocking buffer.  The 
first experiment with this buffer was performed with a primary sera incubation at 37 °C for 2 hr.  
This Super G Blocking Buffer decreased all detected intensities considerably.  However, the 
ability to distinguish between different lysate dilutions and the ability to detect lower dilutions 
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increased.  The error bars of replicate lysate spots were also very small with this blocking buffer.  
The final test print directly compared the Super G and BSA blocking buffer as well as the 1 hr 37 
°C primary incubation condition and the 16 hr 23 °C incubation condition.  The Super G blocking 
buffer results in less smearing, and the overnight condition results in higher signals.  In this 
experiment I was even able to detect 1/10,000 SMC1fs dilutions above background.   
The results from these test prints led us to use nitrocellulose slides, Super G blocking 
buffer, 1:500 sera dilution, and 16 hr 23 °C primary sera incubation conditions for future 
experiments.  A secondary antibody titration experiment was also performed to determine the 
optimal concentration of secondary to use, and a 1 nM concentration was then chosen for many 
experiments.  These conditions were then used to demonstrate that α-SMC1Afs antibody could 
detect the SMC1Afs protein in lysate from clones producing this protein as presented in the 
Results section. 
Note that there are groups of features showing similar intensities.  These were obtained 
in the same bacterial production batch, and this effect can be seen from the patterns of bright and 
faint spots on the nitrocellulose slide (Figure 66).  This bias in intensity which is introduced by 
technical experiment variation rather than a biological phenomenon does not affect the data 
analysis because each lysate feature intensity obtained with naïve sera is compared with the 
same lysate feature intensity obtained with tumor sera.  In other words, the lysates compared are 
identical and are of the same batch, and lysates from different batches were not compared 
against one another. 
2.4.3 PCR Screen 
There were 3,000 tumor cDNA library pools and some of these pools were screened for 
the presence of specific frameshift and chimeric transcripts.  The positive rate of the transcripts 
(displayed in Figure 69) seems reasonable considering that approximately 7 copies of any single 
copy transcripts are expected to be present in the library as indicated in the “2.4.1 Library 
transcript representation” section.  Also note that most of the transcripts searched for were 
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detected with the exception of 2 transcripts.  These may be very low copy transcripts which did 
not make it into the cDNA library. 
2.4.4 Application of sera to tumor cDNA library 
Sera samples from naïve mice, tumor mice, and SMC1fs-immunized mice were applied to 
the cDNA-library.  Note that the sera from the mice with the tumor were the same mice from 
which the tumor cDNA library was constructed (see sections “2.2.1 Procedures with BALB/c 
mice” and “2.2.2 Construction of tumor cDNA library” for more details).  The intensity for each 
pool with SMC1fs sera was compared to the intensity obtained with naïve sera and the p-value 
and fold change were determined (Figure 70A).  The same values were determined with tumor 
sera.  These results show that pools which are known to contain the SMC1fs transcript as 
determined from a PCR screen (section “2.3.4 PCR Screen”) had either significantly different p-
values or fold changes relative to naïve sera.  Almost all of the SMC1fs positive control pools fall 
into this same category as well.  These findings indicate that the platform developed works as 
planned.  Antibodies against a specific target (SMC1fs) detected this target when produced 
artificially in bacteria containing the pGEX-SMC1fs-27mer plasmid.  These antibodies also 
detected the target as it naturally occurred in the tumor cDNA library.  These results suggest that 
this array platform can be used to detect new immunogens against which a host has produced 
antibodies.  These proteins could be studied further to better understand cancer and the 
relationship of these proteins with the immune system, and these proteins are also good 
candidates for a cancer vaccine. 
2.5 Conclusion 
This research outlines a platform for screening tumor cDNA library lysate for tumor-specific 
antigens.  The platform involves using automated equipment to handle large numbers of PCR 
plates, small nitrocellulose slides, high resolution scanners, and the screening of several rounds 
of pools.  As researchers use high throughput methods such as the method demonstrated in this 
paper to discover new tumor immunogens, the reactivity of antibodies for specific proteins will 
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reveal which proteins the immune system responds to during the course of cancer.  Using this 
knowledge scientists will be able to select optimal components to include in a preventative cancer 
vaccine. 
  
 179 
 3: DISCOVERING IMMUNOGENS 
3.1 Introduction 
3.1.1 Screening pooled tumor cDNA library lysates 
A tumor cDNA library was constructed and 3,000 lysate pools each containing 
approximately 1,000 original transformants were contact printed onto a nitrocellulose slide. This 
approach allowed three million library components to be quickly and simultaneously screened on 
one platform. One high binding sublibrary lysate-pool was then selected and re-arrayed onto 
another slide, as 3,000 individual features. Thus ~1,000 unique constituents would be 
represented at approximately one per spotted position since the colonies were diluted to contain 
an estimated one colony per well volume. High binding lysate spots from this array were then 
used to construct an array containing exactly one clone for a final round of screening. This multi-
round pooled lysate approach allowed for the screening of many clones at once.  The high-
throughput tumor lysate screening for tumor antigens approach described here may be the type 
of method that could lead to the discovery of important tumor immunogens that aid in the 
understanding and treatment of cancer, and several potential immunogens from this screen are 
presented. 
3.2 Materials and Methods 
3.2.1 Protein production and lysate printing 
The proteins of the tumor library sequences were produced in pooled cultures in 96 well 
plates. There were three libraries handled: a library containing 3,000 lysate pools representing 
three million clones, a library containing 3,000 lysate pools representing 3,000 clones, and a 
library containing 12 lysates representing 12 clones. 
The soluble protein lysate was printed onto ONCYTE SuperNova Nitrocellulose Film-Slides 
slides from Grace Biolabs (Cat No GBL705177) with the NanoPrint 60 microarray printer from 
Arrayit Technologies with 500 μm spacing between the center of one spot and the center of the 
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next spot. For the data presented in this chapter, four print runs were performed: (1) a three 
million clone library containing ≈3,000 lysate pools (actually 3,072) each containing approximately 
1,000 unique clones each, (2) a validation of performance print of 15 lysate pools of  ≈3,000 each 
selected based on p-values and intensity values from the three million clone library, (3) a pool 
reduction screen print consisting of a 3,000 feature sublibrary (specifically 3,072) with 
approximately one unique clone per feature, and (4) a single clone array screen print consisting 
of 12 lysates deconvoluted from features in the 3,000 feature sublibrary. 
3.2.2 Application of sera to tumor library lysates 
The data from four experiments is presented (Figure 71). The same protocol was 
followed for all four of these experiments with slight variations as knowledge was gained 
throughout the screening process. 
3.2.2.1 Tumor library screen 
The first tumor library screen was performed as described previously during the 
development of the tumor cDNA library screening platform (“2.2.7 Application of sera to tumor 
library lysates”).  After the p-value was determined by comparing the tumor and naïve samples, 
three sets of spots were selected to be used in a validation screen.  Namely, the lysate pools with 
the top five most significant increases in intensity of tumor relative to control sera, the most 
significant lysate pools displaying decreases in intensity in tumor sera, and the five least 
significant p-value lysate pools.  The five least significant p-value lysate pools were chosen as 
negative controls.  The top five most significant lysate pools displaying decreases in intensity in 
tumor sera could be important proteins for which the tumor has somehow caused an immune 
suppression against.  The lysate pools with increases in intensity with tumor sera could be 
important because there could be a strong immune response against these proteins in the mice 
with a tumor. 
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3.2.2.2 Validation of performance of selected lysate pools 
Selected lysate pools (15 total) were printed onto a set of new nitrocellulose slides. Each 
lysate pool was present on the array with ten replicates.  Sera was applied as before at a 500 fold 
dilution to two slides for tumor sera and two slides for naïve sera.  This was followed by 1 nM 
secondary antibody.  The lysate pool with the most significant p-value calculated by comparing 
the tumor and naïve sample was used to construct a new library containing 3,000 lysate pools 
with ≈1,000 unique clones per pool. 
3.2.2.3 Pool reduction screen 
Sera was applied at a 500 fold dilution to four nitrocellulose slide replicates per group 
containing lysate representing ≈3,000 unique clones. This was followed by 5 nM secondary 
antibody. Several lysate pools were chosen for further screening. These lysates corresponded to 
the three lysate pools with the most significant p-value, the greatest fold change, and the highest 
detected intensity with tumor sera. 
3.2.2.4 Single clone array screen 
Individual unique clones derived from the selected pools in the ≈3,000 clone screen were 
printed onto new nitrocellulose slides with three replicates per group and sera was applied at a 
1,000 fold dilution. This was followed by 1 nM secondary antibody. The p-value and fold change 
of the lysates between tumor and naïve samples was then analyzed. 
3.3 Results 
3.3.1 Tumor lysate screening 
3.3.1.1 Tumor library screen 
Pooled tumor lysates were subjected to several rounds of screening as described in the 
Materials and Methods section.  Table 13 lists the array feature selection criteria used through 
the screening protocol, and the results of the screen are presented in Figure 71 A–D.  In the first 
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round of screening, the nitrocellulose slide contained 3,000 pools each consisting of 
approximately 1,000 unique bacteria clones.  Several pools from this round of experiments were 
selected for reduction and further characterization.  The five tumor library lysate pools displaying 
the most significant increases in reactivity between normal and tumor sera samples were 
selected (p-values ranged from 2.04E-5 to 4.27E-3; fdr q-values ranged from 3.78E-3 to 1.86E-2). 
The five pools with the most significant decreases in reactivity were also selected (p-values 
ranged from 2.40E-6 to 2.04E-5; q-values ranged from 1.35E-3 to 3.78E-3).  The five pools with 
the least significant p-values were selected as negative controls (p-value of 1; fdr q-value of 0.5). 
These fifteen selected pools were printed onto a new array for further characterization.   
A scatterplot of the 3,000 lysate pools is presented in Figure 71A.  The base two log of 
the fold change is represented on the x-axis so that values with a decreasing fold change from 
naïve to tumor are on the left side of the y-axis and values with an increasing fold change from 
naïve to tumor are on the right side of the y-axis.  The negative base ten log of the p-value is 
represented on the y-axis so that values with the most significant p-values are present at the top 
of the graph.  Note that false discovery rates (FDR) are useful for making assessments about 
many p-values from an experiment.  An FDR adjusted p-value, or q-value, of 3.78E−3 implies that 
0.378% of all tests with a q-value less than or equal to 3.78E−3 are false positives.  This provides 
a metric to use across the entire experiment rather than to use only for each individual lysate 
pool.  In support of the validity of the array-based library screening method, the pool with the most 
significant p-value within the set of increased reactivities in one screening experiment was also in 
the top three of the same category in a second screening experiment (data not shown). 
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Table 13 Categories of features 
Symbol Description Stage of Screen 
 Significant p-value low tumor 3E6 component library 
 
 
Significant p-value high tumor 3E6 component library 
 
 
Pool selected from 3e6 
component library for further 
partitioning 
3E6 component library 
 Greatest fold change  3,000 component sublibrary 
 Greatest tumor intensity 3,000 component sublibrary 
 Significant p-value  3,000 component sublibrary 
 
Categories of specific features displayed in the scatterplots in Figure 71. 
 
 
 
Figure 71 Scatterplots of tumor library lysate screens 
Naive and tumor sera was applied to the tumor library and sublibrary features.  Values of features 
from tumor to control are displayed for the screen of the tumor library (A).  At this stage of the 
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screen, there are ≈1,000 unique transformants per spot.  In (B) the validation of performance of 
selected lysate pools from the tumor library screen is presented.  In this validation experiment to 
confirm that selected pools exhibited reproducible behavior in a new sera screen, there are still 
≈1,000 unique transformants per spot.  The most significant pool was partitioned onto a new 
array in the pool reduction screen presented in (C) with approximately one unique transformant 
per spot.  A total of 9 spots were selected from this screen and partitioned onto a new array for 
the single clone array screen presented in (D).  In this screen each spot was comprised of exactly 
one single unique transformant.  The categories of features are described in Table 13. In (D), 
each plotted lysate result is labeled with a wild type transcript which the cloned sequence aligned 
with when using BLAST.  
3.3.1.2 Validation of performance of selected lysate pools from tumor library screen 
A validation array containing only the ten lysate pools from the three million clone library 
selected as reacting significantly different to the tumor vs. control sera, and the five negative 
control pools was printed and tested. The results support the outcomes obtained from the original 
full screen. The least significant p-value lysates in the tumor library screen had the least 
significant p-value in the validation screen with p-values and fold changes that would place them 
near the origin of the p-value vs. fold change plots. The lysate pool within the increased intensity 
set with the most significant p-value (2.93E-18) was selected to partition and re-array on a 
nitrocellulose slide as distinct features for further testing and reduction of pool complexity (Table 
13 and Figure 71B). 
3.3.1.3 Pool reduction screen 
Since the number of original transformants being expressed within each pool was 
estimated to be 1,000, the identification of an individual antigen requires further testing.  The 
sublibrary pool with the most significant p-value and increasing tumor intensity was partitioned 
and regrown in 3,000 microtiter wells. The 3-fold redundancy is to facilitate capturing a complete 
sublibrary representation, and each new sample is estimated to be comprised of approximately 
one to three unique clones. Slides were printed and tumor test and naïve control sera were 
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applied. Analysis of fluorescent reactivity readouts was used to select several samples for further 
characterization. Three lysate samples were selected based on the best p-value for increase-
reactivities (2.05E-6, 2.05E-6, and 3.80E-6; q-values of 5.55E-4, 5.55E-4, and 5.84E-4), three 
lysate samples were selected based on the highest fold change in reactivity relative to control 
sera (1.81, 1.82, and 1.84), and three lysate samples were selected based on the highest 
measured reactivity levels (10,052; 9,205; and 9,598) (Figure 71C). 
3.3.1.4 Single clone array screen 
A final set of lysate slides were constructed that contained single clones derived from 
these nine lysate pools (Figure 72), which were selected based on their p-value, fold change, or 
high intensity.  This was done by sequencing ten single colonies from each of the nine 
complexity-reduced pools.  These were determined to contain from one to three unique clones. 
Therefore, the final lysate array consisted of three lysates derived from the high p-value lysate 
pools, five lysates derived from high fold change lysate pools, and four lysates from high intensity 
lysate pools.  Lysates from a bacterium producing no library-derived clone was included as a 
negative control.  A scatterplot of the fold changes in reactivity vs. p-values between test and 
control demonstrates that one of the clone-lysates from each of the three characteristic-category 
displayed a significant increase in reactivity to tumor sera relative to naïve sera (Figure 71D). 
Note that in Figure 71D, the category of each single clone feature represents the category of the 
3,000 component sublibrary feature from which the single clone feature was derived from. In 
other words, the Eif1a feature did not have one of the most significant p-values in the single clone 
array screen, but the Eif1a feature was derived from a feature pool which did have the most 
significant p-value in the 3,000 component sublibrary screen. 
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Figure 72 Single clone lysate array 
In this image there are replicate spots, but they were printed in reverse order so that replicate 
spots are not adjacent. 
3.3.2 Sequence information 
Sequence information was obtained for the single clones tested as lysates on the final 
nitrocellulose arrays.  Most of these sequences matched the 3' end of wild-type mouse RNA 
transcripts but were truncated at the 5' end.  Some of the cDNAs inserted into the plasmid out of 
frame relative to the wild type protein (5/9) or in reverse orientation (1/9).  Several of the 
sequences also contained point mutations relative to the murine database.  Table 14 summarizes 
some of the characteristics of these sequences. Note that the CcoI sequence is an unusual 
sequence since it contains the 3' end of the CcoI mouse mitochondrial gene transcript upstream 
of the tRNA-Ser sequence and a poly A tail.  For the reverse-oriented Hiatl1, a ribosome 
translating this would slip along the poly T region present in the sequence and all three reading 
frames would be expressed which is why multiple lengths to the stop codon are listed in the table 
for this transcript.  The Wfdc17 sequence almost spans the full wild-type sequence; there are only 
12 bp missing from the 5' end. 
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Table 14 Information for sequences in clones 
Sequencea Length 
(bp)b 
Length 
to SC 
(bp)c 
Forward 
Orientation?d 
5' 
truncated?e 
Frame-
shift?f 
No. 
of 
PMg 
Extra 
Seq 
(bp)h 
Rps8 443 9 Yes Yes Yes 0 0 
Eif1a 288 51 Yes Yes No 0 0 
Rnf130 467 276 Yes Yes No 2 17 
Cbx3 483 27 Yes Yes Yes 0 0 
Hiatl1 676 336 or 
42 or 12 
No Yes Yes 2 0 
Sec61b 278 177 Yes Yes Yes 0 0 
Wfdc17 458 111 Yes Yes; only 
12 bp 
missing 
Yes 0 0 
Mxd1 101 20 Yes Yes No 0 0 
Cco1 447 18 Yes Yes No 3 0 
 
Information for the sequences present in the tumor cDNA library clones in the final round of 
screening with tumor and naïve mouse sera.  aThe wildtype mouse transcript which the cloned 
sequence aligned with.  bThe length of the inserted sequence.  cThe length to the stop codon from 
the insertion site.  dIndicates whether the sequence inserted into the plasmid in the forward 
orientation relative to the Lac promoter of the bacterial expression plasmid.  eIndicates whether 
the sequence in the clone is missing the normal 5' end of the corresponding wild type transcript.  
fIndicates whether the sequence expressed from the Lac promoter in the bacterial plasmid is 
frame-shifted relative to the frame of the wild-type transcript.  gIndicates the number of point 
mutations in the sequence.  hIndicates how many additional base pairs are present in the 
sequence which are not present in the wildtype transcript sequence. 
3.4 Discussion 
3.4.1 Summary 
The goal of this research was to explore methods for screening tumor immunogens 
efficiently, and much knowledge has been acquired throughout this process.  The basic process 
utilizes several technologies which were not widely available when the SEREX method was first 
developed.  Such technologies include automated equipment to handle large numbers of 96-well 
plates, accurate printing machinery, and high resolution scanners.  The process of screening 
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multiple rounds of pooled lysates also allows the researcher to hone in on a particular clone of 
interest beginning from clones that cover the entire transcriptome.  Several potential tumor-
specific antigens have also been identified. 
3.4.2 Experiment conditions 
These rounds of cDNA library screening have produced some candidate antigens worthy 
of further investigation.  There are several lysates which bound to tumor sera more than naïve 
sera at the last stage of screening.  Note that the last round of screening resulted in less 
significant p-values than was obtained in the previous rounds of screening.  This last round of 
screening was repeated several times, and p-values comparable to the previous p-values were 
never obtained (data not shown).  A likely reason for these less significant p-values is that the 
protein and lysate production for this batch of slides was not of the same quality as the protein 
and lysate production of the previous experiments. Nevertheless, p-values less than 0.05 were 
still often obtained. Note that several primary sera dilutions were also tried for this single clone 
screen and some counterintuitive results were obtained. The greatest fold change values 
between naïve and tumor with higher intensity for the tumor sera were obtained at the lower 
dilutions used.  Perhaps this reflects greater affinity demanded for successful binding at the lower 
antibody concentrations, thereby reducing off target binding.  Dilutions of 100 fold, 500 fold, 1,000 
fold, and 2,000 fold were tested, and the results from the 1,000 fold dilution are presented in 
Figure 71D.  A general observation from the experiments performed is that the Rps8, Wfdc17, 
Cbx3, Rnf130, and Sec61b clones often bound to sera better than other clones such as Mxd1 
and the poly T clones.  Some of the clones at this final stage of screening came from the same 
pool in a previous round of screening, but this does not imply that only one of the sequences is 
tumor specific.  On the contrary, a lysate pool may have bound to antibodies in the tumor sera 
more than naïve because it contained more than one positive clone (tumor specific sequence).  
With lysate from a higher quality lysate preparation, there is the possibility that all of the positive 
clones might demonstrate higher binding reactivity to tumor than normal sera. 
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3.4.3 Transcript sequences and cancer 
Do any of these sequences encode for proteins that have functions which relate to 
cancer in any way?  Wfdc17, CcoI, Rps8, and Cbx3 produced the best p-values in a screen with 
tumor vs. control sera.  The protein encoded by Wfdc17 acts as a counter-regulator of 
proinflammatory responses 143.  No papers associating this sequence with cancer were found.  
CcoI is a part of a complex in the mitochondria electron transport chain 144.  This protein has been 
found to have altered expression levels in prostate cancer 145.  The Rps8 gene encodes a 
ribosomal protein that is a component of the 40S subunit 146.  Increased expression of this gene 
and other ribosomal proteins has been observed in some cancers such as colorectal cancer 147.  
The protein encoded by Cbx3 can act as a transcriptional regulator and is a component of 
heterochromatin 148.  This sequence has previously been associated with neoplastic 
transformation and progression 149.  Rps and Cbx sequences are currently present in the Cancer 
Immunome Database, but Wfdc and Cco proteins are not 128. 
The other sequences had a p-value less than 0.05 in the screen displayed in Figure 71 D.  
Rnf130 encodes a protein that is a zinc finger protein structural domain, and these proteins are 
often involved in the ubiquitin degradation pathway 150.  RNF130 interacts with miRNAs which are 
overexpressed in tumors 151.  The protein encoded by Sec61b is a component of the machinery 
necessary to translocate proteins across the endoplasmic reticulum 152.  Sec61b has been found 
to be one of the top 20 genes down-regulated by miR-133a which is a tumor-suppressive 
microRNA 153.  Mxd1 is a dimerization protein that competes with MYC for binding to MAX to form 
a DNA binding complex 154, and a mutated version of Myc is found in many cancers 155, 156.  Eif1a 
is an RNA binding protein essential for translation initiation 157.  The EIF1A locus has been 
determined to be hypermethylated in human ovarian carcinoma CP70 cells 158.  Hiatl1 belongs to 
the major facilitator superfamily and is involved in facilitating transport across membranes 159.  
The expression level of Hiatl1 was found to aid in the classification of gastric cancer 160.  Sec, 
Rnf, and Eif sequences are currently present in the Cancer Immunome Database, but Hiatl, and 
Mxd sequences are not 129. 
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Analysis of the sequences in the clones reveals that most of the sequences were 5' 
truncated.  The library was constructed using poly dT primers which would bind to the 3' poly A 
tail of RNA transcripts.  Although the reverse transcriptase used, polymerase used, and the 
SMART (Switching mechanism at 5' end of RNA template) mechanism should have resulted in 
mostly full-length transcripts, many 5' truncated transcripts were present.  There could be 
important information upstream of the 3' region in the original RNA transcript which was not 
detected in the library.  Such information could include certain mutations as well as possible gene 
fusions which could cause expression of a frameshifted string of amino acids.  A number of the 
sequences of the clones in the library were frameshifted relative to wild type murine databases.  
Some of these frameshifts may correspond to genomic events; others may be at the transcript 
level such as alternative splicing or trans-splicing events.  Frameshifts would be good candidate 
proteins or genes to include in a vaccine because frameshifts would be more immunogenic since 
they would be unique or more common in the tumor cells. 
3.4.4 Speculation about translation errors and cancer 
The ultimate goal of this research was to identify specific transcripts which produced 
proteins recognized by the immune system of animals with tumors.  Ideally these antigens would 
be frameshift or chimeric transcripts unique to the tumor cells and not found in normal cells.  
These transcripts could then be used to study cancer further or to develop a cancer vaccine.  
However, after analyzing the results of these immune screens, there may be another approach to 
a cancer vaccine.  Instead of searching for specific frameshift or chimeric transcripts, one could 
develop a cancer vaccine with the frame-shifted versions of abundant proteins. 
More than half of the transcripts that made it into the final single clone screen (“3.3.1.4 
Single clone array screen”) would produce frame-shifted proteins.  This frame-shift is not the 
result of a known frameshift in the RNA transcript in the original cell, but instead is actually an 
artifact of the cDNA construction process since transcripts could be truncated randomly at any 
position along their length.  These truncated transcripts would insert into the plasmid and be 
expressed in a certain frame relative to the bacterial lac promoter, and this frame may or may not 
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be true to the original frame in the tumor cell.  If one could not find an actual frame-shifted 
transcript in the tumor cell, one might conclude that antibodies don’t actually bind to this frame-
shifted transcript.  Instead, the results of any antibody detection are just an anomaly.  If the 
protein were an abundant protein such as a ribosomal protein like Rps8 detected in this screen 
(Table 14), there would be an even greater reason to suspect that antibody detection does not 
reflect actual biological events because these abundant transcripts are more likely to be present 
in clones in the tumor cDNA library.  These abundant clones would have a higher chance of being 
detected. 
However, what if these antibody detection events are not an anomaly, and there also is no 
frame-shifted transcript in the tumor cell?  Perhaps, tumor cells produce more frame-shifted 
proteins from wild-type transcripts during translation even though there are no frame-shifted 
transcripts for many proteins originally in the cell.  This increased error rate during translation in 
tumor cells may be due to an increased rate of translation as the tumor cells rapidly proliferate, or 
these errors may be due to a decrease in quality control.  Whatever the cause may be, if it is true 
that tumor cells produce more frame-shifted proteins during translation than normal cells, then 
one could create a cancer vaccine simply by including many frame-shifted proteins.  Which 
proteins would be the best to choose?  Perhaps frame-shifted versions of house-keeping proteins 
would be the best to choose since there is a high abundance of house-keeping proteins and there 
would be the most frame-shifted versions of these proteins for the tumors to present.  Therefore, 
an effective cancer vaccine might simply consist of frame-shifted versions of abundant proteins 
since there may be more errors during translation in tumor cells. 
3.5 Conclusion 
A high-throughput platform for screening tumor cDNA libraries was used to discover several 
immune reactive proteins.  The platform takes advantage of automated equipment to handle large 
numbers of PCR plates, small nitrocellulose slides, high resolution scanners, and the screening of 
several rounds of pools.  In this demonstration of the technology, nine sequences were 
discovered which are potentially immunoreactive, and at least one of the proteins is a very well-
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known protein involved in cancer pathways (Mxd1).  Several of the sequences would produce 
frame-shifted proteins, but chimeric transcripts which would cause these frame-shifts were never 
discovered in an investigation with PCR.  These results inspired the hypothesis that the immune 
system may be producing antibodies against frame-shifted proteins which resulted from defective 
translation of protein in tumor cells, instead of defective DNA or RNA.  If defective translation is 
more abundant in tumor cells than normal cells, then a vaccine composed of a cocktail of frame-
shifted proteins may prove effective.  Further investigation will be required to support or disprove 
this hypothesis, as well as to identify protein sequences which would be effective in a subunit 
cancer vaccine. 
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 4: RANDOM SEQUENCE MIMOTOPES 
4.1 Introduction 
Characterizing the interactions between disease-specific antibodies and their cognate 
antigens has proven highly informative in the study of host-pathogen relationships and critical in 
the development of effective biomedical products.  Similarly in chronic diseases, the discovery of 
modified antigens or autoantigens that are specifically recognized by patient antibodies is of 
growing importance in disease research and target development for diagnostics, vaccines, and 
therapeutics.  These complexes are typically found by querying immune sera against possible 
ligands in lysates, or in libraries of proteins or peptides made recombinantly or synthetically.  A 
myriad of binding assays such as immunoblots 161, ELISAs 162, phage display 163, ribosome 
display 164, beads 165, and microarrays 166 has been employed to identify the antigen recognized 
by an antibody and the epitope sequence it binds.  While the pros and cons of each assay vary 
with respect to cost, simplicity, bias, breadth, and sensitivity, these methods have collectively 
contributed significantly to our knowledgebase of disease-relevant antigen/antibody complexes.  
However, a rate limiting step toward more comprehensively identifying immune targets of 
biologically relevant antibodies has been developing a robust method for screening ligands 
against complex antibody mixtures.   
In its original description, phage display was used to survey a library of peptides for binding 
to a given antibody 167.  It has now been used extensively to display libraries of peptides or 
antibody fragments, expressed as coat protein fusions on the phages surface, for “panning” 
against a particular molecule of interest.  Phages are washed across an isolated, immobilized 
target; bound recombinant phage are collected and amplified in bacteria for additional rounds of 
panning 168.  One of the major drawbacks of phage display is the technique’s reliance on multiple 
in vivo steps that cannot be well-controlled and incur biases to the output.  For example, any 
peptide-coat protein fusions that reduce the fitness of the phage or reduce secretion to the phage 
surface will not be well represented if at all. In the initial panning round each phage recombinant 
is present in such limited numbers that the probability of a ligand finding a target can be 
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stochastic.  Yet only those recombinants that survive this first round are subsequently propagated 
reiteratively.  As an alternative, in vitro translation systems such as ribosome display have been 
developed for studying protein-protein interactions, including antigen/antibody binding.  Like 
phage, very large libraries can be constructed at minimal cost but the diversities of these 
recombinant mixtures are difficult to maintain and are not reproducible.  In addition, apparent 
diversities can be misleading since the redundancy of the genetic code, incidental stop codons, 
and peptide-dependent effects on translation efficiency will limit the ultimately displayed diversity. 
In vitro combinatorial synthesis of peptides on beads and microarrays of either proteins or 
peptides have been explored as library formats for surveying target binding 165, 166.  Both of these 
methods are performed entirely in vitro, and thereby resolve the vagaries of in vivo propagation 
and biological compatibility.  Since peptides are used directly, the issues of translating DNA are 
avoided.  However for libraries in bead format, the binding steps must be followed by decoding 
what is bound through peptide-sequencing, chemical-tracking, or other reading methods. The 
synthesis, binding, and decoding steps tend to be laborious, time consuming, and often lack 
reproducibility 169.  For libraries in either bead- or array- format, peptide synthesis costs limit the 
size and number of libraries that can be built, relative to the recombinant libraries. Furthermore, 
the antigens or epitopes within the antigen may not be in the known proteome.  Studies can be 
confounded by the fact that immune sera often carry antibodies to mutant, unknown, or even 
exogenously-derived antigens of a host or pathogen proteome.  In these cases, lysates or 
libraries of proteins or epitopes that are made recombinantly or synthetically will be incomplete.   
Non-natural sequence peptide libraries, whether in vivo or in vitro, provide a means for 
identifying mimotopes of unknown antigens and are far more economical since one library can be 
used for all screens.  For example, an antibody panned against phages displaying random 
sequence peptide fusions might select recombinants that mimic or hold similarity to a previously 
unknown ligand 170.  Microarrays consisting of random sequence peptides or peptoids have been 
explored for identifying ligands 171.  Probing of a SPOT synthesis array carrying 5,520 random 15-
mers with three different monoclonal antibodies followed by substitutional analysis was able to 
identify mimotopes of the known wild type epitopes 7.   
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 Each of the described methods, using either natural or random sequences, requires 
knowledge and preparation of either the antibody or ligand, in order to identify the other. If 
antigens instead of epitope-size peptides are screened, then epitope identification requires 
additional knowledge.  Namely, antigen sequence information and a sufficient budget would be 
required to perform “peptide tiling” assays.  Broader identification and characterization of disease-
relevant antibody targets will require an inexpensive method for performing screens for these 
antigen/antibody interactions without specific knowledge of any of the components.  Recently, an 
array platform has been developed in which 10,000 non-natural sequence peptides are printed 
onto a functionalized glass slide and complex sera mixtures are surveyed in parallel 9.  Binding 
analyses have been able to consistently define patterns of immune responses against diseases 
172.  This non-natural sequence peptide array platform is applied to the design of a method for 
capturing disease-relevant antibodies and identifying their biological targets. 
As proof of principle for demonstrating the ability of non-natural sequence peptide arrays 
to identify disease specific antigen/antibody complexes, a tumor-associated mutant of the 
structural maintenance chromosome 1A protein (SMC1A) and immune serum were used.  The 
SMC1A protein was first described in yeast as an essential protein necessary for nuclear division 
173, 174.  It is also involved in human cell division, serving a number of functions including roles in 
the stabilization of sister chromatids during their replication and separation, DNA repair, activation 
of S phase check point, and regulation of gene transcription 175.  Given the critical activity of 
SMC1A in regulating cell division, the possible effect of its mutation in progressing cancer has 
been suggested 175.  In fact increased levels of a particular aberrant transcript encoding a frame-
shifted SMC1A (SMC1Afs) has been correlated with tumor cells relative to normal cells (Luhui 
Shen, manuscript in prep). This exon 4 reading frame shift produces a truncated protein ending 
with 17 unique amino acids.  Here I demonstrate that this non-natural sequence peptide 
microarray screening process can be used to isolate immune-specific antibodies and to identify 
important epitopes to which α-SMC1Afs antibodies specifically bind.  The same methods could be 
used to identify epitopes in previously unknown antigens and aid in the discovery of important 
targets for any infectious or chronic disease. 
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4.2 Materials and Methods 
4.2.1 Peptides and Beads 
A number of free peptides as well as Tentagel bead conjugated peptides were used in 
experiments.  The sequences of these peptides and their assigned names are presented in Table 
15. 
Table 15 Amino acid sequences of free peptides and peptide-bead conjugates 
Assigned 
Name Sequence Description 
SMCfs CCGIYCHEEPQREDSSI 
human SMC1A frameshift 
17mer peptide 
SMCfs-27 TAIIGPNGSGCCGIYCHEEPQREDSSI 
human SMC1A frameshift 
27mer peptide 
RP1 TISKYVMVEPMRQHEEWGSC SMCfs mimotope 
RP2 AVSHQEMNEGEQGPMREGSC SMCfs mimotope 
RP3 RVGEMPMREYDISGGSGGSC SMCfs mimotope 
RP4 TAFYRTLTKHEVDPGIAGSC SMCfs mimotope 
CP1 AVLLMCQLYQPWMCKEYYRLL 
negative control peptide which 
is not a mimotope of SMCfs 
SMCfs-B CCGIYCHEEPQREDSSI 
human SMC1A frameshift 
17mer peptide conjugated to 
Tentagel beads 
RP1-B TISKYVMVEPMRQHEEWGSC 
SMCfs mimotope conjugated to 
Tentagel beads 
RP2-B AVSHQEMNEGEQGPMREGSC 
SMCfs mimotope conjugated to 
Tentagel beads 
RP3-B RVGEMPMREYDISGGSGGSC 
SMCfs mimotope conjugated to 
Tentagel beads 
RP4-B TAFYRTLTKHEVDPGIAGSC 
SMCfs mimotope conjugated to 
Tentagel beads 
CP2-B ATKAAIPGPNTVPRAP 
negative control peptide which 
is not a mimotope of SMCfs 
conjugated to Tentagel beads 
 
The amino acid sequence and name of free peptides and peptide-bead conjugates used is listed.  
The “B” at the end of the assigned name indicates that the peptide is conjugated to a bead, and 
the absence of a “B” indicates that the component is a free peptide. 
4.2.2 Rabbit α-SMCfs Sera 
Serum against the human SMC1Afs protein was generated by Global Peptide Service 
LLC (Fort Collins, CO). The 17 amino acid (a.a.) SMC1A frameshift mutant sequence (SMCfs), 
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identified in human tumor cDNA (CCGIYCHEEPQREDSSI), was synthesized by the peptide 
synthesis lab at Arizona State University and then conjugated to keyhole limpet hemocyanin 
(KLH) by Global Peptide Service LLC.  A New Zealand white rabbit was immunized with the 
SMCfs-KLH conjugate. Blood for the experiment was collected at exsanguinations after two 
immunizations. 
4.2.3 ELISA 
ELISA plates were coated with 50 µL of 10 µg/mL of peptide or protein in carbonate 
coating buffer and incubated at 4 °C overnight.  The coated plates were washed 3X with PBST 
and blocked with 200 µL of 3% BSA in PBST at 37 °C for 30 minutes.  The blocked plate was 
washed 3X with PBST and 50 µL of primary anti-serum or purified antibody diluted in 3% BSA in 
PBST was applied.  The plate was then incubated at 37 °C for 1 hr.  After the incubation, the 
plate was washed 3X with PBST.  The antibody was detected with 50 µL HRP-goat α-rabbit IgG 
diluted 1:2,000 in 3% BSA in PBST.  After the plate was incubated at 37 °C for 1 hr, the plate was 
washed 3X and developed with 50 µL TMB for 10 minutes at room temperature.  The 
development was stopped by adding 50 µL of 0.5 N HCl, and the plate was read with a 
SpectraMax 190 Molecular Devices instrument at OD 450 nm. 
4.2.4 Antibody absorption 
Specific antibodies were absorbed from the rabbit α-SMCfs sera by applying the sera to 
the SMCfs coated plate.  The rabbit sera was diluted 1:250 with 3% BSA in PBST and incubated 
with the SMCfs peptide coated plate at 37 °C for 1 hr.  The unbound antibody in the supernatant 
was then removed and applied to another peptide coated well to remove more antibody specific 
for the peptide.  This process was repeated up to 20 times, and this serum was then later applied 
to the peptide microarray at a dilution of 1:500.  This same method was used to produce negative 
control antibody absorbed sera using the negative control CP1 peptide. 
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4.2.5 Non-natural sequence peptide array printing 
The 10,000 randomly generated peptide sequences were custom synthesized by Sigma, 
Inc. These 20-mers were designed with 17 random a.a. residues (excluding cysteine) and a 3 
amino acid (GSC) linker sequence on the C terminus.  The C terminal cysteine binds to a sulfo-
SMCC coated aminosilane glass slide.  The solutions of different non-natural sequence peptides 
were printed onto the glass slide using a NanoPrint 60 instrument (Arrayit Technologies). 
4.2.6 Application of sera to non-natural sequence peptide array 
Rabbit sera samples were applied to the non-natural sequence peptide microarray using 
a Tecan HS 4800 Pro microarray hybridization station.  Slides were first washed for 30 s with 
TBST, and then blocked with a blocking buffer consisting of BSA, mercaptohexanol, Tween 20, 
and PBS for 1 hr at 23 °C.  Duplicate samples of sera were diluted 1:500 in an incubation buffer 
consisting of BSA, Tween 20, and PBS and incubated with the slide for 1 hr at 37 °C.  The slide 
was then washed, and 5 nM of goat α-rabbit IgG conjugated with AlexaFluor 647 dye was applied 
for 1 hr at 37 °C.  The slide was then washed and dried for 5 min. 
4.2.7 Scanning and analysis of array 
The slides were scanned with an Agilent Technologies DNA Microarray Scanner with 
Surescan High-Resolution Technology instrument and analyzed with GenePix Pro 6.0 software 
(Molecular Devices, Santa Clara, CA) to determine the fluorescence intensity of each spot.  
GeneSpring GX 7.3 (Agilent Technologies, Santa Clara, CA), Microsoft Excel (version 
15.0.4551.1003) 69, simple custom Java code, and GraphPad Prism 4 (GraphPad Software, La 
Jolla California USA, www.graphpad.com) were then used to perform further analysis of this data. 
4.2.8 Antibody purification 
Specific antibodies were purified from sera by flowing sera through a column filled with 
TentaGel beads with synthesized peptides on their surface such as the SMCfs peptide, selected 
non-natural sequence peptides, or the irrelevant CP2-B peptide.  The total IgG of the rabbit α-
SMCfs sera was purified using Pierce Protein A/G Agarose beads with the protocol of the 
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manufacturer.  A volume of 1 mL of the TentaGel beads were mixed with 3 mL of the purified total 
IgG, and this solution was incubated for 1 hr at room temperature. The column was then washed 
with 10 mL PBST. The specific IgG was eluted with 4 fractions of 1 mL IgG Elution Buffer (Pierce, 
Inc) and each fraction was neutralized with 100 l 1M TRIS.  All of the eluted fractions were 
measured at an absorbance of 280nm.  The two fractions with the highest absorbance were 
combined and used for further analysis at a 1 to 40 dilution in 3% BSA in PBST.     
4.2.9 Analysis of Motifs 
GLAM2 software 176 was used to identify and score common motifs among the high binding 
peptides.  Bepipred 177 was used to find and score B cell epitopes. 
4.3 Results and Discussion 
4.3.1 Peptide microarray screening of α-SMCfs serum 
Antibodies against the α-SMCfs peptide were generated by immunization with the 
synthetically produced 17-mer conjugated to KLH.   Harvested rabbit serum was applied to a 
functionalized microarray slide that had been printed with a NanoPrint instrument with a defined 
set of 10,000 (10k) non-natural sequence 20-mers, as detailed in the section (“4.2.5 Non-natural 
sequence peptide array printing”).  Serum-antibodies bound to the peptides after washes were 
measured using fluorescently-labeled α-IgG secondary antibody reagents.  Genepix software 
(Molecular Devices) was used to align the feature-reactivities on the array, and GeneSpring 
(Agilent Technologies) was used to analyze the results by quantifying fluorescence units at each 
feature.  Both specific antibody levels and their binding avidities are components of these 
fluorescence level readouts.  From this queried peptide library, 108 peptides exhibited highly 
specific binding to the immune serum relative to naïve rabbit control serum (p <0.0001).   In 
Figure 1, fluorescence of each of the 108 peptides, as a measure of antibody binding activity, are 
compared between SMCfs-immune and naïve sera.  A color range from green to red is used to 
display these fluorescence intensities and is represented as a heatmap.  This analysis allows 
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visualization of the differential profiles of antibody-reactivity of the immune and naïve sera to the 
selected set of non-natural sequence peptides. 
 
 
Figure 73 Selective binding of α-SMCfs serum to a set of random sequence peptides 
displayed on a microarray 
Polyclonal rabbit serum generated against the SMCfs peptide conjugated to KLH and naive rabbit 
serum were applied to an array of 10,000 synthetic peptides of randomly generated sequence.  
Student’s t-test analyses comparing the probing results identified 108 random 20-mers with 
differential binding to the immune versus naïve sera (p-values <0.0001).  These differences in 
peptide-binding intensities are visually represented as a heatmap. 
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4.3.2 SMCfs immune serum absorption and array analysis 
Total α-SMCfs immune serum contains many different antibody species, including 
antibodies to the co-administered KLH adjuvant carrier molecule. To differentially measure the 
SMCfs-peptide antigen reactivity from that of KLH, an absorption experiment was conducted so 
as to remove the α-SMCfs specific antibodies.  Analysis of the depleted serum would indicate 
SMCfs specific peptide reactivities, by their specific loss. The immune serum was bound to wells 
of a plate coated with SMCfs, and absorption was performed in a step-wise manner.  ELISA-
based confirmation of antibody depletion was assessed after 11 and after 20 re-iterative rounds 
of absorption.   The results of an ELISA experiment performed with the peptide-depleted serum 
samples are shown in Figure 74A.  Binding to the SMCfs peptide decreased as serum samples 
subjected to additional rounds of re-absorption and re-testing were used; binding of the absorbed 
samples to an irrelevant peptide (CP1)  peptide was unchanged. 
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B) 
 
Figure 74 Analyses of α-SMCfs serum pre-absorbed against its cognate SMCfs peptide. 
A)  Validation of SMCfs antibody depletion from immune serum.  The serum-absorption steps (11 
or 20) refer to the number of iterative rounds of SMCfs-peptide or CP1-peptide absorption 
experiments conducted before application of the depleted serum to ELISA plates coated with 
SMCfs peptide. B)  Changes in non-natural sequence peptide binding intensities following α-
SMCfs antibody depletion of serum.  The depleted immune sera samples were applied to the 
peptide microarray. Binding intensities to the 108 peptides, which were shown to be selectively 
recognized by the original α-SMCfs serum, are displayed as a heatmap for their visual 
comparison.  Four α-SMCfs sera samples were applied to the peptide microarray, 1) non-
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absorbed α-SMCfs serum, 2) α-SMCfs serum absorbed 11x against SMCfs peptide, 3) α-SMCfs 
serum absorbed 20x against SMCfs peptide, 4) α-SMCfs serum absorbed 20x against the CP1 
negative control peptide  Colors toward red indicate highest relative fluorescence intensity, and 
colors toward green indicate lowest relative fluorescence intensity. 
The α-SMCfs antibody-depleted samples, as well as the undepleted serum, were applied 
to the 10k non-natural sequence peptide array.   Reactivity profiles of these samples for the 108 
peptides selected in the original screen were compared, and are presented in Figure 74B.  The 
naïve sera reactivity for these 108 peptides is found in Figure 73.  A range of profiles were 
observed.  For example, some peptides displayed binding intensities higher than that of naïve 
serum when probed with serum samples absorbed against the negative control irrelevant peptide, 
but also showed these intensities when probed with the α-SMCfs-absorbed serum samples.  
Other peptides displayed a decrease in signal when probed with the α-SMCfs antibody depleted 
samples, but also showed decreased signal with the control absorbed serum.  Lastly, a set of 
peptides showed decreasing fluorescence intensities when serum from increasing rounds of α-
SMCfs depletion were applied.  These peptides showed no loss of signal when probed with the 
control-absorption serum sample.  Based on these evaluations of specificity, each of the 108 
peptides was assigned a score.  The peptides were scored such that large scores were assigned 
to peptides that displayed low binding to the SMCfs-absorbed serum samples and high binding to 
undepleted sera.  The score was assigned to each peptide as follows: 
 
Equation 7 Peptide score 
Peptide score assigned to each peptide where the variables are as follows: max signal refers to 
the signal of the peptide with the greatest intensity; absorbed signal refers to the signal of a 
peptide with α-SMCfs serum absorbed 20x against SMCfs peptide; and negative control peptide 
refers to the signal of a peptide with α-SMCfs serum absorbed 20x against the CP1 negative 
control peptide. 
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Four of the top 5 scoring peptides were selected for re-synthesis and further testing against 
the α-SMCfs serum. 
4.3.3 ELISA-based validation of α-SMCfs serum binding to screen-selected peptides 
To validate that the peptides which were identified in the peptide-array screening were 
specifically bound by the α-SMCfs immune serum, standard ELISA assays were performed. The 
ELISA determinations confirmed the results of the peptide array: the 4 array-selected peptides 
could be specifically recognized by the rabbit α-SMCfs sera whereas the negative control CP1 
peptide was not (Figure 75A).   
Since the α-SMCfs immune serum was generated by immunization with a SMCfs peptide 
attached to KLH, the specificities of the immune serum-selected peptides for SMCfs were 
compared to KLH.  The IgG-binding activity of each selected peptide against mouse α-KLH sera 
was measured.  The results demonstrated that all four of these selected peptides as well as the 
SMCfs peptide were not recognized by α-KLH antibodies; while the cognate KLH peptide bound 
strongly (Figure 75B).  Therefore, the array-selected peptides behaved as mimotopes of the SMCfs 
peptide and could be specifically recognized by antibodies against SMCfs peptide.  The reactivity 
of the rabbit α-SMCfs serum to the four selected peptides was lower than that to the SMCfs peptide, 
as measured by α-IgG-fluorescence readout. This quantitative difference indicates that the selected 
mimotope peptides are lower affinity ligands relative to the original SMCfs immunogen.  This may 
be due to less optimal or partial epitope sequences. 
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Figure 75 ELISA determinations of α-SMCfs sera binding to array-selected peptides 
A)  Immune serum: rabbit polyclonal α-SMCfs serum was applied to the cognate peptide-antigen, 
four of the array-selected peptides, and a control peptide.  B)  Control serum: mouse polyclonal 
α-KLH serum was applied to the same set of peptides described in A. 
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4.3.4 Affinity purification of α-SMCfs antibodies with mimotope peptides 
To determine whether the non-natural sequence peptide mimotopes could be used to 
specifically isolate antibodies against the original immunogen, Tentagel-attached peptides were 
prepared.  Columns containing beads conjugated to one of the non-natural sequence peptides, 
the SMCfs peptide, or an irrelevant peptide (CP2-B) were used to capture antibodies from the α-
SMCfs immune serum.  The binding specificities of the peptide-purified antibodies were 
measured by determining the activity of the eluted antibodies against the SMCfs-27 or KLH 
antigen by ELISA (Figure 76).  The SMCfs-27 is comprised of the 17 unique, frame-shift created 
residues plus the 10 amino acids found in the wild type protein immediately upstream of the 
frame shift.  This 27mer was used so as to accommodate any possible antibody binding that 
spanned the normal/mutant sequence junction.  However when the 17-mer SMCfs peptide was 
replaced with SMCfs-27 in an ELISA, the results were indistinguishable from those shown in 
Figure 3a. Therefore, the frameshift junction site does not appear to be critical for the α-SMCfs 
antibody binding activity within this immune serum.   
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Figure 76 ELISA analysis of affinity-purified antibodies 
The cognate SMCfs peptide, four highly array-reactive peptides, and a control peptide (CP2-B) 
were synthesized on Tenta-gel beads.  These were used to prepare individual affinity columns.  
Purified total IgG of the α-SMCfs serum was applied; bound antibodies were eluted.  These 
peptide-purified antibody samples were analyzed by ELISA against SMCfs-27 coated or KLH 
coated plates. 
Analysis of mimotope-binding antibodies isolated from the total serum demonstrates their 
specific binding to SMCfs-27 and not to KLH.  Antibodies eluted from the negative control CP2-B 
bead column did not show any reactivity against the SMCfs-27 peptide or KLH.  Thus, this non-
natural sequence peptide library-screen identified mimotopes of an immunogen, and these 
mimotopes successfully captured immunogen-specific antibodies.  
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4.3.5 Measuring cross-reactivity of α-SMCfs antibodies to mimotopes  
The antibody samples that were affinity-purified from the SMCfs immune serum with the 
SMCfs peptide or with the array-selected mimotopes display a range of cross-reactivities for one 
another (Figure 77).  For example, antibodies purified with the RP1, RP2, or RP3 peptides cross-
react strongly with each of the other two mimotopes, as measured by ELISA.  Antibodies purified 
with the RP4 bound beads recognize the RP4 peptide, but these antibodies do not cross react 
well with the other three peptides.  One possible explanation for this behavior is that RP1, RP2, 
and RP3 possess a similar sequence or structural motif whereas RP4 carries a unique one.  
Notably, all four mimotope-purified antibody samples display the highest reactivity levels against 
the cognate SMCfs immunogen, rather than the non-natural sequence peptide ligand used to 
purify them.  This indicates that the mimotope affinities for the SMCfs-elicited antibodies are 
weaker than the SMCfs antibody affinities to the cognate sequence. This may be a consequence 
of the sparse sampling of random space provided by the library of only 10e4 random sequences; 
whereas, greater than 1e22 unique 17-mers with 20 amino acids are possible. 
 
Figure 77 Differential binding of affinity-purified α-SMCfs antibodies to cognate peptide 
and mimotopes, displayed in a three-dimensional bar graph 
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The antibodies affinity purified by SMCfs-B and four array-selected non-natural sequence peptide 
beads (RP1-B through RP4-B) were measured for reactivity against the cognate and mimotope 
peptides by ELISA. 
4.3.6 Sequence Analyses 
Bioinformatic analysis was used to identify the epitopes in the non-natural sequence 
peptides which match with the SMCfs immunogen.  Using the epitope search software Bepipred, 
the strongest B cell epitope within the SMC1A frameshift mutation (CCGIYCHEEPQREDSSI ) 
was predicted to be at the C-terminal end of the 17-mer (SMCfs), with the highest score assigned 
to the proline within HEEPQRE.  The GLAM2 software identifies sequences in the peptide 
mimotopes that are similar to sequence stretches within SMCfs.  The RP1 peptide contains two 
motifs: HEE and YXXXXPMRQ, although they are in reverse order relative to those sequences of 
SMCfs.  RP2 contains PMREGS and RP3 contains EMPMRE.  RP4 contains only the simple 
dimer HE (Table 16).  This analysis shows that three of the four peptides contain a PQRE-like 
motif found in the cognate SMCfs peptide.  Although RP1 contains reversed YXXXXPMRQ and 
HEE motifs, the mimotope is specifically recognized by α-SMCfs antibodies. This may indicate 
that i) the HEE motif acts independently of the PQRE-motif, ii) they work in concert but order is 
not important, iii) or that HEE is not relevant to binding and our analysis failed to identify those 
a.a. that are relevant in RP4. 
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Table 16 Motifs in common between RP1-4 and SMCfs as identified by the GLAM2 software 
Sequence 
ID 
Sequence Motif in 
Peptide 
Matching 
with SMCfs 
Matching 
SMCfs 
sequence 
SMCfs CCGIYCHEEPQREDSSI - - 
RP1 TISKYVMVEPMRQHEEWGSC YXXXXPMRQ YXXXXPQRE 
    PMRQ PQRE 
    HEE HEE 
RP2 AVSHQEMNEGEQGPMREGSC PMREGS PQREDS 
    PMRE PQRE 
RP3 RVGEMPMREYDISGGSGGSC EMPMRE EEPQRE 
    PMRE PQRE 
RP4 TAFYRTLTKHEVDPGIAGSC HE HE 
 
The entire amino acid sequence of each peptide is displayed.  The amino acid sequence of only 
the motif within the whole sequence that matches with the SMCfs sequence as well as the 
corresponding sequence of the motif in the SMCfs sequence itself is also presented. 
The GLAM2-assigned similarity scores of the mimotopes to SMCfs led to a ranking of the 
peptides in the same order that they were ranked by the array absorption scoring described in 
section 3.2.  For example, the RP1 peptide holds two motifs in common with the original antigen, 
exhibits the highest intensity on the peptide microarray, and scored the highest by the GLAM2 
software.  By contrast, the absorbance intensities obtained in the ELISA experiment did not yield 
rankings identical with the other readouts. This suggests that the array format may enable higher 
resolution of antibody-peptide interactions. 
Broader analysis of the array results shows that other peptides on the peptide array, 
which were not selected as α-SMCfs antibody specific binders in the original screen, contain the 
motifs found in the four peptide mimotopes.   The observation that not all peptides containing the 
same motifs exhibit the same binding reactivity empirically suggests that the context in which the 
motif occurs may be important.  Alternatively, the residue positions within the consensus motifs 
may differentially influence binding strength.  Informatic analysis of all 10k random sequences 
shows: 11 peptides with the PQRE-like motifs (4 peptides with PMRQ, 4 peptides with PMRE, 1 
peptide with PQRE, and 2 peptides with PMRD), 920 peptides with HE, 19 peptides with HEE, 
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and no peptides with a Y preceding the PQRE-like motif with more than one amino acid of 
separation other than the RP1 peptide.  Of these, only 5 of the 11 PQRE-like motif containing 
peptides and 1 of the 19 HEE motif containing peptides are in the list of 108 screen-selected 
peptides defined by immune serum-specific reactivity (Figure 73 and Figure 78).   However, the 
rankings of the peptides differ based on these assays that measured specificity by either total 
serum binding or loss of peptide-absorbed serum binding.  This may be a consequence of the 
significant difference in what the two assay formats will detect as a specific response.  Namely, 
non-SMCfs reactivities to KLH will be included in the analysis of total immune to naïve serum, 
while only SMCfs-specific reactivities will be measured as specific interactions by the peptide-
absorbed serum samples.  Thus, this two-step screening approach permitted identification of the 
most informative mimotopes.   
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Figure 78 Motif analysis of peptides bound by the SMCfs antibody depleted 
A heatmap representation of the changes in peptide-binding intensities of SMCfs-depleted 
immune sera samples versus the control sera for PQRE-like and HEE motifs.  A) Heatmap 
displaying differential intensities of binding by the α-SMCfs sera samples to the 11 peptides on 
the peptide microarray with PQRE-like motifs.  B) Heatmap of differential intensities of sera 
sample reactivity to the 19 peptides on the peptide microarray with HEE motifs. 
4.3.7 Conclusion 
The techniques demonstrated here could be more generally employed for epitope 
definition and antigen discovery.  Non-natural sequence peptide arrays can be used to identify 
specific antibodies since the antibodies will separate out across the array due to their varying 
affinities for the different peptides.  Non-natural sequence peptides which are unique and specific 
for a mixture of antibodies found in sera can be used to absorb the desired unique and specific 
antibodies from the rest of the antibodies in the sera.  Once purified, these antibodies can be 
used to identify the particular epitopes in an antigen to which antibodies are raised.  This 
technique of using non-natural sequence peptides is particularly useful for defining the epitopes in 
mutant proteins such as the human SMC1Afs protein used as an example in this paper.  Non-
natural sequence peptides make no assumptions about the epitopes that will be present in a 
biological sample, and therefore new mutant immunogens which are absent from current 
 213 
databases can be discovered.  Furthermore, the information acquired from probing non-natural 
sequence peptides with antibodies could be useful in the development of subunit vaccines.  In 
addition to defining epitopes, there is also potential for discovering new antigens since the 
purified antibodies can be used to probe biological material.  Non-natural sequence peptide 
microarrays hold promise for efficiently and inexpensively dissecting the complexity of vast 
antibody repertoires. 
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A.1 Introduction 
Could part of the aging process be due to an autoimmune reaction against stem cells 
necessary for repairing damaged tissue?  The idea that the aging process is partly caused by 
autoimmunity against stem cells has not been previously proposed or even suggested to the 
knowledge of the authors, and therefore this hypothesis requires some justification supported with 
several background facts.  One symptom of the aging process is a decrease in wound healing 
rates 81.  Some of the cells required to heal wounds and damaged tissue in the body are 
proliferating stem cells.  One very interesting and recent finding is that stem cells from an aged 
organism can repair damage very well in a younger host, even though these very same stem 
cells are incapable of repairing damage as well in the aged hosts 178,179,180.  This somewhat 
counterintuitive result suggests that the problem may lie in the environment of the stem cells 
rather than in the aged stem cells themselves.  A number of explanations could account for this 
result.  Perhaps the aged environment is damaged beyond repair or perhaps epigenetic shifts in 
gene expression may hinder proper cell to stem cell signaling.  In reality, probably both the stem 
cells and the environment become damaged with age.  However, the explanation proposed here 
is that the immune system has learned to recognize and attack these stem cells, particularly 
proliferating stem cells.  The T cell assay experiments that follow in this paper support this 
hypothesis that the immune system interferes with stem cells, and this finding may have 
implications for aging research. 
The immune system may attack stem cells because it may fail to distinguish between stem 
cells and cancerous cells since these cell types have many similarities.  The immune system 
undergoes many changes with the aging process.  For example, the immune system responds 
less effectively to vaccines with age 15, and autoimmunity also increases with age 16 so an 
autoimmune reaction is not unlikely.  Cancer rates also increase with age.  Some of this 
increased cancer risk is due to a change in behavior in stem cells.  In fact, researchers have 
discovered that in aging drosophila, intestinal stem cells over-proliferate and mis-differentiate 
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which leads to dysplasia 181.  Since cancer cells and stem cells have many similarities, the 
proposition that the immune system would fail to distinguish between the two is not unreasonable.  
In fact, more than 85% of all cancers overexpress the telomerase enzyme 182, which is also 
expressed in stem cells 183, particularly when stem cells are proliferating.  Stem cells also become 
cancerous more often than somatic cells 184 since they already meet one of the requirements for 
becoming cancerous: telomerase expression or an alternative lengthening of telomeres 
mechanism.   
The immune system plays a large role in dealing with cancer, and would therefore also 
play a role in interacting with stem cells and therefore the aging process.  The immune system is 
capable of recognizing and combating cancer cells as evidenced by methods such as whole cell 
tumor vaccines 185.  Vaccination with telomerase, which is found in both cancer cells and stem 
cells, in mice has demonstrated a decrease in cancer occurrence 186 which demonstrates the 
immune system is capable of targeting telomerase.  Note that the lifespan of the mice was not 
documented.  Additionally, one link between the immune system and aging is that immune 
suppression drugs such as rapamycin have lengthened the lifespan of mice when maintained in 
pathogen free environments 187.  This increase in lifespan is usually explained by referring to the 
interaction of rapamycin with the mTOR pathway which results in autophagy 188, and decreased 
cellular growth and proliferation 189.  However, the immune suppression itself along with the 
decreased inflammation associated with this suppression may play a large role in the health 
benefits observed. 
All of these facts combined suggest there is a relationship between aging, cancer, stem 
cells, and the immune system.  In this paper, a chromium release T cell cytotoxicity assay is 
performed to determine whether aged splenocytes kill young cells from the bone marrow more 
than young splenocytes kill young cells from the bone marrow.  Aged and young splenocytes 
were also combined with aged cells from the bone marrow.  During the experiment some of the 
aged mice became wounded, and these wounds dramatically affected the results.  More wounds 
correlated with more T cell killing, and this may have been the result of increased inflammation 
overall.  
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One can speculate about the implications if the age associated stem cell autoimmunity 
hypothesis presented here is true.  Experiments that address the hypothesis that the immune 
system incorrectly interferes with normal healthy stem cells in old age may lead to new strategies 
for mitigating the aging process.  While stem cell autoimmunity is certainly not the only cause of 
aging, many improvements in health might be made by inducing tolerance for healthy stem cells.  
Although no widespread effective method for inducing tolerance exists, there is no reason to 
believe there will never be such methods, and developing such methods will be required to 
effectively treat autoimmune diseases.  Additionally, the immune system may continue to operate 
properly if one were to vaccinate against cancer cells so that the immune system does not later 
confuse stem cells for cancer cells.  Future stem cell treatments may improve the health of 
certain organs, but such treatments would be impaired if the immune system impairs stem cell 
function in old age.  Understanding the relationship between the immune system and stem cells 
may result in increased understanding of the mechanisms of the aging process as well as result 
in methods to aid stem cells to more effectively repair the aging body. 
 
Figure 79 Age Associated Stem Cell Autoimmunity Hypothesis 
In a young mouse stem cells repair tissues and few stem cells become cancerous.  In a middle 
aged mouse, fewer stem cells can repair tissues and more stem cells become cancerous as 
mutations accumulate.  At this stage the immune system will start to combat some of the cancers.  
In an old mouse, increasingly fewer stem cells repair and increasingly more stem cells become 
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cancerous.  At this point, I hypothesize that the immune system fails to discern between the two 
cell types and combats cancerous stem cells as well as healthy stem cells. 
A.2 Materials and Methods 
Two experiments were performed to test the reactivity of young and aged splenocytes for 
young and aged cells derived from the bone marrow.  The first experiment used one young and 
one aged mouse.  The second experiment used three young and three aged mice. 
A.2.1 One young and one aged mouse 
A.2.1.1 Mice 
One 3 month 11 day old C57BL/6 mouse was used for this experiment, and this mouse 
was classified as the “young” mouse.  One 1 year 11 month 25 day old C57BL/6 mouse was 
used, and this mouse was classified as the “aged” mouse. 
A.2.1.2 Splenocyte preparation 
Splenocytes were obtained from the spleen of mice according to a protocol outlined in 
Current Protocols in Immunology 135.  Briefly, the mice were anaesthetized with 300 µl of 0.05 
mg/mL Avertin injected i.p.  A cervical dislocation was then performed.  The surgical area was 
cleaned with ethanol and then an incision was made midway between the last rib and the hip.  
The spleen was removed and placed in RPMI-10 media on ice.  The spleen was homogenized 
and passed through a 40 µM filter.  Splenocytes were collected by centrifugation at 1,200 rpm 5 
m 4 °C.  3 mL of Red Blood Cell Lysis Buffer Hybri-Max (Sigma Cat No R7757) solution was 
added, and the mixture was incubated at RT 5 m.  10 mL complete RPMI-10 media was added to 
stop the lysis reaction, and the cells were washed twice with 10 mL RPMI-10. 
A.2.1.3 Cells from bone marrow 
Cells from the bone marrow were obtained in a manner similar to a protocol found in Current 
Protocols in Immunology 190.  The mice were anaesthetized with 300 µl of 0.05 mg/mL Avertin 
injected i.p.  The hind legs were removed from the mice.  Muscle tissue was removed with a 
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Clorox disinfecting wipe.  The thigh bone was then placed into DMEM media.  The tip of the 
bottom and top of the thigh bone was cut, and the marrow was flushed with cold RPMI-10 media 
with a 3 mL syringe using a 25-G needle.  The resulting suspension was filtered through a 40 µM 
mesh to remove any remaining bone spicules.  Hematopoietic progenitor cells were isolated from 
the bone marrow through a process of negative selection which removed CD5, CD11b, CD19, 
CD45R, Ly-6G/C, TER119, and 7-4 positive cells using the EasySep Negative Selection Mouse 
Hematopoietic Progenitor Cell Enrichment Kit (Cat no. 19756) according to the manufacturer’s 
instructions. 
A.2.1.4 Chromium release assay protocol 
T cell cytotoxicity assays were performed using the chromium release assay method 
outlined in Current Protocols in Immunology 191.  Cells were first counted using trypan blue.  The 
target cells from the bone marrow were incubated with 20 µl FBS per 100 µl cell solution and 0.1 
mL 1 mCi/mL radioactive sodium chromate in a 14 mL round bottom tube for 1 to 3 hr at 37 °C 
5% CO2.  After the target cells were labeled with chromium, the cells were washed 2 to 3 times 
with 10 mL complete RPMI-10 media.  The cells were then resuspended to a concentration of 
1e5 cells/mL.  A volume of 100 µl of effector cells from the spleen were dispensed into the wells 
of 96-well microtiter plates with 4 replicates of each effector cell concentration: 1e7 cells/mL, 3e6 
cells/mL, 1e6 cells/mL, and 3e5 cells/mL.  This resulted in E:T (effector to target) ratios of 100, 
30, 10, and 3.  The chromium labeled target cells were then added to wells containing effector 
cells.  The 96 well plate was then centrifuged for 30 s at 200Xg to promote contact between the 
effector and target cells.  Triton X-100 detergent was added to some of the wells as a control to 
lyse all of the target cells.  Some wells also contained target cells alone without any splenocytes.  
The plate was then incubated 6 hr 37 °C 5% CO2.  The plates were then centrifuged 5 m at 
200Xg and 0.1 mL of each supernatant was added into the wells of a LumaPlate (Packard Cat no 
4096).  The plate was dried at 55 °C overnight in an Affymetrix GeneChip Hybridization Oven 640 
(Model no. OVNAA115S) and then sealed with TopSeal-A (PerkinElmer TopSeal-A 605019).  The 
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amount of radioactive chromium in each well was detected using a TopCount HTS (Packard 
model no. B384V00) instrument to detect cpm (counts per minute) for each well. 
A.2.2 Three young mice and three aged mice with zero, one, or two wounds 
A second chromium release T cell assay experiment was performed using three young mice 
and three old mice. 
A.2.2.1 Mice 
Three 3 month 16 day old C57BL/6 mice were classified as the “young” mice.  Three 1 year 
11 month 30 day old C57BL/6 mice were classified as the “aged” mice.  Two of the aged mice 
were wounded.  One mouse had no wounds (aged mouse no. 1).  One had one wound on the 
side (aged mouse no. 2).  Another mouse had a very large wound on the back of the neck with a 
large wound on the side (aged mouse no. 3).  These wounds were not inflicted by the authors.  
Perhaps one of the mice had wounded the other two since the unwounded mouse was larger 
than the other two.  The weights of the mice and the size of the wounds were not quantitatively 
measured. 
A.2.2.2 Splenocyte preparation 
The splenocytes were prepared in the same manner as the first experiment. 
A.2.2.3 Cells from bone marrow 
The cells were isolated from the bone marrow in the same manner implemented for the first 
experiment except the hematopoietic progenitor cells were not isolated using the EasySep 
Negative Selection Mouse Hematopoietic Progenitor Cell Enrichment Kit (Cat no. 19756).  
Therefore, all of the cells derived from the bone marrow were classified as “stem cells” for this 
experiment. 
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A.2.2.4 Chromium release assay protocol 
The chromium release assay protocol was performed in the same manner as the first 
experiment.  Stem cells from the six different mice in the two groups (three young mice and three 
aged mice) were combined with young and aged splenocytes at various E:T ratios. 
A.2.2.5 Graphs and calculations 
Calculations and t-tests were performed with Microsoft Excel 2007 for Windows 
(Microsoft, Redmond Washington USA, www.microsoft.com).  All t-tests were performed as two-
tailed distributions with the two-sample unequal variance type selected.  Graphs were created 
using GraphPad Prism 4 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com).  The corrected percent lysis was calculated using the following formula:  
%𝑙𝑦𝑠𝑖𝑠 = 100 ∗ (
𝑡𝑒𝑠𝑡_51𝐶𝑟 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙_51𝐶𝑟
𝑚𝑎𝑥_51𝐶𝑟 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙_51𝐶𝑟
) 
In this equation, test_51Cr refers to the amount of chromium released by a particular sample, 
control_51Cr refers to the amount of chromium released by target cells alone without any 
splenocytes or Triton X-100 detergent, and max_51Cr refers to the amount of chromium released 
by target cells with Triton X-100 detergent added to lyse all of the cells. 
A.3 Results 
The results can be grouped into two different experiments.  The first experiment was 
performed with one young and one aged mouse, and the second experiment was performed with 
three young mice and three aged mice.  The second experiment produced results for each group 
of radioactive sodium chromate labeled stem cells from the six different mice used in these 
experiments.  All of the figures in this section have the same format, and the names of groups 
obey the following convention: Y = young, A = aged, Sp = splenocyte, St = stem cell, and _# 
indicates an effector to target ratio.  The number following Sp or St indicates which mouse the 
splenocytes or stem cells derived from.  For example, the group ASp1YSt2_3 indicates that 
splenocytes from aged mouse no. 1 were combined with stem cells from young mouse no. 2 at 
an effector to target ratio of three to one for this group.   
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The results from these experiments help answer several questions.  How do aged and 
young splenocytes compare in regards to their reactivity for young stem cells?  How do aged and 
young splenocytes compare in regards to their reactivity for aged stem cells?  How do aged 
splenocytes from an unwounded mouse (aged mouse no. 1), a mouse with one wound (aged 
mouse no. 2), and a mouse with two large wounds (aged mouse no. 3) compare in regards to 
their reactivity for aged stem cells?  How do splenocytes from individuals of the same age 
compare in regards to their reactivity for aged stem cells?   Are aged stem cells killed by young 
splenocytes and aged splenocytes more than young stem cells are killed? 
A.2.3 One young and one aged mouse 
The results from the experiment with one aged mouse and one young mouse are presented 
in Figure 1.  The average cpm from the YSpYSt (young splenocytes with young stem cell) group 
is higher than the average of YSt alone, and the average cpm from the ASpYSt group is higher 
than YSpYSt (Figure 80A).  However, this difference is not statistically significant (p-value of 
0.459).  In Figure 80B, the young and aged splenocytes are combined with aged stem cells.  The 
average of YSpASt is about 400 cpm higher than the average cpm of ASpASt, but the difference 
is not statistically significant (p-value of 0.0565).  A following experiment with three young mice 
and three aged mice was then performed. 
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Figure 80 T cell assay results for one young mouse and one aged mouse 
A) Young splenocytes and aged splenocytes combined with young stem cells.  B)  Young 
splenocytes and aged splenocytes combined with aged stem cells.  Cpm refers to counts per 
minute detected from a scintillation counter in radioactive chromium release assay. 
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A.2.4 Three young mice and three aged mice with zero, one, or two wounds 
A.2.4.1 Young and aged splenocytes with young stem cells 
How do aged and young splenocytes compare in regards to their reactivity for young stem 
cells?  Aged and young splenocytes were combined with young stem cells at several different 
effector to target ratios to answer this question.  The results from YSp1, YSp2, ASp1, ASp2, and 
ASp3 with YSt1 targets at E:T ratios of 3, 10, 30, and 100 are presented in Figure 81A.  For any 
given E:T ratio the average cpm of the aged splenocyte groups two and three is higher than the 
average of the young splenocyte groups one and two with the exception of the YSp1YSt1_100 
group.  The same results are presented for YSt2 and YSt3 targets in Figure 81B and Figure 81C 
respectively.  The average cpm of each ASp group is higher than the average cpm of each YSp 
group within each E:T ratio with the exception of ASp1YSt2_3.  These results may indicate that 
aged splenocytes kill young stem cells more than young splenocytes.  Note that results from the 
combination of every possible group were not obtained due to insufficient cell numbers.  These 
results were obtained with young stem cells and the following results are with aged stem cells. 
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Figure 81 Young and aged splenocytes with young stem cells 
(A) Cpm counts for YSt1 target cells. (B) Cpm counts for YSt2 targets.  (C) Cpm counts for YSt3 
targets.  P-values from a t-test are indicated as follows: one star (*) for less than 0.05 and greater 
than 0.01, two star (**) for less than 0.01 and greater than 0.001, and three star (***) for less than 
0.001. 
A.2.4.2 Young and aged splenocytes with aged stem cells 
How do young and aged splenocytes compare in regards to their reactivity for aged stem 
cells?  Young and aged splenocytes were combined with aged stem cells in Figure 82.  
Specifically YSp1, ASp1, and ASp2 were combined with ASt3.  In every comparison of YSp with 
ASp, the ASp groups have a higher average cpm with a statistically significant p-value with the 
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exception of the ASp2ASt3_30 group since this group did not have any replicates to allow for a t-
test. 
 
Figure 82 Young and aged splenocytes with aged stem cells 
The cpm values from ASt3 are displayed. 
A.2.4.3 Aged splenocytes from wounded mice with aged stem cells 
How do aged splenocytes from an unwounded mouse (aged mouse no. 1), a mouse with 1 
wound (aged mouse no. 2), and a mouse with two large wounds (aged mouse no. 3) compare in 
regards to their reactivity for aged stem cells?  The results obtained from combining ASp1, ASp2, 
and ASp3 with ASt2 at various E:T ratios are presented in Figure 83.  The average cpm of the 
ASp3 group which contains splenocytes from a mouse with two wounds is higher than the 
average of the ASp1 group (no wounds) at every E:T ratio. 
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Figure 83 Aged splenocytes from wounded mice with aged stem cells 
Aged mouse no. 1 had no wounds, aged mouse no. 2 had one wound, and aged mouse no. 3 
had two large wounds.  The cpm results for the ASt2 target cells are displayed. 
A.2.4.4 Comparison of splenocytes of same age 
How do splenocytes from different individuals of the same age compare in regards to their 
reactivity for aged stem cells?  The results from YSp1 and YSp3 combined with ASt1 are 
presented in Figure 84.  There was no statistical difference between YSp1 and YSp3 at any of the 
E:T ratios. 
 
Figure 84 Comparison of splenocytes of same age 
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The cpm results of ASt1 targets are displayed. 
A.2.4.5 Comparison of stem cell age 
Are aged stem cells killed more by young splenocytes and aged splenocytes more than 
young stem cells are killed?  One cannot directly compare the cpm values of young stem cells 
with aged stem cells since the two cell types uptake the radioactive sodium chromate very 
differently.  When the Triton X-100 detergent is used to completely lyse the stem cells to release 
all of the chromate that entered the cell, much more radioactivity is detected from the aged cells 
than the young cells in a statistically significant manner.  The average YStT cpm was 196 and the 
average AStT cpm was 2,350 (p-value of 1.10E-4).  Therefore, the corrected percent lysis as 
defined in the Materials and Methods was used to compare YSt groups and ASt groups with YSp 
(Figure 85A).  The corrected percent lysis from the YSt groups and ASt groups with ASp is 
plotted in Figure 85B.  Note that outliers were determined from a box and whisker plot and were 
excluded from Figure 85A and Figure 85B.  All of the raw cpm values for each St group without 
any splenocytes are presented in Figure 85C. 
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Figure 85 Comparison of young and aged stem cells 
A)  Corrected percent lysis of YSt and ASt with YSp.  B) Corrected percent lysis of YSt and ASt 
with ASp.  C)  Raw cpm values of each St group without any Sp. 
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A.4 Discussion 
In general, these experiments support the hypothesis that an aged immune system kills 
young stem cells more than a young immune system, and unintended discoveries were made as 
well.  Two experiments were performed in which young and aged splenocytes and stem cells 
were collected from mice and used in T cell killing assays to assess whether the T cells killed the 
stem cells.  Comparisons were then made about whether young or aged splenocytes kill young or 
aged stem cells more.  I found that aged splenocytes do more killing.  Serendipitously, I also 
discovered that splenocytes from wounded aged mice demonstrate an even more pronounced 
effect of stem cell killing. 
The result that aged splenocytes kill young stem cells is not completely intuitive since the 
argument could be made that no young stem cells would be killed by aged splenocytes or young 
splenocytes since the immune system should not be attacking self-cells.  Note that in these 
experiments the term “young” refers to mice that were about 3 months old and the term “aged” 
refers to mice that were about 2 years old.  Mice usually finish sexually maturing by 6-8 weeks 
192, and they usually die around 2 years of age193.  Aged splenocytes killed young stem cells more 
than young splenocytes killed young stem cells in the first experiment presented in Figure 80A as 
well as in the subsequent experiment in Figure 81A, Figure 81B, and Figure 81C.  Although the 
average cpm of YSp groups vs ASp groups with YSt targets was not always statistically 
significant, 40 of the 51 (78%) possible YSp vs ASp group comparisons reveal that the ASp 
groups had a higher average.  Additionally, of the three instances in which statistical significance 
was achieved, the ASp group had the higher average in each case.   
The results obtained from aged stem cells are less clear than the results from young 
stem cells.  YSp killed ASt more than ASp killed ASt in the first experiment in Figure 80B, but this 
result was not statistically significant.  In the following experiment, ASp killed ASt more than YSp 
killed ASt (Figure 82), and statistical significance was achieved in every instance with more than 
one replicate.  The second experiment may have more reliable data since the protocol was better 
established in the lab at this point, the data points are less sporadic with smaller standard 
deviations, and the data from the second experiment has statistical significance.  Interestingly, 
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the aged mouse with one wound (aged mouse no. 2) always had a higher average than the aged 
mouse with no wounds (aged mouse no. 1).  Perhaps there was more inflammation, non-specific 
killing, and an increased immune response in the aged mouse with one wound compared with the 
unwounded aged mouse. 
Wounded mice were not part of the plan of the second experiment, but the results from 
these mice were quite interesting.  The cause of these wounds is still unknown.  However, the 
unwounded aged mouse (aged mouse no. 1) was much larger than the other two aged mice, and 
I speculate that this mouse wounded the other two: aged mouse no. 2 and aged mouse no. 3.  
The more wounds a mouse had, the more the splenocytes derived from this mouse killed YSt and 
ASt as presented in Figure 81A, Figure 81B, Figure 82, and Figure 83.  This increased killing may 
be due to increased inflammation. 
Splenocytes from two different mice of the same age did not exhibit any statistical 
difference in their reactivity for aged stem cells as presented in Figure 84.  This result is expected 
since two mice of the same age, strain, and cage would not be expected to have a different 
immune response against stem cells. 
In addition to the immune system becoming more inflammatory and non-specific with 
age, the stem cells themselves are liable to accumulate more mutations as well as errors in RNA 
splicing.  This may make these stem cells more prone to become cancer cells as well as to 
become targets of the immune system.  Therefore, the following question can be asked: Are aged 
stem cells killed more by young splenocytes and aged splenocytes than young stem cells are 
killed?  This may be the case, but this conclusion cannot be reached from the results of this 
experiment.  At first glance, the aged stem cells seem to be killed much more than young stem 
cells since the cpm values for aged stem cells are much higher.  However, the aged stem cells 
label with sodium chromate much more easily than the young stem cells do as well.  The better 
sodium chromate labeling of aged cells may be due to a more permeable cell membrane. Results 
from the two different types of stem cells are never placed side by side in any of the figures in this 
paper until Figure 85.  In order to compare the two different types of stem cells in Figure 85A and 
Figure 85B, the corrected percent lysis was calculated as described in the Materials and 
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Methods.  Figure 85 A and B show that there is no statistical difference in the percent lysis for YSt 
or ASt with YSp or ASp.  A more sensitive assay may detect a difference if there is one. 
Many of the comparisons between groups were statistically significant while others were 
not, and this result may be due to the qualities of the chromium release assay protocol used.  
Four replicates were included for each group since this is often the standard for chromium 
release assays.  If one of the comparisons which was not statistically significant is selected as an 
example, how many replicates would need to be performed with the same difference and 
standard deviation to obtain a significant p-value?  For example, with YSp3YSt3_30 and 
ASp1YSt3_30 in Figure 81C, a few calculations show that 58 replicates instead of 4 would be 
needed to achieve a p-value less than 0.05 between these two groups which have an average of 
58.3 and 65.5 as well as a standard deviation of 14.5 and 18.9 respectively.  This many replicates 
would certainly not be practical and indicates that an alternative more sensitive method for 
detecting T cell cytotoxicity may be more suitable for investigating the phenomenon in question 
further.  Note that there also did not appear to be a dose response with increased E:T ratios.  
Perhaps the E:T ratios tested were too similar for the particular phenomenon being tested.  The 
chromium release assay is also a highly variable method.  Despite the fact that researchers often 
perform four technical replicates for every combination of effectors and targets, chromium release 
interassay cv values are often above 20% 194. 
The hypothesis that the immune system interferes with stem cells in old age could be 
investigated further in many ways.  The current results could be repeated and validated using the 
same chromium release assay method.  The experiment could also be performed using a method 
such as flow cytometry since this method can actually be even more sensitive than the chromium 
release assay, and more information about the markers on cells and specific types of cells used 
can be acquired 194.  Valuable information might also be gained by determining exactly which 
antigens in stem cells that the aged splenocytes might be targeting.  Such antigens could be 
elucidated using assays such as ELISPOT and ELISA.  For example, since cancer cells express 
telomerase, aged splenocytes might target stem cells that express telomerase as well.  Other 
potential antigens to investigate could be stem cell antigen (Sca-1), stem cell factor (SCF), Pax6, 
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MyoD, as well as many other known stem cell markers 195.  Another very novel method of 
searching for antigens could be to use young and aged antibody containing sera on a non-natural 
sequence peptide array and search for patterns that distinguish young and aged sera 1,9.  If the 
immune system impairs the ability of stem cells to repair damaged tissue, one could test this 
hypothesis by measuring wound healing rates in SCID mice and normal mice of the same age 
treated with young stem cells.  The SCID mice would be predicted to receive a greater benefit 
from the treatment.  As an alternative to using SCID mice, one could try to implement a bone 
marrow transplant to replace the immune system of an aged mouse with fresh young cells and 
compare wound healing rates with non-treated aged mice.  Apheresis would be another method 
that could be performed to remove aged immune cells. 
Results from these initial experiments support the hypothesis that aged splenocytes kill stem 
cells more than young splenocytes.  More experiments should be performed to elucidate the 
exact relationship between splenocytes and stem cells and to verify or disprove the current 
results.  The knowledge gained from the fact that the aged immune system impairs stem cells 
necessary for repairing damage could lead to treatments to mitigate the aging process.  For 
example training the immune system against true cancer cells or inducing tolerance for stem cell 
self-proteins may result in an increased healthspan. 
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B.1 Introduction 
 One of the main targeting molecules of the immune system is an antibody or 
immunoglobulin which is a Y-shaped molecule produced by B cells.  These antibodies can be 
used to assess whether a certain immune system targets a cancer protein.  An antibody is made 
up of four chains connected by disulfide bonds with two heavy chains, and two light chains.  The 
antibody is a mirror image of itself so that the two heavy chains are identical and the two light 
chains are identical.  A large portion of the antibody is the constant region which is not involved in 
binding to the antigen protein target.  A small region at the tip of both arms of the “Y” known as 
the variable region contains the paratope of the antibody which binds to the epitope of the 
antigen.  Both the heavy and light chains have a variable region, but they each have a slightly 
different composition.  The heavy chain variable region is made up of a combination of V, D, and 
J genes whereas the light chain variable region only consists of a combination of V and J genes.  
This variable region allows different antibodies to bind to different antigens. 
 Since antibodies are so useful for targeting molecules for research purposes and 
therapeutic purposes, researchers have attempted to devise ways to make them quickly and 
cheaply.  One of the strategies employed is to make hybridomas formed by the combination of a 
B cell of interest and a lymphoma cell 196.  However, this method can be expensive and labor 
intensive.  The resulting molecule is also a large full antibody molecule with the constant region.  
This constant region is not always desired, and in many applications a small molecule is ideal.   
 Another strategy developed is to produce single chain variable fragments (scFv).  These 
scFv are small molecules that only consist of a combination of the heavy chain variable region 
and the light chain variable region.  They are created by performing PCR to amplify the heavy 
and light chain variable regions from the antibody encoding mRNA of B cells 197.  These amplified 
heavy and light chains are then connected by an artificial flexible linker.  This new scFv gene can 
then be cloned into the genome of a phage which is a virus that infects bacteria.  The scFv is then 
produced as a fusion with the phage coat protein.  These phage can replicate indefinitely in 
bacterial hosts.  This system allows for the amplification of antibodies in an abbreviated form by 
phage 198. 
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 Once a phage antibody library has been produced, it can be used much the same way 
that antibody containing sera would be used to probe for antigens to which the antibodies bind.  
One of the first uses of a phage library actually still used antibodies.  The phage displayed a 
library of peptides and the antibodies were screened against this library 199.  Once phage could 
display scFv, the phage could take the place of the antibody and be “panned” against a molecule 
of interest.  Basically the phage are applied to a surface with an immobilized target, and the 
unbound phage are washed away.  The bound phage are then eluted, and can be used for further 
rounds of panning 168.  The identity of a particular scFv of interest can also be characterized since 
the sequence of the scFv is contained within the phage genome. 
 Although phage libraries have many advantages such as the amplification of antibodies 
and the production of small molecule versions of antibodies, these libraries also have some 
disadvantages.  For example, although scFv exhibit very similar binding patterns to the antibodies 
from which they were derived there may still be specific instances in which the binding is not 
similar enough for the application in question.  These scFv are smaller molecules with a slightly 
different structure that could bind differently in some cases.  Phage libraries also require work to 
produce.  This is work that would not be required if the sera were used directly.  The diversity of 
the phage library is also dependent on biological factors such as whether the bacteria and phage 
are still viable when interacting with particular phage and scFv combinations.  Some scFv might 
display better on the surface of the phage coat than other scFv as well which could introduce 
some bias into the library.  Despite these drawbacks however, researchers have already identified 
many scFv which bind to specific antigens.  The fact that these libraries can identify antigen 
binders, allow for amplification of the antibody, allow for the sequencing of the antibody, and also 
utilize small molecules ensures that scFv libraries will continue to be used for some time. 
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Figure 86 Potential of phage antibody libraries for discovering cancer antigens 
Phage antibody libraries could be used to discover cancer antigens.  In this figure, memory B 
cells are isolated from the spleen of a mouse with cancer or a normal mouse as a control, and 
then antibody coding DNA is isolated from these cells.  This DNA is re-engineered to code for 
scFv, instead of the original large antibody structure, and this scFv DNA is inserted in phage and 
infected into E. coli.  The E. coli are then induced to produce the phage displaying scFv on the 
surface, and these phage can be used to probe the peptide microarray to determine which 
peptide features bind significantly different to tumor phage antibody libraries compared to normal 
phage antibody libraries.  The identified peptides could be used to isolate phage for further 
screening against a cancer cDNA library to identify cancer antigens. 
B.2 Materials and Methods 
B.2.1 Isolation of RNA from B cells 
RNA was isolated from B cells using Trizol from Invitrogen (Cat No 15596-018) according 
to the instructions from the manufacturer. 
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B.2.2 PCR Construction of scFv 
A total of 73 PCRs were required to construct the scFv fragments.  The developed PCR 
scheme is presented in Figure 87, and the primers designed derived from the primers in a 1994 
paper with mouse primers 197.  The sequences of the primers used are listed in Table 17.  In the 
first reaction to amplify the variable domains of the immunoglobulin genes, the heavy chain 
variable domains and the light chain variable domains were amplified separately.  A total of 27 
reactions are required to amplify the light chain kappa segments since a PCR reaction has to be 
performed for every combination of the light chain forward primers (MKV_FOR 1-3) and the light 
chain back primers (MKV_BACK 1-9).  Just one PCR reaction was performed for the lambda light 
chain with the MLV_FOR and MLV_BACK primers.  A total of 40 reactions was performed for 
every combination of heavy chain forward (MHV_FOR 1-4) and heavy chain back (MHV_BACK 
1-10) primers. 
Once the light chain and heavy chain variable fragments were amplified, they were linked 
together.  First a linker section (Figure 88) was added to the light chain fragments and heavy 
chain fragments in a total of 3 PCRs.  A linker was added to the light chain kappa fragments with 
Linker_Light and MKV_FOR_NOTI; a linker was added to the light chain lambda fragments with 
Linker_Light and MLV_FOR_NOTI; and a linker was added to the heavy chain fragments with 
Linker_Heavy and MHV_BACK_SFII.  This process also added NotI and SfiI restriction enzyme 
sites to aid in cloning the fragments into a vector at later steps.  Next the fragments with the 
added linkers were linked together in two PCRs: one PCR for the kappa fragments 
(MKV_FOR_NOTI and MHV_BACK_SFII primers) and one PCR for the lambda fragments 
(MLV_FOR_NOTI and MHV_BACK_SFII).  These scFv fragments were then ready to clone into a 
phagemid vector with NotI and SfiI sites. 
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Figure 87 PCR Construction of scFv 
The scFv genes can be constructed in several stages of PCR.  First the variable domains are 
amplified by performing PCR with the different variants of light chain and heavy chain variable 
genes.  Next a linker is added to connect the 28 different types of light chains amplified and 40 
different types of heavy chain genes amplified.  After the linker is added, an additional PCR is 
performed to amplify the construct for both the lambda and kappa construct types.  The scFv can 
then be cloned into a vector using the SfiI and NotI restriction sites. 
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Table 17 Primers used for scFv Construction 
Primer Type Primer Name Primer Sequence 
Light Chain 
Kappa MKV_FOR1 GTTCTTGCGGCCGCCCGTTTCAGCTCCAGCTTG 
  MKV_FOR2 GTTCTTGCGGCCGCCCGTTTTATTTCCAGCTTGGT 
  MKV_FOR3 GTTCTTGCGGCCGCCCGTTTTATTTCCAACTTTG 
  MKV_BACK1 TCTGGCGGTGGCGGATCGGATGTTTTGATGACCCAAACT 
  MKV_BACK2 TCTGGCGGTGGCGGATCGGATATTGTGATGACGCAGGCT 
  MKV_BACK3 TCTGGCGGTGGCGGATCGGATATTGTGATAACCCAG 
  MKV_BACK4 TCTGGCGGTGGCGGATCGGACATTGTGCTGACCCAATCT 
  MKV_BACK5 TCTGGCGGTGGCGGATCGGACATTGTGATGACCCAGTCT 
  MKV_BACK6 TCTGGCGGTGGCGGATCGGATATTGTGCTAACTCAGTCT 
  MKV_BACK7 TCTGGCGGTGGCGGATCGGATATCCAGATGACACAGACT 
  MKV_BACK8 TCTGGCGGTGGCGGATCGGACATCCAGCTGACTCAGTCT 
  MKV_BACK9 TCTGGCGGTGGCGGATCGCAAATTGTTCTCACCCAGTCT 
Light Chain 
Lambda MLV_BACK TCTGGCGGTGGCGGATCGCAGGCTGTTGTGACTCAGGAA 
  MLV_FOR GTTCTTGCGGCCGCCTTGGGCTGACCTAGGACAGT 
Heavy Chain MHV_BACK1 CATATGGCCCAGCCGGCCATGGCCGATGTGAAGCTTCAGGAGTC 
  MHV_BACK2 CATATGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGAAGGAGTC 
  MHV_BACK3 CATATGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGAAGCAGTC 
  MHV_BACK4 CATATGGCCCAGCCGGCCATGGCCCAGGTTACTCTGAAAGAGTC 
  MHV_BACK5 CATATGGCCCAGCCGGCCATGGCCGAGGTCCAGCTGCAACAATCT 
  MHV_BACK6 CATATGGCCCAGCCGGCCATGGCCGAGGTCCAGCTGCAGCAGTC 
  MHV_BACK7 CATATGGCCCAGCCGGCCATGGCCCAGGTCCAACTGCAGCAGCCT 
  MHV_BACK8 CATATGGCCCAGCCGGCCATGGCCGAGGTGAAGCTGGTGGAGTC 
  MHV_BACK9 CATATGGCCCAGCCGGCCATGGCCGAGGTGAAGCTGGTGGAATC 
  MHV_BACK10 CATATGGCCCAGCCGGCCATGGCCGATGTGAACTTGGAAGTGTC 
  MHV_FOR1 GCCTCCACCTGCAGAGACAGTGACCAGAGT 
  MHV_FOR2 GCCTCCACCTGAGGAGACTGTGAGAGTGGT 
  MHV_FOR3 GCCTCCACCTGAGGAGACGGTGACTGAGGT 
  MHV_FOR4 GCCTCCACCTGAGGAGACGGTGACCGTGGT 
Primers for 
Linking MKV_FOR_NOTI GTTCTTGCGGCCGCCCGT 
  MLV_FOR_NOTI GTTCTGCGGCCGCCTTGG 
  MHV_BACK_SFII CATATGGCCCAGCCGGCCA 
  Linker_Light TTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCG 
  Linker_Heavy CAGAGCCACCTCCGCCTGAACCGCCTCCACCTGAGGAGAC 
 
The nucleotide sequences of the primers used in the scheme presented in Figure 87 are 
presented.  There are three light chain kappa forward primers, nine light chain kappa back 
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primers, one light chain lambda back primer, one light chain lambda forward primer, four heavy 
chain forward primers, ten heavy chain back primers, a kappa chain primer to add a NotI 
restriction site, a lambda chain primer to add a NotI site, a heavy chain primer to add a SfiI site, a 
light chain linker primer, and a heavy chain linker primer. 
 
Figure 88 Diagram of linker primers 
The light chain and heavy chain genes are linked together using linker primers.  In this diagram 
the MLV_BACK1 light chain sequence and the MHV_FOR1 heavy chain sequence are 
presented, but the same linker primers would work for any of the light chain or heavy chain 
combinations.  The annealing temperature of the linker primers at each section of the interaction 
with other DNA strands is presented. 
B.2.3 Preparation of vector 
Modifications were made to the pComb3XSS vector to prepare to clone in the scFv 
fragments.  The pComb3XSS vector was from the Scripps Research Institute, and this vector has 
previously been used by other researchers to produce phage libraries 200.  This vector did not 
originally contain NotI and SfiI sites at the correct location, and therefore these changes had to be 
made.  The NotI site had to be removed, and the SfiI site had to be replaced with a NotI site in 
order to insert the scFv fragments after the lacZ promoter and in front of GeneIII necessary for 
phage production.  The necessary changes are outlined in Figure 89.  Plans were made to make 
these changes by linearizing the vector with primers that would make the appropriate changes, 
and then performing an In-Fusion reaction (Clontech Cat no 120513). 
The plasmid linearization was performed with multiple polymerase enzymes to select the 
best one: Herculase II, Iproof, PrimeSTAR Max, Pfu Turbo, and Advantage HD.  For the 
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Herculase II polymerase a 0.5% step DMSO gradient was performed so that many reactions were 
tried with different amounts of DMSO.  Two different template amounts with 1 ng and 5 ng were 
tested with the Iproof, Pfu Turbo, and Advantage HD polymerases.  Two different extension times 
(35 s and 3 min) were also tested for PrimeSTAR Max.  The results with PrimeSTAR Max 
resulted in clear bands so then multiple annealing temperatures were tested with this polymerase 
from 50 to 68 °C. 
Note that after vector preparation, the scFv fragments were never cloned into the vector 
as planned. 
 
 
Figure 89 Planned pComb3XSS Modifications 
The plan to modify the pComb3XSS primer would remove the NotI site furthest downstream from 
the lac promoter and change the SfiI site to a NotI site.  This would allow scFv flanked by NotI 
and SfiI sites to be quickly inserted after the lac promoter and before the pIII gene fusion.  The 
exact nucleotide sequence changes to be made are given in boxes with the final sequences given 
in the box on the right.  Note that the SfiI restriction site contains “N” nucleotides so the exact 
sequence of the particular SfiI site planned is given below these “N” nucleotides. 
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B.3 Results 
B.3.1 Isolation of RNA from B cells 
The quantitative results of the isolation of RNA from B cells from tumor or naïve mice are 
presented in Figure 90.  The 260/280 absorbance ratio for the Tumor B cell RNA was 2.08 and 
the 260/280 ratio of the Naïve B cell RNA was 1.89. 
 
Figure 90 RNA isolated from B cells 
RNA isolated from B cells of BALB/c mice.  One group of mice was injected with 4T1 cells and 
had a tumor at the time the RNA was isolated. 
B.3.2 PCR Construction of scFv 
The final fragments from the scFv PCR construction resulted in bands of the correct size 
for the heavy chain genes connected to the kappa or lambda light chain genes for all four groups 
(SMC1, Naïve, 1-78, and Tumor).  The expected size of the scFv fragment was approximately 
750 bp, and the gel of these fragments is displayed in Figure 91. 
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Figure 91 Constructed scFv DNA Fragments 
A gel with PCR products from the scFv gene construction is displayed for scFv constructed from 
naïve mice, mice immunized with SMC1fs, or mice immunized with the 1-78 frameshift transcript 
in (A) and mice injected with tumor cells in (B).  In (A) two different pictures of the same gel with 
different exposure times to increase or decrease the brightness of the gel are presented.  For 
each mouse type both the “H+L” (heavy chain linked to lambda light chain) and the “H+K” (heavy 
chain linked to kappa chain) scFv are presented. 
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B.3.3 Preparation of vector 
The results of the pComb3XSS linearization with a variety of different polymerases and 
conditions are presented in Figure 92.  The PrimeSTAR Max polymerase produced the strongest 
bands, and another test with this polymerase was performed at different annealing temperatures 
in Figure 92 part D. 
 
 
 
Figure 92 Plasmid Linearization of pComb3XSS 
In A) and B) a DMSO gradient with the Herculase II polymerase was performed.  In B) the Iproof 
polymerase was also tested with 1 ng and 5 ng of starting template material.  In C) the 
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PrimeSTAR Max polymerase, the Pfu Turbo polymerase, and the Advantage HD polymerase 
were tested.  In D) the PrimeSTAR Max polymerase was tested with annealing temperatures 
ranging from 50-68 °C. 
B.4 Discussion 
Phage antibody libraries provide a tool for amplifying an antibody repertoire, and an attempt 
was made here to produce a phage antibody library to probe for cancer antigens.  First quality 
RNA was isolated from B cells from the spleens of mice with tumor or no tumor.  Next this RNA 
was used with PCR to construct scFv fragments.  An efficient method was developed with Dr. 
Andrey Loskutov and Dr. Kathryn Sykes to produce the scFv needed to cover the mouse 
immunoglobulin repertoire in just 73 total PCRs, which is less than the number of PCRs that 
would be required by many other methods for a fully representative library.  Next, initial steps 
were made to clone the scFv fragments into a vector.  We originally tried to clone the fragments 
into the PCANTAB5E vector, but we later discovered that the PCANTAB5E plasmid in our lab’s 
possession was actually a different plasmid.  We then decided to use the pComb3XSS vector.  
First, however, the pComb3XSS vector had to be modified to contain the appropriate restriction 
enzymes which required linearization of the plasmid.  Several conditions were tested to optimize 
the PCR of such a long DNA fragment, and the PrimeSTAR Max polymerase proved to be the 
most suitable polymerase for the challenge.  Ultimately, the fragments were never cloned into the 
vector since other projects took priority.  In theory though, the scFv fragments produced from 73 
PCR reactions could be cloned into a modified pComb3XSS vector to produce a phage antibody 
library with an abundant amount of material (as opposed to pure sera) for discovering tumor 
antigens for a tumor vaccine.
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C.1 Introduction 
A researcher may want to purify antibodies using the non-natural sequence peptide microarray 
before screening a cDNA library.  Using purified antibodies, it might be possible to obtain much stronger 
signals, and fewer false positives.  The purification of antibodies should be possible since researchers in 
our lab have discovered that there are some non-natural sequence peptides which specifically bind to 
tumor sera compared to naïve sera.  Therefore, these non-natural sequence peptides can be used to bind 
and elute just the antibodies of interest. 
C.2 Materials/Methods and Results 
An attempt was made to purify specific antibodies using selected non-natural sequence peptides.  
The basic process followed derives from a protocol outlined in Current Protocols in Immunology 9.3 Basic 
Protocol 3 Using an Affinity Column with Acidic, Basic, or Chaotropic Elution 201.  Six peptide sequences 
which bound more to tumor sera than naïve sera were synthesized onto Tentagel beads (RAPP-
Polymere).  A 100 µl aliquot of a 50% DMF slurry of these beads was washed in the organic solvent DMF 
in a 5 mL polypropylene column (Thermo Cat no 29922), and were gradually transitioned to a wash with 
approximately 5 mL PBS aqueous solution.  The sera was then diluted 1 to 10 in equilibration buffer 
(TBST) and washed through the column.  The unbound sera fraction was collected.  The column was 
then sealed and incubated on a rotisserie shaker for 1 to 2 hr at 37 °C.  The column was then washed 
with approximately 20 mL equilibration buffer.  Several Protein LoBind tubes (Eppendorf Cat no 0030 
108.116) for collecting the elution fractions were prepared by adding 0.2 mL neutralization buffer (1.5 M 
Tris ⋅ Cl 150 mM NaCl pH 8) to each tube.  Elution was performed by adding 5 mL acidic elution buffer 
(0.1 M glycine 0.15 M NaCl pH 2.8) and collecting 1 mL fractions in the tubes containing neutralization 
buffer.  A Nanodrop instrument (Thermo Scientific) was used to determine which fractions contained 
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antibody and these fractions were pooled together.  Dialysis was performed with these solutions using 
Slide-A-Lyzer (Thermo Scientific) according to the manufacturer's instructions. 
After the antibodies were purified, these antibodies were used in a dot blot to test for reactivity to 
the selected peptides.  Peptides were spotted (2 µl of 30 ng/µl peptide) onto a nitrocellulose membrane.  
The membrane was then dried for 20 min and blocked in 5% BSA in TBST overnight.  The selected 
sample (original sera, elution fraction, or unbound flow-through) was then diluted into 20 mL 5% BSA 
TBST and used to probe the membrane 1hr RT.  The membrane was washed and the 2 mg/mL goat anti-
mouse IgG H+L AF647 secondary at a 1:10,000 dilution in TBST 5% BSA was applied to the membrane 
1 hr RT.  The membrane was washed, dried, and then scanned with a Typhoon Trio+ instrument 
(Amersham Biosciences).  Specific binding for the selected peptides in the eluted fraction could not be 
detected. 
The selected sample (original sera, elution fraction, or unbound flow-through) was then applied to 
the non-natural sequence peptide microarray using the standard protocols for the microarrays in our lab 
(1:500 dilution of primary and 5 nM secondary).  The expectation was that the purified and eluted 
antibodies would bind to the same peptides used to purify them.  However, the purification did not work.  
The flow through which did not bind to the peptides could still bind to the 6 peptides on the array, but the 
purified fraction did not bind to these 6 peptides Figure 93.  Therefore, the method of purification had to 
be redesigned.  The major issue may have been that the peptides on the array are at a much higher 
density than the peptides on the Tentagel mesh.  The orientation of the peptides may also have been an 
issue. 
Peptides were synthesized onto the Tentagel beads at 4X the density, but similar results as before 
were obtained. 
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Figure 93 Purification of selected antibodies with peptides 
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A column containing TentaGel beads with six different peptides was used to purify antibodies from A) 
naïve sera and B) tumor sera.  Unpurified sera, sera eluted from the column, and sera in the unbound 
fraction was applied to the non-natural sequence peptide microarray and the intensity of each of the six 
peptides used for the purification is presented on the y-axis. 
C.3 Discussion 
A method for purifying antibodies using selected peptides from a non-natural sequence peptide 
microarray would be very useful.  The purified antibodies could then be used to probe for antigens in a 
cDNA library screen, western blot, or pull-down assay.  Theoretically, one could apply sera from a sick 
patient onto a non-natural sequence peptide microarray, identify unique peptides for the patient, use 
these peptides to isolate the relevant antibodies, and then use these antibodies to probe for important 
antigens which could be used in a vaccine or to study the disease.  An attempt was made here to purify 
antibodies using peptides synthesized onto Tentagel beads.  The results demonstrated that reactivity 
against the selected peptides could be detected, but only with the unbound fraction and not the eluted 
fraction which should have contained antibodies which bound to the peptides.  Other approaches will 
need to be pursued in order to identify a method which can successfully purify antibodies using selected 
peptides.  Perhaps a different equilibration buffer (such as ethylene glycol 202) or peptide synthesis 
substrate instead of Tentagel beads could work more effectively.  Note that non-natural sequence 
peptides were successfully used to purify antibodies in “4: RANDOM SEQUENCE MIMOTOPES” in this 
dissertation.  However, in that chapter, sera from a hyper-immunized rabbit rather than sera from a 
mouse with a tumor was used.  There may not have been enough antibody to a specific target in the 
mouse with a tumor.  Also note that antibodies from rabbits typically exhibit superior antigen recognition 
when compared to mouse antibodies 203-205.  Once an effective protocol is developed, this process could 
be an invaluable tool for quickly identifying important antigens and infectious agents.  
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D.1 Introduction 
In the Center for Innovations in Medicine many students, technicians, graduate students, post-
docs, and professors have spent a considerable amount of time aligning lighted features in an image with 
assigned features, which is a necessary but tedious task.  On some of the arrays there are 10,000 
features, and on some of the arrays there are 330,000 features.  This alignment process is performed 
using the GenePix 8.0 software (Molecular Devices, Santa Clara, CA).  While this software does have 
some rudimentary automatic aligning features, there are many situations in which this automatic 
alignment does not perform well and the user still has to manually look through the alignment and make 
corrections.  Additionally, the user still has to open up a file, roughly align all the grids before performing 
any automatic alignment, obtain the results, and then save the file.  Ideally, it would be better to have 
software that could just automatically go through an entire folder of files and output the results, which 
would be a process the program could perform all night and day without fatigue.  I was ambitious and 
thought that I could create such a program.  I did create a program which successfully reached some 
benchmarks, but ultimately a program which could automatically align an entire array was never 
completed. 
D.2 Materials and Methods 
A Java program was created to perform the automatic alignment of one block on the array.  The 
program takes a red reflect (pre-experiment) 16 bit TIFF image file, a gal file, and a post-experiment 16 bit 
TIFF image file containing the spots for one block of the array as input and outputs the x-y coordinates of 
each feature thus performing an alignment.  Note that a gal file contains the general pattern of features 
along with their identity. 
The constructed Java program proceeds through several steps.  First the intensity values are 
extracted from the red reflect image.  Note that in the red reflect image, every spot has an intensity and 
this is scanned before any sera is applied to the array.  In order to extract intensity values from the 16 bit 
TIFF image the Java Advanced Imaging (JAI) API was used.  Specifically the jai_codec.jar, jai_core.jar, 
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and mlibwrapper_jai.jar files were included in the project.  A threshold was applied to retain pixel intensity 
values above a certain value, and then the density-based spatial clustering of applications with noise 
(DBSCAN) algorithm was used to find the coordinates of clusters of high intensity pixels (spots).  Once 
the x,y coordinates of all of the points are identified the program then finds the vertical and horizontal 
edges formed by rows and columns of spots.  These edges are found by identifying ranges in which many 
points lie within approximately the same x or y value.  From the edges, the corner points are also 
identified.  Next the program roughly aligns a gal file which contains the feature names and the basic 
pattern of the spots with the grid identified in the red reflect.  The gal file is rotated and resized 
appropriately.  Next the position of each feature in the roughly aligned gal file points are fine-tuned by 
moving them to an actual image spot in the red reflect if there is an image spot very nearby. 
 Once the features have been identified in the red reflect image, this arrangement of features is 
then matched up with the actual image after the experiment has been performed and sera has been 
applied to the array.  Note that the alignment was performed with the red reflect image first because this 
is a very clean image in which just about each spot is present, whereas in the image after the experiment 
there are many false spots and real spots that are missing from the image.  Matching with the post-
experiment image is performed by first identifying the landing lights, which are like the regular spots, but 
they have a very high intensity.  The pattern of points established with the red reflect image is then 
rotated and resized to match the landing lights.  These points are then fine-tuned to move any point to a 
new post-experiment image spot.  In other words any features are moved to very close spots in the post-
experiment image.  The last step was to simply extract the median intensity of each spot.  The code to 
perform these functions is stored at 
"\\biofs.biodesign.asu.edu\CIM\Administration\Biostatistics\Kurt\Automatic Slide Alignment" as of this 
writing. 
D.3 Results 
A diagram illustrating the process the program takes as it automatically aligns a slide is presented 
in Figure 94.  Note that the image at each stage was not a constructed diagram, but was actually an 
image output by the program itself.  The end result was a program that has a 0.94 correlation coefficient 
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with a human alignment, and that is correctly aligned with the bright spots of the image upon manual 
visual inspection.  The program could only work for one block, however, and was never completed 
enough to automatically align an entire array. 
 
Figure 94 Automatic array alignment figure 
The image of the red reflect is first input into the program and the centroids identified from the DBSCAN 
algorithm are located.  The program then determines the locations of the edges of columns and rows to 
determine where the corners of the grid are located, and roughly aligns the centroids from the gal file with 
every labeled peptide feature present to the centroids identified from the red reflect.  This rough alignment 
is accomplished by rescaling, rotating, and moving the gal file grid to match up with the corner points of 
the red reflect centroid grid.  The program then fine tunes the rough alignment to move each centroid to 
the nearest red reflect centroid if there is one nearby.  Next the program identifies the high intensity 
landing light centroids on the experiment array image (rather than the red reflect), and then transforms 
the gal file aligned with the red reflect to the real image from the experiment using the landing light 
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information.  The correlation coefficient obtained by comparing a human alignment with the program 
alignment was 0.94. 
D.4 Discussion 
Aligning features on our non-natural sequence peptide microarrays is a time consuming task which 
could potentially be automated.  I attempted to write a program to automatically align the features on the 
array, and I achieved some success.  My program demonstrated that it could align one block on the array 
(there are 48 blocks on the CIM10K array) with a correlation of 94% to the alignment of a human  
The program operated simply by using an algorithm called DBSCAN (density-based spatial 
clustering of applications with noise) to identify bright spots in the image.  Before an experiment is 
performed with the peptide microarray slides, the slides are scanned to obtain a red reflect image.  These 
red reflect images are much cleaner than the images obtained after an experiment since all of the peptide 
feature spots are present, the spots have about equal intensity, and there are not smears or streaks 
across the array.  My program took the alignment from the red reflect and then performed a 
transformation to match up as closely as it could with the actual array image.  Then the spots were moved 
to the closest DBSCAN identified spots on the experiment image if a DBSCAN spot was within a certain 
limit range.  After I demonstrated that the technique could work for one block, the project was transferred 
to the programmer Nate Sutton in another lab to automate the alignment of the whole array with all of the 
blocks.  Unfortunately correctly identifying the position of all of the blocks turned out to be a difficult task 
and the project was not completed.  Perhaps a more distinguishing arrangement of the landing lights in 
the blocks would have made the task easier. 
As of the current date several programmers in our lab have attempted to write programs to automate 
this task: Preston Hunter, Muskan Kukreja, and Kevin Brown.  Our lab has also tried to make some 
arrangements with a Chinese software company to automate this task, but this arrangement did not pan 
out.  Automatically aligning the arrays has proved to be a challenging task, but I still maintain that this is 
certainly something which should be possible.   
If I were to start the project all over again, I think I would try to use a method with SVMs (support 
vector machines) which would not require any landing lights to be present on the slide at all.  Basically, a 
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SVM can classify an object as belonging to one of two categories based on values of the features of that 
object.  The SVM learns to make this classification from a set of training data.  A method for alignment 
could involve using DBSCAN to identify the bright spots on the array.  Then an SVM would determine 
whether a certain DBSCAN spot was spot “A” by looking at the features of that spot.  The features would 
be assigned to be the position of other features on the array.  In other words, the spot would basically be 
defined by its relative position to other spots.  An SVM would be applied to each spot on the array to 
determine whether this is spot “A”, whether this is spot “B”, etc.  Each SVM could make these judgments 
based on some previously human aligned training data. 
This SVM alignment method could be performed by using the x,y coordinates of the 10 nearest spots 
to the spot in question.  I think multiple SVMs would have to be trained with all possible orderings of the 
10 nearest spots so that the collective group of SVMs is not restricted to assigning an identity to a spot 
only if "feature 1" is in an approximate location.  If "feature 2" is in that approximate location then the 
correct assignment would be made by one of the SVMs in the group.  In other words, "feature 1" can be 
at any number of one of the 10 spot locations.  This is necessary because there could be an extra stain 
on the array which makes all the subsequent features have a different assignment.  For example, if the 
4th point is a stain, then the real 4th point would be the 5th, the real 5th point would be the 6th, etc.  
Likewise, instead of a stain which adds an extra spot, there could be spots that are missing which would 
also change the normal order of the real spots.  Therefore, it would be necessary to train multiple SVMs 
for the identity of a feature with each different SVM trained with a different ordering of the closest 10 
spots.  In order to account for every possible ordering of the 10 closest spots, 10! = 3,628,800 SVMs 
would need to be trained in order to assign the identity of one spot.  Although this is a very large number, 
this approach may still be computationally feasible since the speed of one single SVM with only 10 
features is virtually instantaneous on a standard PC.  One of the beautiful aspects of this method is that 
the assignment of an identity to one feature is completely independent from the assignment of an identity 
to the other features.  Therefore, even if there is very large bad region on the array which makes it 
impossible to assign an identity to a large group of spots, this would not interfere with the correct 
assignment of spots in a different good region of the array.  This method also does not rely on any 
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landing lights.  For the spots that did not receive an assignment, a human could even go in and inspect 
these unassigned spots manually if desired. 
In summary, a strategy was pursued to automatically align bright spots in an image with a pattern of 
features.  This strategy implemented the DBSCAN algorithm, landing lights, and many spatial 
transformations.  The end result was a program which could align one block of a 10k array of 48 blocks 
with a correlation coefficient of 0.94 with a human alignment.  The program was never completed to 
automatically align an entire array.  If the project was started again, a strategy that implemented the SVM 
algorithm would have many benefits and may be a superior method.  Regardless of the method used, a 
program capable of automatically aligning the arrays would save researchers a considerable amount of 
time so that they can pursue other tasks. 
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First steps toward the construction of a human tumor cDNA library were taken.  Human breast tumor 
RNA was obtained from Dr. Stephen Lyle at the Cancer Center Tissue and Tumor Bank from the 
University of Massachusetts.  The characteristics of this RNA sample are presented in Table 18. 
Table 18 Human breast tumor RNA characteristics 
Sample 
ID 
Sample 
Date 
Organ Cancer/Met Cancer 
Type 
Grade ER PR HER-2 Age Gender 
2802T 10/25/2010 Breast Malignant Ductal Carcinoma - - - 53 Female 
 
The attributes of the human breast tumor RNA sample are presented.  The RNA came from a malignant 
breast ductal carcinoma from a 53 year old female.  The carcinoma was negative for all three of the 
markers ER, PR, and HER-2. 
 Next cDNA was synthesized from this RNA using random hexamers as presented in Figure 95.  
The cDNA made from 18 cycles was selected for cloning into a vector and transforming. 
 
Figure 95 Tumor cDNA synthesized from random hexamer primers 
The DNA from a PCR of human breast tumor RNA with random hexamer primers with 15, 18, 21, 24, or 
27 PCR cycles. 
 After this DNA was transformed into E. coli and the plasmids inside some of the colonies were 
sequenced, most of the results were short poly T sequences.  Therefore, the library had to be remade.  
However, when remaking the library, random pentadecamers were used instead of random hexamers 
since pentadecamers increase the yield and quality of the resulting cDNA 206.  The integrity of the RNA 
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was checked before constructing the random pentadecamer library (Figure 96).  After the library was 
constructed with random pentadecamers, the cDNA was purified using AMPURE magnetic beads, but 
then there were no colonies after the transformation into E. coli.  When the library was constructed again 
(Figure 97), electroelution was used to purify the cDNA rather than using magnetic beads (Figure 98).  An 
ethanol precipitation was then performed on this electroeluted DNA (Figure 99).  This purified DNA was 
ligated into a vector by performing an in-fusion reaction, and another ethanol precipitation was performed 
(Figure 100).  After all of these steps, the final percent recovery of cDNA was calculated as 6.19% with a 
final sample concentration of 13.2 ng/µl. 
 
Figure 96 RNA integrity check before random pentadecamer library construction 
One aliquot of the RNA was incubated at 37 °C, and one aliquot was incubated at -80 °C for 2 hours.  The 
samples were then run on a gel and the intensity of the 28S to 18S bands were compared. 
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Figure 97 Second strand synthesis with random pentadecamer primers 
Second strand synthesis was produced using random pentadecamer primers rather than random 
hexamer primers.  In the first two gel images, the PCR is performed with 35 cycles at a variety of different 
annealing temperatures (30.9, 42, 50.6, 60.3, and 68.1 °C).  In the two gel images on the right, the PCR 
is performed with 40 cycles at a variety of different annealing temperatures (30.9, 42, 50.6, 60.2, and 68.1 
°C). 
 
 
Figure 98 Gel fragments pre and post electroelution 
Images of cut out gel fragments pre and post electroelution.  The “1”, “2”, and “7” just refer to the lanes 
from which the fragments were cut from in Figure 97, and in this case the “1” refers to cDNA made with 
35 cycles 30.9 °C Tm, “2” corresponds to 35 cycles 42 °C Tm, and “7” refers to 40 cycles 42 °C Tm.  
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Figure 99 cDNA library after electroelution and precipitation 
Human breast cancer cDNA after electroelution and ethanol precipitation purification.  The other ladder, 
linear vector, and control insert were controls that would be subjected to the following in-fusion and 
precipitation steps along with the cDNA. 
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Figure 100 cDNA library after electroelution, ethanol precipitation, in-fusion, and ethanol 
precipitation 
The cDNA and PUC19 control insert were electroeluted, ethanol precipitated, in-fused into a vector, and 
ethanol precipitated.  The amount of DNA in each lane estimated from the brightness of the bands is 
indicated below the gel image. 
 Some experiments were also performed to test variables that would affect the transformation 
efficiency.  The conditions tested were as follows: presence or absence of glycogen; use of heat (50 °C 
10 m) or not on DNA sample before transformation; and use of 10 mM Tris buffer or water (Figure 101).  
These results demonstrate that if glycogen is used as a carrier molecule, then a much higher 
transformation efficiency can be obtained if the sample is heated preceding transformation. 
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Figure 101 Electroporation condition test 
The transformation efficiency of electroporation with many different conditions was tested.  A “-“ indicates 
absence of a condition, and a “+” indicates presence of a condition.  “G” indicates that glycogen was 
added to the mixture, “H” indicates that the DNA was heated to 50 °C for 10 m before electroporation, and 
“T” indicates that 10 mM Tris buffer was used instead of water.  A “T1”, T2”, or “T3” at the end of the 
group designation indicates that the cells used were previously thawed one, two, or three times 
respectively.  
 In conclusion, initial steps were taken to construct a human tumor cDNA library.  Unlike many other 
cDNA libraries, this library was constructed using random pentadecamers instead of random hexamers.  
The DNA was also purified using electroelution instead of beads.  Transformation conditions were also 
tested, and heating the glycogen DNA sample to 50 °C before transformation resulted in a higher 
transformation efficiency.  Using these procedures may result in a library with good representation of the 
original transcripts, but this particular library was not completed as other projects took priority. 
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 The first chapter of this dissertation discusses the AbStat metric, and the second and third 
chapters discuss screening a tumor cDNA library constructed from a mouse tumor.  Therefore, one might 
be curious about the AbStat results of the tumor mice used to construct the tumor cDNA library.  Sera 
samples from these naïve and tumor mice were applied to the non-natural sequence peptide microarray, 
and therefore the AbStat results can be determined.  The tumor sera sample was composed of a pool of 
sera from the five tumor mice, and the naïve sera sample was composed of a pool of sera from the five 
naïve mice.  The Peptide Array Core then applied these samples to the CIM10Kv2 peptide microarrays 
with a replicate for each sera sample.  The resulting fluorescence intensity distributions from the 
experiment were used to obtain AbStat results.  Graphs of the entropy for both groups (Figure 102), a 
heatmap displaying the relative intensities of the AbStat values for each sample (Figure 103), and the 
statistical significance of each measure (Figure 104) are displayed below.  These results show that the 
tumor sample has a higher average entropy than the normal group.  The p-value from a t-test with the 
entropy values is 0.0638.  The p-value may have been more significant if the sample size of each group 
was larger than the minimum of two required for a t-test.  The heatmap shows that most of the AbStat 
measures are relatively higher for the tumor samples compared to the normal samples.  The bar graph of 
the statistical significance for each measure reveals that the max, median, and entropy were the 
measures which distinguished between the two groups the best.  Overall these results support the 
previous findings that samples from organisms with cancer often have higher entropy values (“1.3.5 
Mouse cancer progression” and “1.3.6.2 HT330K wafer 46”). 
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Figure 102 Entropy of naive mice and tumor mice used to construct a cDNA library 
The entropy calculated from the peptide fluorescence intensity distribution after the application of naïve 
mouse sera or tumor sera is plotted in a bar graph.  There was a technical replicate for each group for a 
total of two samples per group.  The naïve sera sample consisted of a pool of five naïve mice, and the 
tumor sample consisted of a pool of five tumor mice. 
 
 
Figure 103 Heatmap of measures for naive mice and tumor mice used to construct cDNA library 
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Each column corresponds to an AbStat measure and each row corresponds to a sera sample.  The 
relative average value of each AbStat measure for the samples is represented by a color with blue 
indicating the lowest relative value and red indicating the highest relative value.  The class of each 
sample is designated as follows: N = normal, T = tumor. 
 
Figure 104 Statistical significance of measures comparing normal and tumor mice used to 
construct cDNA library 
Sera samples were applied to the CIM10Kv2 array and the AbStat measures were calculated.  A p-value 
from a t-test was then determined for each measure for tumor vs normal.  The negative logarithm in base 
10 of the p-value was then plotted in a bar graph. 
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BIOGRAPHICAL SKETCH 
There is an interesting quote from Freeman Dyson: "a new generation of artists will be writing 
genomes with the fluency that Blake and Byron wrote verses".  What if it were possible to engineer 
biological systems as easily and reliably as computer systems are engineered today, and as a result 
enjoy much longer healthier lives?  With the advent of biological engineering and synthetic biology, this is 
becoming more of a reality.  I have taken several steps to be a part of this exciting new area of science.  I 
obtained by undergraduate degree in Chemistry at Southern Utah University where I also worked at the 
university Water Lab to test for the presence of harmful chemical compounds.  During this time, I started 
an iGEM (international Genetically Engineered Machines) team to make bacteria with a cyanide 
biosensor.  During my PhD degree I screened a tumor cDNA library for antigens which the immune 
system would recognize.  In another project, I tested my own proposal that part of the aging process may 
be due to an age associated stem cell autoimmune disease.  I also developed the idea that the way a 
repertoire of antibodies from an organism reacts with an array of non-natural sequence peptides will 
change during the aging process and during poor health.  I calculated the Shannon information entropy of 
the resulting fluorescence intensity distribution from the non-natural sequence peptide array, and found 
that the entropy was higher in aged organisms and organisms with cancer compared to healthy 
individuals.  I want to continue to participate in research that will lead to the maintenance of good health 
at a level that was not possible with previous technology. 
